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The human leukocyte antigen (HLA)-C belonging to MHC Class I molecules, have 
emerged to have a role in T-cell antigen presentation apart from its dominant role in 
NK cell recognition. In this project, we undertook a structural approach to understand 
the features unique to HLA-C molecules that are important for function and immune 
specificity. By studying the antigen binding groove of HLA-C molecules, data about 
the peptide binding pockets can be compared against the well-studied HLA-A*02 
molecules and existing HLA-C crystal information which are limited.  
However, low surface expression and poor serotyping of HLA-C molecules have 
impeded molecular and structural characterisation. Thus, using HLA-A*02 molecules 
as a model, a set of cloning, refolding and purification conditions have been optimised 
and derived for HLA-C structural determination. Initial small-scale refolding assays, 
with Western blot as a read-out system, enabled the identification of binding peptides 
to a panel of highly-occurring HLA-C alleles in vitro. Of which, two potential high-
affinity HLA-C-peptide complexes were selected for large-scale refolding 
experiments designed for crystallisation. 
The novel crystal structures of HLA-C*08:01-Cytomegalovirus (CMV) 
phosphoprotein 65 (pp65) peptide (VVCAHELVC) and HLA-C*08:01-Influenza 
matrix peptide (GILGFVFTL) were determined to a resolution of 2.18Å and 1.84Å 
respectively. The HLA-C*08:01-VVCAHELVC is known to elicit a cytotoxic T-cell 
response and the peptide belongs to the pp65 structural protein which is abundant 
throughout CMV infection. Thus, this peptide serves as an appropriate antigen to 
target in efforts to provide immunity to CMV. The second strong binding peptide to 
HLA-C*08:01 is identified as the minimal HLA-A*02-restricted peptide epitope from 
the Influenza virus matrix protein which is involved in virus budding. Therefore, the 
vii 
 
data suggest that both HLA-A*02:01 with HLA-C*08:01 can bind the same peptide in 
vitro and HLA-C*08:01 may share a common peptide-binding motif and have a 
similar role as HLA-A*02 in antigen presentation. 
The overall topology of both structures is similar to that of HLA-A and HLA-B 
molecules with 2 α-helices forming a deep antigen binding groove in which a single 
antigenic peptide can bind in an extended conformation. Furthermore, the groove has 
a shape and size which is dependent on the properties of the residues lining it. The 
heavy chain residue side-chains pointing towards the peptide will make important 
hydrogen bonding networks that may in turn influence the properties of the binding 
peptide.  
Taken together, we have identified potential HLA-C-peptide complexes that refold in 
vitro by defining a set of refolding parameters specific for HLA-C molecules. In 
addition, the refolding assay and purification scheme allowed the high resolution 
structural determination to provide information about the HLA-C peptide binding 
pockets and helped to characterise the peptide binding specificities of HLA-C 
molecules in greater depth. Due to the lack of HLA-C structural information for the 
past 10 years, the crystallisation data presented in this thesis also provided a structural 
basis of HLA-C-peptide complex formation to understand the unique role of HLA-C 
in immunity and propose an increasing role of HLA-C in antigen presentation similar 
to HLA-A and HLA-B molecules.   
viii 
 
LIST OF TABLES 
Table 1 List of primers used for cloning 37 
 
  
Table 2 Characterised HLA-C Cytotoxic T Lymphocyte (CTL) 
epitopes from various sources 47 
 
  
Table 3 Table of other peptides used for refolding assay 48 
 
  
Table 4 HLA-C expression levels 64 
 
  
Table 5 Data collection and refinement statistics for novel HLA-C 
crystal structures 96 
 
  
Table 6 Hydrogen bonds from CMV pp65 peptide VVCAHELVC to 
HLA-C*08:01 heavy chain 103 
 
  
Table 7 Hydrogen bonds from Influenza matrix peptide 
GILGFVFTL to HLA-C*08:01 heavy chain 111 
 
  














LIST OF FIGURES  
Figure 1(A) Schematic diagram of the HLA-A*02:01 molecule 10 
Figure 1(B) Peptide interaction with HLA molecule viewed from the 
side of the antigen binding groove 10 
 
  
Figure 2 World map illustrating the global distribution of the HLA-C 
alleles chosen for our study 14 
 
  
Figure 3 Proposed workflow to obtain an optimal set of cloning, 
refolding, purification and crystallisation conditions 34 
   
Figure 4 PCR products from various cell lines 57 
 
  
Figure 5 Restriction enzyme analysis of pET-30a-HLA-C plasmids 59 
 
  
Figure 6 Protein expression levels of HLA-A, -B and –C alleles 62 
 
  
Figure 7 Quantitation of the expression of HLA-C*08:01 inclusion 
bodies using denaturing SDS-PAGE 63 
 
  
Figure 8 Quantitation of the expression of β2-microglobulin light 
chain using denaturing SDS-PAGE 66 
 
  
Figure 9 Refolding of known HLA-C-peptide complexes 71 
 
  
Figure 10 Refolding assay of HLA-C*08:01 with HBV peptides 74 
 
  
Figure 11 Refolding assay of HLA-C*08:01 with other peptides 75 
   
Figure 12 Refolding assay of HLA-C alleles with other peptides 76 
 
  
Figure 13 Phylogenetic analysis of the amino acid sequences of all 18 
HLA-C alleles using the Clustal W method 78 
 
  
Figure 14 Small-scale refolding assay of HLA-C*08:02 79 
 
  
Figure 15 Sequence alignment for HLA-C*08:01 and HLA-C*08:02 81 
 
  
Figure 16 HLA-C*08:02 amino acid differences 82 
 
  
Figure 17 Two-step purification scheme for HLA-C*08:01-CMV pp65 
peptide VVCAHELVC 85 
  
 
Figure 18 Two-step purification scheme for HLA-C*08:01-Influenza 
matrix peptide GILGFVFTL 88 
   
   
x 
 
Figure 19 Crystal growth formation of HLA-C*08:01-CMV pp65 
peptide VVCAHELVC observed under the transmitted 




Figure 20 Crystal growth formation of HLA-C*08:01-Influenza matrix 
peptide GILGFVFTL observed under the transmitted 




Figure 21 X-ray diffraction pattern of the HLA-C*08:01-Influenza 
matrix peptide GILGFVFTL. 94 
 
  
Figure 22 Schematic top view of the α1 and α2 domains of HLA-
C*08:01 heavy chain and the VVCAHELVC peptide 99 
 
  
Figure 23 Schematic overview of the structure of HLA-C*08:01 in 
complex with the CMV-pp65 peptide VVCAHELVC 100 
 
  
Figure 24 Hydrogen bonds interactions between the peptide residues 
of CMV pp65 VVCAHELVC peptide and HLA-C*08:01 
heavy chain 
104 
   




Figure 26 Schematic top view of the α1 and α2 domains of HLA-
C*08:01 heavy chain and the GILGFVFTL peptide 110 
 
  
Figure 27 Hydrogen bonds interactions between the peptide residues 





Figure 28 Schematic overview of the structure of HLA-C*08:01 in 
complex with the Influenza matrix peptide GILGFVFTL 114 
 
  








Figure 31 Top and side views of the CMV pp65 peptide 
VVCAHELVC and Influenza matrix peptide GILGFVFTL 119 
 
  
Figure 32 Positioning of Ser 77 and Asn 80 on HLA-C heavy chain 120 
   
Figure 33 Pocket F residues that are important in determining the 
nature of the P9 residue 123 
   
   
xi 
 
Figure 34 Structural alignment of HLA-C*04:01-QYDDAVYKL 




Figure 35 Relative orientations of P7 and P8 positions of the peptides 
in HLA-C*04:01-QYDDAVYKL (1QQD), HLA-C*08:01-




Figure 36 Structural alignment of KIR2DL2-HLA-C*03:04-





Figure 37 Superimposition of the peptides bound to HLA-C*03:04 





Figure 38 Structural alignment of HLA-A*02:01-GILGFVFTL 
(2VLL) with HLA-C*08:01-GILGFVFTL 139 
 
  
Figure 39 Superimposition of the GILGFVFTL peptide bound to 
HLA-A*02:01 and HLA-C*08:01 140 
 
  
Figure 40 Orientation of P5Phe in Influenza matrix GILGFVFTL 
peptide when bound to HLA-A*02:01 and HLA-C*08:01 141 
 
  
Figure 41 Circular dichroism thermal unfolding 145 
 
  
Figure 42 Schematic top view of the antigen binding groove of HLA-
C*08:01, CMV pp65 peptide (VVCAHELVC) and the 








ADA [N-(2-acetamindo)iminodiacetic acid]  
BSA Bovine Serum Albumin 
CD Circular dichroism 
cDNA Complementary Deoxyribonucleic Acid 
CMV Cytomegalovirus 
CTL Cytotoxic T Lymphocytes 
DEAE Diethylaminoethyl 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic Acid 
DTT Dithiothreitol 
E.coli Escherichia coli 
EBV Epstein-Barr Virus 
EDTA Ethylenediaminetetraacetic Acid 
ELISPOT Enzyme-linked Immunosorbent Spot 
ER Endoplasmic Reticulum 
FBS Fetal Bovine Serum 
FID Free Interface Diffusion 
HBV Hepatitis B Virus 
HCC Hepatocellular Carcinoma 
HCV  Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
xiii 
 
HLA Human Leukocyte Antigen 
HRP Horse-Radish Peroxidase 
hsp Heat Shock Proteins 
HTLV-I Human T-cell Lymphotropic Virus Type I 
HVR Hypervariable Regions 
IEDB Immune Epitope Database 
IFN-γ  Interferon-gamma 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
kDa Kilo-Daltons 
KIR Killer-cell Immunoglobulin-like Receptor 
LB Luria-Bertani 
MAGE-A3 Melanoma-associated Antigen 3 
MD Molecular Dynamics simulations 
MES Morpholineethanesulfonic acid  
MHC Major Histocompatibility Complex 
NK Natural Killer cell 
PBS Phosphate Buffered Saline 
PCR  Polymercase Chain Reaction 
PDB Protein Data Bank 
PEG Polyethylene Glycol 
PEG MME Polyethylene Glycol Monomethyl Ether 
PES Polyethersulfone 




pp65 Cytomegalovirus Phosphoprotein 65 
PVDF Polyvinylidene difluoride 
RMSD Root Mean Square Deviation 
RNA Ribonucleic Acid 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
SNP Single Nucleotide Polymorphism 
SPR Surface Plasmon Resonance 
TAP Transporter associated with Antigen Processing 
TBS Tris-Buffered Saline 
TBST Tris-Buffered Saline-Tween 20 





CHAPTER 1 INTRODUCTION 
Major Histocompatibility Complex (MHC) molecules have a pivotal role in the field 
of immunology due to their importance in helping the immune system to distinguish 
between ‘self’ and ‘non-self’ molecules, cells and other molecules. In addition, MHC 
molecules are also central in the functioning of the immune system where they have a 
role in organ and tissue transplantation (Glucksberg et al., 1974; Zou and Stastny, 
2009) and disease immunity (Fu et al., 1993).  
MHC molecules execute their functions in the initiation of immune responses through 
the presentation of peptides to T lymphocytes (Townsend et al., 1985; Yewdell et al., 
1988). However, the complexity of their study is compounded by high variability of 
the different MHC types (Parham et al., 1988). Furthermore, the high polymorphism 
of MHC molecules, coupled with an enormous and diverse pool of binding peptides, 
contribute to the complex interactions of MHC-peptide binding. Thus, it is important 
to derive a rule set for understanding and predicting these complex MHC-peptide 
interactions. The rule sets will then offer insights into the underlying dynamics of 
MHC-peptide interaction. 
In this thesis, we first summarise the biological and functional information of MHC 
Class I molecules, in particular the Human Leukocyte Antigen (HLA)-C molecules, 
and outlined the available structural information for HLA-C. Next, we derived an in 
vitro refolding assay, a two-step purification scheme and an optimised crystallisation 
approach for structural determination of novel HLA-C-peptide complexes and 
performed a comprehensive structural analysis. Finally, we reviewed the protein 
biochemistry properties of these novel complexes compared with the existing 
structures and discussed the functional implications of the similarities and differences.  
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1.1  Major Histocompatibility Complex (MHC) molecules 
1.1.1 Classification and subgroups 
The MHC region is located on chromosome 6 in humans and extends to about 4 x 106 
base pairs encoding for over 200 genes. There are basically 3 classes of MHC 
molecules. MHC Class I molecules are found on all nucleated cells and they play a 
key role in triggering the immune response upon viral infection through recognition of 
a wide repertoire of foreign peptides (Barouch et al., 1995; Pohlmann et al., 2004; 
Townsend and Bodmer, 1989). The MHC Class I genes are also responsible for 
encoding heterodimeric peptide-binding proteins as well as antigen-processing 
molecules such as the transporter associated with antigen processing (TAP) and 
tapasin.  
In humans, MHC Class I molecules can be sub-divided into classical and non-
classical molecules. The classical Human Leukocyte Antigens (HLA)-A, HLA-B and 
HLA-C genes are highly variable or polymorphic molecules that function mainly to 
present endogenous antigenic peptides to cytotoxic CD8+ T lymphocytes and target 
infected cells for destruction. The non-classical HLA-E, HLA-F and HLA-G genes 
have limited polymorphism and although they are also involved in peptide binding, 
their functions remain less well-understood (O'Callaghan and Bell, 1998).  
MHC Class II molecules present exogenously derived proteins such as fragments of 
bacterial cells or viruses that are engulfed and processed by an antigen-presenting cell 
to CD4+ helper T cells (German et al., 1996; Malnati et al., 1993). MHC Class II 
molecules are found mainly on antigen-presenting cells and are responsible for 
encoding heterodimeric peptide-binding proteins and proteins that modulate antigen 
loading onto MHC Class II proteins in the lysosomal compartment such as MHC II 
DM, MHC II DQ, MHC II DR and MHC II DP (Cresswell, 1994).  
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MHC Class III molecules, on the other hand, do not share the same function as MHC 
Class I and Class II molecules and they encode for other immune components such as 
the complement components (C2, C4, factor B) and molecules related with 
inflammation such as cytokines and heat-shock proteins (hsp) (Colten, 1984). 
1.1.2 Function 
The major function of MHC Class I molecules is to activate cytotoxic T lymphocytes 
for killing of cells compromised through environmental effects such as infection, 
irradiation, chemical modification or some other causes of malignancy. They perform 
their function by the presentation of peptides to cytotoxic T lymphocytes via the T-
cell receptor (TCR). This process is tightly regulated through the control of 
interactions between the cells and the TCR. HLA-A and HLA-B molecules are known 
to efficiently present a wide repertoire of viral peptides (Barouch et al., 1995) to the 
TCR whereas limited information about the association of HLA-C with peptides can 
be found despite the fact that HLA-C-restricted cytotoxic T lymphocytes (CTL) 
responses have been identified.  
Recently, increasingly more evidence shows that HLA-C is able to bind peptides and 
present them to the TCR to elicit a CTL response (Makadzange et al., 2010). Before 
the discovery of HLA-C-restricted CTL responses, peptide binding to HLA-C is 
usually associated with binding to killer-cell immunoglobulin-like receptors (KIR) 
found on the surface of natural killer (NK) cells (Colonna, 1996). This interaction is 
particularly important for the generation of inhibitory signals that will decide the fate 
of the infected target cell depending on the nature of the peptide which is presented. 
Nonetheless, allele-specific and peptide-dependent interactions between the KIR3DL1 




Taken together, presentation of different peptides to the TCR or KIR by various MHC 
Class I molecules will exert a different immunological response and may determine 
the outcome of cell fate.  
1.1.3 Antigen presentation pathway 
Assembly of MHC Class I molecules takes place in the lumen of the endoplasmic 
reticulum (ER) and is largely facilitated by chaperone proteins. The newly synthesised 
heavy chain binds rapidly to the transmembrane chaperone protein calnexin and 
associated oxidoreductases ERp57. Thereafter, binding of the β2-microglobulin (β2m) 
light chain occurs and calreticulin replaces calnexin (Garbi et al., 2005). Association 
of β2m to the heavy chain alters its conformation, greatly enhancing its ability to bind 
peptide and enter the peptide loading complex (PLC).  
The peptides that bind to MHC Class I molecules are produced mainly in the cytosol 
by a series of proteolytic events in the proteasome (Rock et al., 1994) as well as from 
the action of cytosolic peptidases (Saric et al., 2004; York et al., 2003). The 8 to 16-
residue peptides generated are then imported into the ER lumen by means of the TAP 
transporter (Ortmann et al., 1997). In the ER lumen, the ER aminopeptidase ERAAP 
may further trim the peptides to 8-9 residues (Serwold et al., 2001). Peptides of 8-10 
residues are optimal for MHC Class I binding and those peptides that match the 
binding requirements of the MHC Class I antigen binding groove may be loaded onto 
the Class I molecule through the help of the PLC.  
Together, the heavy chain-β2m heterodimer, calreticulin, Erp57, tapasin and TAP 
form the PLC and upon peptide binding, the assembled Class I molecule clusters at 
the ER exit sites and gets exported to the plasma membrane in a process involving 
export receptors (Garbi et al., 2005). In the event that a sub-optimally loaded Class I 
molecule is formed, recycling back to the ER occurs through the actions of tapasin 
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and/or calreticulin (Hsu et al., 1991). During recycling, peptide loading and 
optimisation occur until a high-affinity peptide is able to occupy the antigen binding 
groove.  
In some circumstances, antigens derived from the extracellular compartment can be 
presented on MHC Class I molecules and stimulate a T-cell response, in a process 
called cross-presentation. The mechanisms of cross-presentation remain unclear but 
the role of phagosomes and endosomes cannot be ruled out. Both phagocytosis and 
endocytosis, coupled with several other pathways, may allow access of exogenous 
proteins to the ER. Depending on the nature of the antigen, both processes can drive 
cross-presentation and lead to tolerance to self or immunity to virus.   
1.1.4 Structure 
Each of the HLA Class I alleles comprises of two polypeptide chains - the heavy 
chain and a non-covalently bound β2m light chain (Bjorkman et al., 1987). The 
45kDa heavy chain is folded into a short intracytoplasmic domain, a hydrophobic 
transmembrane portion and a major extracellular region arranged into three domains. 
These three domains are encoded by exons 2, 3 and 4 of the HLA Class I gene 
respectively.  
The α1 and α2 domains, held together by disulfide bridges, form an antigen binding 
groove made up of 2 α-helices resting on a sheet of 8 β-strands in which the antigenic 
peptides of 8-10 amino acids in length derived from proteins expressed within the cell 
can bind. The α3 domain is plasma membrane-spanning and interacts with the CD8 
co-receptor of the TCR (Bjorkman et al., 1987).  
The 12kDa β2m light chain is a non-MHC encoded protein that is invariant among the 
HLA Class I molecules. β2m, required for stable peptide binding (Sugita and Brenner, 
1994), extends diagonally beneath the α1α2 domains and maintains the overall 
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conformation of the HLA Class I molecule and the heavy and light chains are linked 
non-covalently via the interaction of the heavy chain α3 domain and β2m.  
1.1.5 HLA polymorphism 
The HLA gene is highly polymorphic and is thought to be maintained by natural 
selection for pathogen immunity. Polygeny and extensive polymorphisms at each 
locus contribute to the diversity of MHC molecules that are expressed by an 
individual. This results in many different alleles being expressed in different 
individuals in a population.  
HLA polymorphisms are mainly concentrated in the amino-terminal domains (α1 and 
α2 domains) which form antigen binding groove and this property creates specific 
clefts in which only certain types of peptides can bind. Variations in the amino acid 
sequences of these 2 domains are functionally advantageous for the binding of 
different antigenic peptides which may result in positive selection for certain 
replacement substitutions.  
Detailed sequence analysis of HLA molecules also shows that polymorphisms are 
concentrated on three regions, namely amino acid positions 62 to 83, 92 to 121 and 
135 to 157 which are known as the hypervariable regions (HVR) (Steinmetz and 
Hood, 1983). Accessible amino side-chains located on the α-helical regions can either 
interact with the peptide by pointing into the antigen binding groove or interact with 
the TCR by pointing up from the antigen binding groove. The properties of these 
residues may influence peptide specificity and in turn, affect T-cell recognition. 
Nonetheless, some important regions such as the α3 domain are conserved to maintain 
proper function. This is because amino acid changes in the α3 domains may abolish 
receptor interactions important for functions, leading to a negative selection against 
coding changes in exon 4. For instance, the α3 domain contains a conserved seven 
7 
 
amino acid loop (positions 223 to 229) which serves as a binding site for CD8 and the 
TAP interaction site between amino acid positions 219 and 233. Similarly, amino acid 
residue at position 227 in the α3 domain is critical for the interaction of MHC class I 
molecule with the chaperone calreticulin (Harris et al., 1998). Class I heavy chain 
residues of 77 to 83 of the α1 helix are also important in NK cell recognition 
(Gumperz et al., 1995). 
Hence, HLA polymorphism creates diversity in epitope specificity and T-cell 
repertoire by influencing both peptide binding and the contacts between TCR and the 
HLA molecule.  
1.1.6 HLA binding pockets 
The prominent groove between the α1 and α2 domain α-helices serves as a foreign 
antigen recognition site which binds a processed antigen in the form of a peptide. The 
antigen binding groove is about 25Å long by 10Å wide by 10Å deep and contains 6 
binding pockets or depressions designated pockets A-F, of diverse shape and 
composition (Saper et al., 1991). Each of the 6 pockets has a critical role in providing 
the specificity for interactions with the peptide side-chains and in turn, determines the 
properties of the bound peptide (Figure 1).  
In the well-studied HLA-A*02 structures, pocket A forms the extreme left boundary 
of the cleft and the pocket surface is prominently polar. Four conserved residues (Met 
5, Tyr 7, Tyr 59 and Tyr 159) can be found in pocket A which binds P1 position of 
the peptide. Of the conserved residues, 3 of the tyrosine residues have their hydroxyl 
group pointing into the antigen binding groove and this may be required for precise 
positioning of the peptide N-terminal end.   
Pocket B is entirely hydrophobic and this pocket is large enough to accommodate a 
Leu or Ile side-chain. Pocket B is proposed to be a primary anchor for peptide binding 
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as it forms a deep pocket in which the peptide side-chains can point into the HLA 
molecule. Furthermore, residues such as Tyr 7, Glu 63, Lys 66, His 70 and Tyr 99 
surround the rim of pocket B and are responsible for forming important interactions 
with the peptide.  
In HLA-A*02, there are no deep pockets in the center of the groove which explains 
why peptides bind in an extended or bulged-out conformation. This is because pocket 
C is a shallow depression, limited in size by residues such as Arg 97 and Phe 9 that is 
polar or bulky respectively.  
Both pockets D and E are hydrophobic but pocket D is deep enough to accommodate 
a P3 phenylalanine ring whereas pocket E is shallow. Hydrophobicity of pocket D is 
attributed by residues such as Tyr 99, His 114, Leu 156, Tyr 159 and Leu 160. Pocket 
E is located adjacent to pocket D and hydrophobicity is mainly contributed by 
residues such as Trp 147, Val 152 and Leu 156.  
The extreme right end of the cleft is defined by a large and polar pocket F whereby 
polar atoms found at the rim can make hydrogen bonds with the main-chain polar 
atoms of a peptide residue whose side-chains fit into the pocket (Saper et al., 1991). 
Residues surrounding pocket F include Thr 80, Tyr 84, Thr 143 and Trp 147. In 
addition, other residues such as Asp77, Tyr 116, Tyr 123 and Lys 146 line the pocket 
and are also responsible for making contacts with the C-terminal side-chain (P9) of 
the peptide which is lodged in pocket F. These hydrogen bond contacts are important 
in the stability of the MHC-peptide complex, making pocket F another primary 
anchor site for peptide binding. 
The P2 and P9 positions of the peptide, binding pockets B and F respectively, are 
known as anchor positions as these peptide positions are primarily occupied by a 
particular residue or by a few closely related residues (Carreno et al., 1993; Matsui et 
9 
 
al., 1993). The different MHC class I alleles are capable of binding a large number of 
peptides due to their polymorphism but the peptides may differ in their sequences but 
share two or three amino acid residues that fit into the anchoring pockets. This will in 








Figure 1 (A) Schematic diagram of the HLA-A*02:01 molecule. The 6 binding 
pockets are labelled A to F and indicated at various regions along the antigen binding 
groove. (B) Peptide interaction with HLA molecule viewed from the side of the 
antigen binding groove. The side-chains of amino acid residues in the peptide are 
labelled P1-P9 while the main-chain carbon atoms are indicated in closed circles. The 
P1, P4 and P5 side-chains of the peptide point towards the solvent and likely to 
interact with the T-cell receptor (TCR). The side-chains of P2, P3, P6 and P9 face the 
groove and are accommodated in the corresponding pockets. The amino (NH3+) and 
carboxyl (COO-) groups of the peptide interact with the residues lining pockets A and 
F respectively. (Saper et al., 1991) 
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1.1.7 Peptide-binding motifs 
The peptide-binding motifs of HLA-A molecules in particular the HLA-A*02 allele 
group are well-characterised. For instance, by peptide elution and mass spectrometry 
studies, HLA-A*02:01 showed a strong preference for hydrophobic amino acid 
residues such as Leu and Met at the P2 position and a Leu or Val at P9 position (Falk 
et al., 1991; Hunt et al., 1992). On the other hand, HLA-B*27 subtypes were 
demonstrated to bind peptides with Arg at the P2 position but have significant 
differences in their specificity for the P9 anchor residue (Lamas et al., 1999). The 
peptide-binding motifs of HLA-C molecules are not well-studied but preliminary 
results showed that HLA-C molecules present a set of viral peptides that are not 
efficiently presented by HLA-A and HLA-B (Neisig et al., 1998). With only a few 
sets of pool sequencing studies being done, the set of peptides derived for HLA-C 
showed a preference for a Asp and/or Glu at the P4 position, a hydrophobic residue 
such as Tyr as an auxiliary anchor at the P6 and P9 position (Falk et al., 1993). 
However, these set of studies are thought to be weak and tentative as the studies were 
limited to peptides that the cells could process intra-cellularly and present on the cell 
surface. In addition, expansion of peptide elution studies to alleles other than those 
frequently studied will aid in the understanding of HLA-C peptide binding specificity.  
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1.2 Human Leukocyte Antigen (HLA-C) 
For the past few decades, functional and structural knowledge about MHC Class I 
molecules have always focused on HLA-A and HLA-B molecules. This is because of 
their high sequence polymorphism as well as their dominating presence at the cell 
surface. In contrast, the HLA-C allele group is deemed to be of minor importance due 
to its limited sequence polymorphism and low surface expression. As such, HLA-C 
has often been neglected in immunology studies as well as in disease association 
studies.  
However, recent research developments point out the emerging role of HLA-C as a T-
cell restriction element and further support the involvement of HLA-C in negative 
regulation of cytotoxicity through KIR interaction. This inhibitory function serves as 
an essential component of the immune system to prevent autoimmunity and disease 
developments. Therefore, the in-depth study of HLA-C molecules should be put forth 
for better understanding of the roles of MHC Class I molecules in immunology. With 
the increasing amount of functional data and limited structural information on HLA-C, 
it is of interest to explore and explain the functional aspect of HLA-C through 
structural characterisation.   
1.2.1 Global distribution of HLA-C 
HLA-C allele frequencies vary between populations and contribute towards diversity 
and functional variation in immune responses to viruses. The Allele Frequency Net 
Database [http://www.allelefrequencies.net/] (Middleton et al., 2003) compiles the 
allele frequencies at various regions of different populations and serves as a central 
source for obtaining immune gene frequencies in worldwide populations. Searches in 
the HLA section have enabled the collation of data with regards to the genotype, 
haplotype or allele frequency of each HLA-C allele in the collection of populations. 
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Based on the currently available information of all the HLA-C alleles being typed, a 
range of HLA-C alleles that is occurring on a high frequency worldwide can be 
compiled (Figure 2). Distribution of HLA-C is likely to be related to natural selection 
that is associated with its function in antigen presentation and driven by selective 
advantages provided by some alleles that confer resistance to infections of some 
pathogens. These common alleles account for the diversity of HLA-C and will 
therefore be of general interest to characterise them in terms of function and structure. 
In addition, the strong linkage disequilibrium of HLA-C with HLA-B also resulted in 
the most common HLA-C alleles having strong associations with the most frequent 
HLA-B alleles of each population. For instance, in the Caucasian population, the 
HLA-C*07:01, HLA-C*07:02 and HLA-C*05:01 alleles can be found in strong 
associations with HLA-B*08:01, HLA-B*07:02 and HLA-B*44:02, respectively (Cao 
et al., 2001). As a consequence, this adds on another level of complexity for accurate 


















Figure 2 World map illustrating the global distribution of the HLA-C alleles chosen 
for our study. Alleles with a high frequency occurrence in major regions of the world 
were selected and cloned for refolding studies (Middleton et al., 2003).  
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1.2.2 Polymorphism of HLA-C 
There exist distinctive patterns of polymorphism at the HLA-A, -B and –C loci. 
Pairwise sequence comparisons showed that, in comparison with HLA-A and HLA-B, 
the HLA-B and HLA-C locus products are thought to be more closely related. This 
comparison, together with the strong linkage disequilibrium of HLA-B and HLA-C, 
highlights that antigenic stress is driving the evolution of HLA-C. Furthermore, it can 
be hypothesised that HLA-B and HLA-C are the products of a more recent 
duplication, with the earlier events forming HLA-A molecules and the common 
ancestor of HLA-B and HLA-C. As such, HLA-C molecules have functional and 
structural properties that are intermediate between those of HLA-A and HLA-B and 
share common sequence elements with HLA-A and HLA-B.  
The α1 domain in HLA-C molecules is unusually conserved whereas the α2 domain 
shares the highest degree of similarity with HLA-B. This sequence conservation may 
indicate that HLA-C molecules respond to antigenic pressures differently from HLA-
A and HLA-B molecules. Indeed, sequence analysis of 26 alleles of the HLA-C locus 
also revealed that HLA-C alleles were more closely related to each other as there were 
less variation in residues of the antigen binding groove and more variation at other 
positions (Zemmour and Parham, 1992). In particular, the KYRV motif of residues 66, 
67, 69 and 76 of the α1 helix and the Gly at the base of the B pocket (position 45) 
were conserved in all HLA-C alleles. These unique polymorphic features may affect 
the peptide binding affinities and also TCR binding through conformationally-induced 
changes at the sites of interaction. Moreover, these features confer restriction of the 
peptide repertoire bound to the HLA-C molecule and this may in turn reduce the 
efficiency of HLA-C assembly and expression at the cell surface.  
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More recently, sequence-based typing of 1823 HLA-C types provided new insights to 
HLA-C diversity (Turner et al., 1998). Apart from the conserved α1 helix, a 
conserved Gly residue at position 45 and clustering of unique polymorphisms around 
the Gly 45 pocket, the sequence-based typing analysis also showed that a 
heterozygous state is favoured at the HLA-C locus. This observation is similar to the 
HLA-A and HLA–B loci, although more conclusive evidence can be drawn if the 
study population can be extended to a non-Caucasian group.  
Moreover, there was a predominance of coding substitutions found in the peptide 
binding site (α1 and α2 domains) that resulted in new HLA-C alleles being formed 
under selective pressure. At the same time, coding substitutions at the α3 domains 
may be selected against due to the importance of this domain in receptor recognition, 
reiterating the functional significance of HLA-C.  
Apart from the accumulation of point substitutions in HLA-C allele sequences, 
diversification of HLA-C alleles also occurred via segmental exchanges involving 
recombination of various segments of different alleles. For example, HLA-B*46 and 
HLA-B*54 arose as a result of recombination of HLA-C*01 with HLA-B*15 and 
HLA-B*55, respectively. Specifically, HLA-B*46:01 was formed by through an 
inter-locus recombination of residues 66-76 of the α1 helix of HLA-B*15:01 with the 
homologous segment of HLA-C*01:02 (Barber et al., 1996). This feature can 
potentially bring about increased peptide selectivity as HLA-B*46:01 possesses the 
characteristic structural elements of both HLA-B and HLA-C molecules. The HLA-
B*46 and HLA-C*01 allotypes have a frequency of as high as 20% in south-east 
Asian populations and their similar geographical distribution may imply strong 
functional and geographically-associated selection for maintaining both HLA-B*46 
and HLA-C*01.  
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1.2.3 Functions of HLA-C  
The binding of peptides to the antigen binding groove of HLA-A and HLA-B 
molecules can be thought to be the key event in T-cell activation. However, the 
binding of peptides to HLA-C may mediate antigen-specific T-cell responses as well 
as play a role in NK cell activation. However, there are few instances of HLA-C-
specific CTL responses being characterised. To date, HLA-C-restricted CTL 
responses have only been reported for Epstein-Barr virus (EBV) (Chen et al., 1989), 
Human Immunodeficiency Virus (HIV) (Makadzange et al., 2010) and Influenza and 
Sendai viruses (Dill et al., 1988). Therefore, the major role of HLA-C molecules can 
be thought to be in acting as a ligand for KIR receptors expressed on NK cells.  
Regardless of this, it is likely that HLA-C-restricted CTL may have been undetected 
or underestimated (if present) for various reasons. First, the low surface expression of 
HLA-C molecules and possibly the presence of HLA-C serological blanks impeded 
accurate HLA-C typing. A second potential source of underestimation may occur as a 
result of the close linkage disequilibrium between certain HLA-C and HLA-B alleles. 
Therefore, an HLA-C-restricted CTL response may be attributed to HLA-B if the 
HLA-C allele cannot be detected by serological methods.  
Nonetheless, increasing HLA-C alleles have been implicated to the susceptibility of 
various human diseases despite their low surface expression and limited molecular 
analysis. It is however unclear whether the relationship is a result of HLA-C 
functioning as a T-cell restriction element or due to HLA-C/KIR interactions.  
As seen from the available crystal structures, the precise contact regions differ for the 
TCR and KIR. From the first crystal structure of KIR2DL2 bound with HLA-C*03 
and a nonameric self peptide GAVDPLLAL from importin-α1, it was found that 
KIR2DL1 bound to HLA-C in a 1:1 stoichiometry. In addition, KIR2DL2 binds 
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across both the α1 and α2 helices of HLA-C with its long axis nearly orthogonal to the 
peptide binding site. Binding is mostly centered over the P7-P8 positions at the C-
terminal end of the peptide (Boyington et al., 2000). Similar observations were 
reported in the second crystal structure of KIR2DL1 complexed with HLA-C*04:01-
QYDDAVYKL (Fan et al., 2001). Therefore, residues 7 and 8 of the peptide serve as 
sites for KIR recognition (Boyington and Sun, 2002).  
On the other hand, the TCR interacts with the central region of the bound peptide at 
residues 4-6. There is hence a slight overlap of the two footprints and it is 
theoretically impossible that a HLA-C molecule can simultaneously engage both a T-
cell and an NK cell. So at any one time, the HLA-C molecule can only bind to either a 
T-cell or an NK cell to allow HLA-C to fulfill the recognition requirements for both 
the innate and adaptive immune systems.  
1.2.4 HLA-C interaction with Killer-cell Immunoglobulin-like Receptors (KIRs) 
The KIR receptors recognise HLA-C molecules as ligands depending on the structural 
basis of HLA-C molecules. Polymorphic HLA-C alleles can broadly be classified into 
the C1 and C2 subgroups according to the dimorphic residues 77 and 80 in the α1 
helix of HLA-C. Alleles in the C1 subgroup is characterised by a Ser at position 77 
(S77) and Asn at position 80 (N80) whereas alleles in the C2 subgroup has an Asn at 
position 77 (N77) and Lys at position 80 (K80) (Biassoni et al., 1995; Mandelboim et 
al., 1996).  
Inhibitory receptors KIR2DL1, 2DL2 and 2DL3 are specific for HLA-C: KIR2DL1 
binds alleles belonging to the HLA-C2 subgroup while KIR2DL2 and 2DL3 bind 
HLA-C alleles belonging to the C1 subgroup (Winter and Long, 1997). The different 
HLA-C/KIR interactions differ in their binding affinities and some HLA-C/KIR 
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combinations have been linked with the outcome of various diseases (Rajagopalan 
and Long, 2005).   
KIR spans the 2 α-helices of the HLA-C molecule with its binding site shifted 
towards the C-terminal part of the peptide. This KIR footprint is dominated by 
charged and hydrophilic interactions that are present at the HLA-C/KIR interface. 
These interactions are mainly provided by the residues that are exposed on the surface 
of the HLA-C molecule and also of the bound peptide. Therefore, peptides with 
different biochemical properties will have different abilities to enable a functional 
interaction between HLA-C and KIR due to the charge complementarity found at the 
HLA-C/KIR interface.  
Due to the KIR footprint, there is also a P7 and P8 preference of the bound peptide 
that will confer another level of specificity to the HLA-C/KIR interaction. In 
particular, charged residues such as Asp or Arg are mainly preferred at P7 position 
whereas Glu or Lys at P8 position rendered target cells more susceptible to lysis.  
Recognition of HLA-C molecules by inhibitory KIRs generally leads to the 
generation of a negative signal in NK cells to inhibit cell lysis (Long et al., 2001). In 
the event of virus infection, surface expression of HLA Class I molecules gets down-
regulated and this will mediate the destruction of infected cells as there are less 
negative signals to inhibit lysis.  
1.2.5 HLA-C disease associations 
HLA-C alleles have been implicated in a number of human diseases but it is often not 
always clear whether the HLA-C disease associations are a result of HLA-C acting as 
a T-cell restriction element or because of its interaction with KIR.  
Despite the fact that HLA-C is assumed to play a key role in mediating NK cell 
responses, increasingly more HLA-C-restricted CTL responses have been identified 
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and these CTL responses are particularly relevant in chronic infection settings. The 
CTL responses also extend to more viruses other than EBV, HIV, Influenza and 
Sendai viruses. For example, short peptide sequences from the Cytomegalovirus 
(CMV) pp65 antigen have been identified as HLA-C CTL epitopes for alleles such as 
HLA-C*04 and HLA-C*06 in ELISPOT assays (Bihl et al., 2005). Similarly, 
melanoma-associated CTL epitopes from the MAGE-A3 proteins have also been 
linked with HLA-C*07 (Breckpot et al., 2004), reiterating the role of HLA-C as a T-
cell restriction element.   
Nonetheless, it is clearly evident that some disease associations are due to different 
combinations of HLA-C/KIR interactions. For instance, there is a strong association 
between the presence of KIR2DL3, along with homozygosity for the C1 group of 
HLA-C molecules in a large population of Hepatitis C Virus (HCV)-exposed 
individuals. The KIR2DL3/HLA-C1 interaction, determined by KIR and HLA 
genotyping experiments, is also correlated with clearance of HCV infection (Khakoo 
et al., 2004).  
More recently, it was demonstrated that different KIR and specific HLA-C gene 
combinations can confer susceptibility to or protection against chronic hepatitis B 
(Gao et al., 2010). Combinations of the inhibitory receptor KIR2DL1 with HLA-C2 
ligand will confer susceptibility to chronic hepatitis B whereas the inhibitory receptor 
KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype will 
result in protection against chronic hepatitis B. All these suggest that different HLA-
C/KIR combinations have a role to play in antiviral immunity and the distinct affinity 




A number of autoimmune diseases also show HLA-C associations. The HLA-C*06 
allele has frequently been linked with increased susceptibility to psoriaritic arthritis by 
candidate gene studies and genome-wide association studies (Ho et al., 2008).  
Individuals expressing the HLA-C*06:02 allele tend not only to have an early onset of 
disease but also a more extensive and severe skin disease. Alleles such as HLA-
C*07:01 have also been implicated in Type I autoimmune hepatitis (Strettell et al., 
1997). There was an increased frequency of HLA-C*07:01 which contributes to 
disease susceptibility, perhaps by interaction with the cytotoxic T lymphocytes or 
natural killer cells.  
1.2.6 Characteristic features of HLA-C  
The major distinguishing feature of HLA-C from HLA-A and HLA-B is its low 
expression level at the cell surface. The levels of HLA-C transcripts vary from those 
of HLA-A and HLA-B depending on the type and function of the immune cells and 
also the nature of immune response. However, in cells whereby HLA-C mRNA levels 
are the same, cell surface expression is only about 10% of the average level of HLA-
A and HLA-B.   
As such, there are many speculations revolving this unique feature and they include 
lower levels of HLA-C mRNA, poor assembly of the HLA-C heavy chain with β2m 
and restricted peptide binding. First of all, the reduced surface expression of HLA-C 
was proposed to be attributed to the faster turnover rate of HLA-C mRNA transcripts 
(McCutcheon et al., 1995). The rate of HLA-C heavy chain biosynthesis and faster 
degradation compared to the HLA-A and HLA-B transcripts were thought to be 
driven by regulatory elements found on the HLA-C sequence that resulted in lower 
amounts of transcripts being available for translation.  
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The second view was supported by evidence that the HLA-C heavy chain assembled 
poorly with β2m leading to an accumulation of folding intermediates free of β2m in 
the ER (Neisig et al., 1998). Poorly assembled HLA-C heavy chains remain 
associated with calnexin and will be degraded in the ER. Thus, not many properly-
folded HLA-C-peptide complexes can be exocytosed to the cell surface for expression. 
On the other hand, some HLA-C heavy chains do bind to β2m and become assembled 
but HLA-C being more restrictive in terms of peptide binding, required a 10-fold 
higher concentration of peptide for release of HLA-C from TAP (Neefjes and Ploegh, 
1988). The stable association with TAP similarly results in slower exocytosis and 
reduced surface expression.  
Furthermore, even before the structure of HLA-C is resolved, HLA-C has been found 
to be structurally homologous to the HLA-A and HLA-B antigens through serological 
and molecular studies (Snary et al., 1977). However, there exist conserved HLA-C-
specific sequence motifs and/or limited polymorphism in the antigen binding groove 
compared to its counterparts that contribute to the restricted peptide binding property 
of HLA-C. For these reasons, the plasticity of the antigen binding groove is greatly 
reduced by the limited range of peptides that could bind. Hence, the low surface 
expression may be a consequence of the HLA-C heavy chain interacting with TAP in 
a prolonged manner while waiting for the right peptide to bind.  
Another characteristic feature of HLA-C molecules is the presence of conserved 
residues in the α1 and α2 domains that limit the binding peptide repertoire. In the α1 
domain, there is a unique KYRV motif of residues 66, 67, 69 and 76 and a conserved 
Gly 45 residue (Zemmour and Parham, 1992). In addition, the presence of 4 HLA-C-
unique residues (170, 173, 175 and 177) and reduced diversity at the B pocket of the 
antigen binding groove also correlate with binding of a restricted set of peptides 
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compared with HLA-A and HLA-B molecules. In this manner, the efficiency of HLA-
C assembly and expression at the cell surface may be reduced.  
1.2.7 HLA-C binding pockets 
Previously, 6 binding pockets or sites have been defined in the grooves of human 
MHC Class I molecules and of which, some are likely to be involved in peptide 
anchoring (Saper et al., 1991). In the known structures of HLA-C, pockets interacting 
with P2 and P9 of the peptide act as primary anchors whereas the remaining pockets 
for P1 and P7 positions serve as secondary anchors (Fan and Wiley, 1999). 
Characteristics such as the size, polarity and hydrophobicity of the amino acid side-
chains that line the antigen binding groove directly influence the peptide sequence 
that can bind and in turn, define a peptide-binding motif.  
The precise position of the peptide N-terminal is achieved by conserved residues such 
as Tyr 7, Tyr 159 and Tyr 171 that form hydrogen bonds with the peptide. Presence of 
these bulky tyrosine residues also limits the size of pocket A to allow the 
accommodation of only medium-sized polar P1 residues.  
There are basically two functional groups of residues in pocket B. The first group of 
residues surrounds the rim of the pocket and the polar side-chains of the amino acids 
(Tyr 7, Glu 63, Lys 66, Gln 70 and Tyr 99) help to establish the hydrogen bonds with 
the peptide backbone atoms at position 2. The second group of residues is mainly 
located on the inner wall (Gly 45, Tyr 67) and the bottom (Tyr 9, Ala 24, Val 34) of 
the antigen binding groove. These residues create a hydrophobic environment for the 
insertion of a non-polar side-chain of the peptide. This is in line with the P2 
preference of Leu or Met in HLA-A*02 molecules where the hydrophobic pocket is 
formed by Met 45 and Val 67 on the inner wall and Phe 9, Ala 24, Val 34 on the 
bottom of pocket B (Parker et al., 1992).  
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Furthermore, the conserved Glycine at amino acid 45 on the α1 helix of HLA-C 
molecules is also important in determining the allele-specific peptide-binding motif. 
The peptide-binding motif of HLA-C remains uncharacterised for many years until 
recent technological development. Pool sequencing of peptides eluted from cell lines 
revealed an extensive consensus motif of a few HLA-C alleles that prefer bulky 
residues such as Phe, Tyr or Pro at the P2 position (Falk et al., 1993). The small Gly 
45 side-chain possibly permitted for accommodation of the large and bulky side-
chains into pocket B. This phenomenon is also observed for HLA-B*27. Elution of a 
pool of endogenous peptides bound to HLA-B*27 revealed a preference for an Arg 
residue at the P2 position of the peptide and this is attributed to the presence of a 
negatively charged Glu 45 (Jardetzky et al., 1991).  
1.2.8 HLA-C peptide-binding motifs 
The peptide-binding motifs of HLA-C are not as well-studied as HLA-A and HLA-B 
molecules and there are only a few papers that the peptide-binding motif of HLA-C 
can be inferred. This is because, for many years, molecular analyses of HLA-C alleles 
have been impeded by limitations such as low surface expression and technical 
difficulties in protein isolation, purification and characterisation. But with the 
development and progress of cloning techniques, the physiological relevance of HLA-
C begins to be uncovered.  
Even so, the HLA-C peptide-binding studies are only restricted to a limited number of 
alleles. For instance, the consensus motifs of HLA-C*03:01, C*04:01, C*06:02 and 
C*07:02 have been determined by pool-sequencing of peptides eluted from cell lines 
(Falk et al., 1993). However, the identified motif was thought to be weak and tentative 
as these studies were limited to peptides that the cells could process intra-cellularly 
and present on the cell surface. Thereafter, a more extensive binding motif for alleles 
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such as HLA-C*04:02, C*06:02 and C*07:01 has been reported whereby the use of 
recombinant molecules overcomes the problem of peptide processing to give a more 
accurate representation of the peptide binding rules of HLA-C (Dionne et al., 2004).  
Interestingly, some of the peptide epitopes can be restricted by both HLA-A and 
HLA-C. For instance, the Cytomegalovirus (CMV) pp65-specific epitope, 
QYDPVAALF (amino acids 341-349) can be restricted by both HLA-A*24:02 and 
HLA-C*04:01 (Gillespie et al., 2000). The two alleles may share a similar peptide-
binding motif of having a Tyr at P2 and Leu or Phe at P9 and this confers great 
advantages in the field of immunotherapy whereby populations have both the alleles.  
Additionally, it was observed that many HLA-C ligands do not have a dominant P2 
anchor but have dominant and strong anchors in the P4-P6 positions of the peptide 
(Mandelboim et al., 1996). This could be due to the unique cluster of HLA-C residues 
on the floor of the peptide binding site near the Gly 45 pocket that affects the 
positioning of the peptide near the end of the α2 helix.  
Taken together, although primary anchors are necessary for peptide binding, these 
anchors are not sufficient for high affinity peptide binding, suggesting that secondary 
anchors may have a significant role in peptide binding.  
The role of secondary anchor residues for HLA-C molecules has not been defined 
conclusively but it can be predicted to be in good agreement with HLA-A*02 
molecules. Previously, the use of quantitative molecular binding assays and a 
chemically synthesised library of naturally occurring epitopes had proposed 




1.2.9 Thermal stability of MHC molecules 
The secondary structures of HLA molecules can be examined by circular dichroism 
(CD) spectroscopy. Circular dichroism spectrometry measures the thermal stability of 
HLA molecules and the ellipticity at 218nm is representative of the amount of 
secondary structures present in the protein. In general, a more stable complex will 
require a higher destabilisation temperature to see an increase in ellipticity at 218nm. 
This technique is widely used for determination of the thermal stability of HLA-A and 
HLA-B molecules.  
The thermal stabilities of several HLA-A*02 molecules have been determined by CD 
(Liu et al., 2011). It was found that thermal stabilities of these molecules is in the 
order of HLA-A*02:06>HLA-A*02:07>HLA-A*02:01>HLA-A*02:03. This supports 
the findings of in vitro experiments that investigated the functional presentation of the 
HBV Core 18-27 peptide in a Chinese population that expresses the same few alleles 
(Tan et al., 2008). Pulsing EBV cell-lines expressing the various HLA-A*02 subtypes 
with the HBV Core 18-27 peptide stimulated T-cell activation in a similar pattern, 
where cells expressing HLA-A*02:03 exhibited minimal T-cell activation.  
Similarly, CD spectroscopy has proven to be useful in thermodynamic and structural 
studies of HLA-B*27 molecules. HLA-B*27:05 is frequently being associated with 
susceptibility to autoimmune inflammatory diseases and it is postulated that misfolded 
and unfolded complexes may be responsible for this association (Reinelt et al., 2001). 
This observation was confirmed by thermal denaturation experiments done by CD 
spectroscopy where a single amino acid can influence the unfolding process of HLA-
B*27:05 in a subtype-specific and pH-dependent manner. As such, application of CD 
spectroscopy technique to HLA-C molecules may offer insights into the thermal 
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stability of HLA-C-peptide complexes and allow comparison with known HLA-
peptide complexes. 
1.3 Protein crystallisation  
1.3.1 Protein crystallisation methods 
The functions of proteins are often determined by their three-dimensional structures 
and protein crystallography plays a key role in contributing to structural information 
and functional inferences. However, the protein crystallisation of HLA-C has not been 
very successful, with only 3 HLA-C crystal structures being available to date 
(Boyington et al., 2000; Fan et al., 2001; Fan and Wiley, 1999). The low surface 
expression of HLA-C and inability to correctly serotype HLA-C alleles impacted on 
the ability to obtain a concentrated pure protein solution during the protein 
purification process. Furthermore, finding an optimal crystallisation condition remains 
a challenge for many crystallisation projects whereby screening trials to expose the 
HLA-C-peptide complex to a variety of agents have to be performed in order to find a 
condition that may be conducive for crystallisation. Thereafter, an optimisation 
experiment to vary the protein concentration, type and concentration of precipitant, 
pH or temperature or even the addition of additives has to be done to obtain a 
diffraction-quality crystal.  
One method of crystallisation is vapour diffusion whereby the protein drop is either a 
hanging drop or sitting drop that equilibrates against a reservoir containing 
crystallising agents that are of either higher or lower concentrations than in the drop. 
The vapour diffusion method is the most commonly used method but it suffers from a 
number of problems such as the requirement for a large protein quantity and the 
uncontrollable change in drop volume and exact composition during crystallisation. 
Other methods include microscale batch experiments, dialysis, free interface diffusion 
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(FID) and microfluidics but the choice of methods largely depends on sample quality 
and quantity.  
For these reasons, crystallisation of HLA-C together with a binding peptide might be 
a technical challenge but nonetheless, there are currently 3 crystals of HLA-C crystals 
available in the Protein Data Bank (PDB) (Boyington et al., 2000; Fan et al., 2001; 
Fan and Wiley, 1999).  
Upon obtaining a big and well-ordered crystal of diffraction quality, it is then crucial 
to devise a method to carefully mount the crystal onto the cryo-loop and collect a 
large oscillation angle image during X-ray diffraction.   
1.3.2 X-ray crystallography 
For many years, X-ray crystallography has enabled the visualisation of protein 
structures at atomic levels and more than 85% of the known protein structures are 
determined by X-ray crystallography. This is because structural determination at a 
high resolution has facilitated the detailed understanding of protein-ligand interactions, 
conformational changes induced by ligand binding and the mechanisms of biological 
processes at a molecular level.  
The crystal is first mounted onto a cryo-loop after soaking in a cryoprotectant. This 
step is fundamental as data collection is done at cryo-temperatures and long-term 
exposure to low temperatures may cause radiation damage. Subsequently, after 
correctly aligning the crystal to the X-ray source, monochromatic X-rays produced 
from an X-ray generator or a synchrotron may be directed at the crystal. The 
diffracted waves can be recorded by a suitable detector and the scattered waves may 
reinforce one another at certain points to give rise to diffraction spots. The crystal can 
be gradually rotated during the data collection process and the position and intensity 
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of each spot taken at different rotations will contain information about the atoms from 
the crystal.  
The intensity of each diffracted ray can be converted into a three-dimensional 
electron-density map using the mathematical Fourier transform principle. The 
electrons surround the atoms in a uniform manner and hence, it is possible to locate 
the atoms and fit the amino acid side-chains into the electron-density map. Protein 
crystals generally exist as three-dimensional well-ordered structures that exist as 
repetitions of identical unit cells. The dimensions of an unit cell can be described by 3 
edge lengths (a, b, c) and 3 angles (α, β, γ). These properties of an unit cell and the 
inherent symmetry within the protein crystal will ultimately determine the position 
and intensity of the diffraction spots.  
With the detailed electron-density map obtained, a crystallographic model can be built 
upon the basis of the shape of the electron density using a search model. As there are 
currently 3 crystal structures of HLA-C bound with a peptide, the structures can serve 
as search models for model building. The molecular replacement method may then be 
employed to determine the orientation and positions of the molecules within the unit 
cell.   
1.4 Crystal structures of HLA-C 
1.4.1 HLA-C*04:01 complexed with QYDDAVYKL (1QQD) 
In 1999, the first crystal structure of HLA-C, HLA-C*04:01 complexed with a 
nonameric consensus peptide with sequence QYDDAVYKL, was determined to 2.9Å 
resolution (Fan and Wiley, 1999). Crystallisation was achieved with the hanging drop 
vapour diffusion method and was optimised with 12% polyethylene glycol (PEG) 
8000, 0.2M calcium acetate and 0.1M sodium cacodylate, pH 6.5 as the reservoir 
solution at 18ºC. 
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The peptide was derived from a consensus peptide motif determined by pool- 
sequencing (Falk et al., 1993) and included an aromatic residue or Pro for P2, the 
frequent use of Glu and Asp at P4, a hydrophobic auxiliary anchor at P6 and a 
hydrophobic C-terminal anchor position. Peptide residues P4 and P8 are mostly 
exposed and P3 and P4 form the kink in the peptide main-chain conformation that has 
been observed for many known structures of peptide-bound MHC Class I molecules. 
In addition, peptide residues at P7 and P8 appeared to affect the binding of KIR 
directly and the interaction was abolished when the residues at these positions became 
negatively charged. Furthermore, the bound peptide conformation was found to be 
stabilised by internal hydrogen bonding among peptide residues and the peptide side-
chains mainly fit into 4 specificity pockets. The C-terminal of the α1 helix was also 
seen to form a potential KIR binding site on HLA-C*04. 
The 4 specificity pockets (P1, P2, P7 and P9) in HLA-C*04:01 contained conserved 
residues which were responsible for peptide anchoring and these results may suggest 
the role of primary and secondary anchors in peptide binding. The interactions 
between pocket residues and the peptide may exert profound influence in determining 
the bound peptide conformation.  
1.4.2 HLA-C*04:01 complexed with QYDDAVYKL and KIR2DL1 (1IM9) 
In 2001, the same research group solved the structure of the HLA-C*04:01-
QYDDAVYKL complex coupled to the KIR2DL1 inhibitory receptor to 2.8Å 
resolution (Fan et al., 2001). The crystals of the KIR2DL1-HLA-C*04 were grown at 
4ºC in 5% polyethylene glycol (PEG) 6000, 80mM magnesium chloride, 6% glycerol 
and 50mM [N-(2-acetamindo)iminodiacetic acid] (ADA) at pH 6.5 with 12mg/ml of 
KIR2DL1 and HLA-C*04 at a 1:2 molar ratio using the hanging drop vapour 
diffusion method.  
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As observed from the structure, the C2 specificity between HLA-C*04:01 and 
KIR2DL1 was achieved by the polar and hydrophobic interactions between Met 44 in 
KIR2DL1 and Lys 80 of HLA-C*04 within a specificity pocket. The structure also 
revealed a 1:1 stoichiometry between HLA-C*04 and KIR2DL1. In addition, the 
KIR2DL1-HLA-C*04 interface exhibited charge complementarity whereby basic 
HLA-C*04 residues bound to the electronegative binding surface of KIR2DL1 made 
up of acidic residues. Shape complementarity was also evident at the interface. 
Furthermore, the group determined a minimal role of the peptide in interacting with 
KIR as there was no conformational change in the bound peptide upon receptor 
binding. Nonetheless, the significance of P7 and P8 residues remained indisputable 
through examination of surface accessibility of these 2 peptide residues.  
1.4.3 HLA-C*03:04 complexed with GAVDPLLAL and KIR2DL2 (1EFX) 
In 2000, an independent research group solved the structure of HLA-C*03:04 
complexed with GAVDPLLAL and KIR2DL2 (1EFX) by molecular replacement 
methods and refined the structure to 3.0Å resolution (Boyington et al., 2000). 
Crystallisation was done using the hanging drop vapour diffusion method with the 
conditions set at 6% polyethylene glycol (PEG) 20,000, 50mM calcium chloride and 
50mM sodium cacodylate at pH 6.5, 25ºC.  
The structure revealed the nearly orthogonal orientation footprint of KIR2DL2 across 
the α1 and α2 helices of HLA-C*03 and further highlighted the importance of 
positions 7 and 8 of the peptide. The importance of charge complementarity at the 
HLA/KIR interface was also demonstrated in surface plasmon resonance (SPR) 
experiments where disruption of salt-bridge formation reduced the binding affinity for 
KIR. This emphasised the crucial role of charge in establishing HLA recognition and 
the low tolerance to mutations of contact residues present at the interface. 
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Furthermore, specificity of the interaction was conferred by a hydrogen bond between 
Lys 44 of KIR2DL2 and Asn 80 of HLA-C*03. This structure also revealed a 1:1 




1.5 Aims and significance of project 
Structural analysis has remained a strong focus in the understanding of the molecular 
mechanism of HLA-C/KIR or HLA-C/TCR interactions. Current understanding of the 
HLA-C/KIR interactions or even HLA-C-restricted T-cell responses has been well-
established by many genetic studies. However, the functional mechanisms and 
structural elements of these epidemiological associations remain poorly defined.  
The only 3 available crystal structures of HLA-C deposited in the Protein Data Bank 
(PDB) (Boyington et al., 2000; Fan et al., 2001; Fan and Wiley, 1999) have provided 
much insight into the specificity of interaction and may be used to explain the 
physiological importance of the HLA-C in disease associations. 
However, since the deposition of the last structure in 2000, there has not been any 
crystal structures of HLA-C published or deposited into PDB. The extension of 
crystallisation efforts to other HLA-C alleles will allow further characterisation of the 
properties that underlie the differences in peptide binding of HLA-C compared with 
HLA-A and HLA-B. Nonetheless, the inability to obtain HLA-C crystals may be 
complicated by the technical difficulties associated with low surface expression of 
HLA-C and also problems in protein isolation.  
Thus it is the main aim of this project to derive a set of optimal experimental 
conditions to obtain a novel HLA-C-peptide crystal structure (Figure 3). In order to 
achieve the aim, it is necessary to first establish a highly efficient cloning and 
homogenous refolding assay that overcomes the shortcomings of previous assays. In 
addition, a high refolding yield is crucial for high-throughput purification of HLA-C-
peptide complexes. Thereafter, crystallisation screens and optimisation can take place 
to obtain a crystal of X-ray diffraction quality from which structural information can 
















Figure 3 Proposed workflow to obtain an optimal set of cloning, refolding, 
purification and crystallisation conditions.  
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Cell culture 
A total of 18 commonly occurring HLA-C alleles were chosen for the study and a 
panel of EBV-transformed B-Lymphoblastoid cells containing the gene of the allele 
of interest was cultured for cloning purposes.   
The suspension cell lines were cultured at 37oC, 5% CO2, in RPMI 1640 medium 
supplemented with 10mM Hepes, pH 7.0 and 10% FBS and cells were harvested 
when confluent. A total of 1x106 cells were pelleted down at 300 x g for 5min at 4oC, 
washed with 1 x phosphate buffered saline (PBS) buffer and removed of any residual 
medium before storage of the cell pellet at -80oC until further handling. 
2.2 Cloning of HLA-C gene into bacterial expression vector 
2.2.1 RNA extraction 
Total RNA extraction was carried out using the RNeasy Mini Kit (Qiagen Gmbh, 
Hilden, Germany) as per the manufacturer’s instructions with addition of 600µl of 
Lysis Buffer RLT provided by the kit. Total RNA was eluted from the spin column 
using 40µl of RNase-free water. To improve the RNA quality, the sample was 
incubated at 70oC for 10mins and then on ice for 2mins before cDNA synthesis. 
Alternatively, the RNA sample can be stored at -20oC for longer periods.  
2.2.2 cDNA synthesis 
The RNA concentration was determined using the Nanodrop 1000 Spectrophotometer 
(Thermo Fisher Scientific) and approximately 2µg of template RNA was used for a 
20µl reaction volume. cDNA synthesis was carried out using the OmniscriptTM 





2.2.3 Polymerase Chain Reaction (PCR) primers design 
The sequences corresponding to exons 2 to 4 of all 18 HLA-C alleles were aligned 
using the DNASTAR Lasergene 7 software. Thereafter, PCR primers were designed 
to prime out the HLA-C gene of interest from exons 2 to 4 and to insert enzymatic 
restriction cut-sites onto both ends of the PCR product. With the use of the online 
NEBcutter V2.0 software, enzymes that have internal restriction cut-sites within the 
gene of interest can be eliminated. Subsequently, the NdeI (5’-CATATG-3’) and 
XhoI (5’-CTCGAG-3’) were chosen and 8 general primers were designed for the 





























Table 1 List of primers used for cloning. The use of different combinations of the 
Forward (Fwd) and Reverse (Rev) primers, different HLA-C alleles can be cloned 
from the cDNA library generated from various cell lines.  
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2.2.4 PCR using allele-specific primers 
Two 50µl PCR reactions were set up using allele-specific primers to isolate the allele 
of interest from each respective cell line. The PCR master mix was prepared using the 
Expand High Fidelity System (Roche Applied Systems) with addition of 1µl of 
template cDNA and 20µM each of the Forward (Fwd) and Reverse (Rev) primers. 
The thermal cycling profile was set on the GeneAmp 9700 PCR System (Applied 
Biosystems) as follows: an initial denaturation of 95oC for 10mins, followed by 32 
cycles of 95oC for 30s, 58oC for 30s and 72oC for 1min, and a final extension of 72oC 
for 10mins.  
The amplified products were subjected to agarose gel electrophoresis on a Mini-Sub 
cell GT system (Bio-Rad, Berkeley, California). A 1% agarose gel was ran at 100V 
for 45mins and subsequently visualised with GelRedTM (Biotium) on a UVP GelDoc-
ItTM Imaging System. The desired band of approximately 800 base pairs was 
compared against a GeneRulerTM 1kb DNA ladder (Fermentas) and excised for gel 
purification with the QIAQuick Gel Extraction kit (Qiagen) as per the manufacturer’s 
protocol. The purified DNA product was eluted in 30µl of DNase-free water. 
2.2.5 TA cloning 
PCR cloning was done using the pGEM-T vector systems from Promega (Madison, 
USA). Buffers and components were added according to the manufacturer’s protocol. 
The insert:vector molar ratio was optimised to be 3:1 and a 10µl pGEM-T vector 
ligation reaction was set up after determining the concentration of the purified PCR 
product using the Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific). The 
ligation reaction was incubated at room temperature for 1h before transformation of 
5µl of the reaction mix into 30µl of JM109 High Efficiency Competent Cells 
(Promega). Other transformation parameters were as suggested in the kit and 100µl of 
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the transformation culture was plated onto a LB/ampicillin/IPTG/X-Gal plate. The 
screening of pGEM-T transformants for inserts was carried out using the blue-white 
selection whereby white colonies are usually clones which contain the PCR fragment. 
2.2.6 Checking of plasmid sequence  
Positive clones were picked and each single isolated colony was inoculated into 4ml 
of Luria-Bertani (LB) broth supplemented with 50µg/ml ampicillin and grown 
overnight with shaking at 250rpm, 37oC. Thereafter, the overnight culture was 
pelleted down at 4,000rpm for 10mins before plasmid extraction was done using the 
protocol and reagents supplied in the QIAprep Spin Miniprep kit (Qiagen). The 
concentration of the plasmid was determined by the Nanodrop 1000 
Spectrophotometer (Thermo Fisher Scientific). Approximately 1µg of pGEM-T 
plasmid DNA was sent for a full DNA sequencing service using the T7 universal 
primer (5'-TAA TAC GAC TCA CTA TAG GG-3') and SP6 universal primer (5'-
ATT TAG GTG ACA CTA TAG-3'). The sequence of the desired HLA-C gene in the 
plasmid was confirmed before sub-cloning into the pET-30a (+) expression vector 
(Novagen, Merck).  
2.2.7 Sub-cloning into bacterial expression vector 
To sub-clone the correct HLA-C fragment into the pET-30a (+) expression vector, 
6µg of pGEM plasmid containing the specific HLA-C subtype was enzymatically 
digested by XhoI and NdeI (New England Biolabs). A 40µl digestion reaction 
comprising of 6µg of pGEM plasmid DNA, 4µl of 10x NEB Buffer 4, 1µl of BSA 
(100x), 1µl of XhoI (New England Biolabs) was set up at 37oC for 45mins. 
Subsequently, 1µl of NdeI (New England Biolabs) was added for 37oC for 45mins 
after inactivation of XhoI at 65oC for 20mins. A separate digestion reaction for the 
pET-30a (+) expression vector was also set up using 6µg of the vector, 10µl of 10x 
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NEB 4 buffer, 2µl of BSA (100x) and 2.5µl of XhoI for 45mins at 37oC. Similarly, 
XhoI was inactivated at 65oC for 20mins before addition of 2.5µl of NdeI and 
incubation at 37oC for 45mins.  
The digestion products were separated on a 1% agarose gel at 100V for 45mins and 
viewed with a UV Transilluminator. The band with the expected size of about 800 
base pairs was excised for gel purification with the QIAQuick Gel Extraction kit 
(Qiagen) as per the manufacturer’s protocol. The purified DNA product was eluted in 
30µl of DNase-free water. 
Thereafter, an overnight ligation reaction with a total volume of 20µl was set up at 
16oC. The ligation reaction consists of 4µl of 5x ligase buffer, 14µl of insert digest, 
1µl of vector digest and 1µl of T4 DNA ligase (Invitrogen). No further treatment was 
done to the reaction mixture until transformation into E.coli DH5α strain.  
Chemical transformation was carried out using the heat-shock method. A total of 10µl 
of the ligation reaction was added directly into 50µl of DH5α cells and mixed gently. 
The mixture was incubated on ice for 30mins, followed by a 30sec heat shock at 42oC 
and then immediate cooling on ice for 2mins. The cells were then mixed with 250µl 
of SOC medium (Invitrogen) and incubated at 37oC with shaking at 250rpm for 1h. 
Subsequently, 150µl of cells were plated onto a LB plate with 30µg/ml kanamycin 
and incubated at 37oC for 16h.  
Likewise, the sequence of the pET-30a-HLA-C plasmid was verified by DNA 
sequencing. A single isolated colony was picked and inoculated into 4ml of Luria-
Bertani (LB) broth supplemented with 30µg/ml kanamycin and grown overnight with 
shaking at 250rpm, 37oC. The pET-30a-HLA-C plasmid was then extracted from the 
overnight culture using the protocol and reagents supplied in the QIAprep Spin 
Miniprep kit (Qiagen). Full DNA sequencing service using the T7 universal primer 
41 
 
(5'-TAA TAC GAC TCA CTA TAG GG-3') and T7 terminator primer (5'-TAT GCT 
AGT TAT TGC TCA G-3') was carried out with 1µg of the pET-30a-HLA-C plasmid. 
The sequence of the desired HLA-C gene in the plasmid was confirmed before 
expression of the protein in E.coli strain BL21 (DE3).  
2.3 Protein expression of HLA-C heavy chain and β2-microglobulin 
2.3.1 Buffers 
Resuspension buffer (pH 8.0) was prepared by adding 50ml of 1M Tris-HCl (pH 8.0) 
to a final concentration of 50mM, 25% (w/v) sucrose and 2ml of 0.5M NaEDTA to a 
final concentration of 1mM and topped up with milli-Q water to a final volume of 1L. 
The resuspension buffer was stored at 4°C.  
Lysis buffer was prepared by adding 50ml of 1M Tris-HCl (pH 8.0) to a final 
concentration of 50mM, 10g of sodium deoxycholate and 5.84g of sodium chloride 
and topped up with milli-Q water to a final volume of about 1L. Last, 10ml of Triton 
X-100 was added slowly into the buffer. The lysis buffer was stored at 4°C. 
Wash buffer I (pH 8.0) was prepared by adding 50ml of 1M Tris-HCl (pH 8.0) to a 
final concentration of 50mM, 20ml of 5M sodium chloride solution to a final 
concentration of 100mM and 2ml of 0.5M NaEDTA to a final concentration of 1mM 
before topping up with milli-Q water to a final volume of about 1L. Triton X-100 was 
added last to make up to 1% (v/v) of 1L of Wash buffer I. Wash buffer I was stored at 
4°C. 
Wash buffer II (pH 8.0) was prepared by adding 50ml of 1M Tris-HCl (pH 8.0) to a 
final concentration of 50mM and 2ml of 0.5M NaEDTA to a final concentration of 
1mM before addition of milli-Q water to make up a final volume of 1L. Wash buffer 
II was stored at 4°C. 
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Urea buffer (pH 6.0) was prepared by dissolving 2.44g of 4-
Morpholineethanesulfonic acid (MES) to make up a final concentration of 25mM, 
240.24g of urea to make up a final concentration of 8M and 10ml of 0.5M NaEDTA 
to make up a final concentration of 10mM for a 500ml buffer. The pH was adjusted to 
6.0 with addition of concentrated hydrochloride acid and the urea buffer was stored at 
4°C. 
2.3.2 Transformation into E.coli strain BL21 (DE3) 
Chemical transformation using the heat-shock method was employed to introduce the 
pET-30a-HLA-C plasmid into E.coli strain BL21 (DE3). About 100ng of the plasmid 
was added into 100µl of BL21 (DE3) bacteria. The mixture was incubated on ice for 
30mins, followed by a 30sec heat shock at 42oC and then immediate cooling on ice 
for 2mins. The cells were then mixed with 250µl of SOC medium (Invitrogen) and 
incubated at 37oC with shaking at 250rpm for 1h. Subsequently, 150µl of cells were 
plated onto a LB plate with 30µg/ml kanamycin and incubated at 37oC for 16h.  
The pET-30a expression plasmid for β2-microglobulin was also transformed into 
BL21 (DE3) E.coli bacteria using the same protocol and expressed separately from 
the HLA-C heavy chain.  
2.3.3 Protein expression 
To express the desired HLA-C heavy chain protein in bacterial culture, a starter 
culture containing a single isolated colony in 15ml of Luria-Bertani (LB) broth 
supplemented with 30µg/ml kanamycin was prepared. The 15ml starter culture was 
grown overnight with shaking at 250rpm, 37oC and 5ml of the starter culture was 
further inoculated into 500ml of LB with 30µg/ml kanamycin in a 2L culture flask 
and incubated with shaking at 250rpm, 37oC. The final volume of the bacterial culture 
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can be scaled up according to proportions that vary with the expression level of each 
HLA-C protein.  
The OD600 of the bacterial culture was monitored at regular intervals using the 
GeneQuant 1300 Spectrophotometer (GE Healthcare). When the OD600 is about 0.6 to 
0.8, the bacteria are in mid-log phase and ready for protein induction. Expression of 
the HLA-C protein was induced for 4h with shaking at 250rpm, 37oC after addition of 
0.5mM of 1M IPTG (Isopropyl β-D-1-thiogalactopyranoside) from Fermentas.   
Bacteria cells were then harvested by centrifuging at 10,000rpm, 4oC for 10mins. The 
supernatant was discarded and the pellet was drained before resuspending in 
Resuspension Buffer. Typically, for every 500ml of bacteria culture, 5ml of 
Resuspension Buffer was added with the addition of 10mM Dithiothreitol(DTT) 
(Sigma), 0.1M Phenylmethanesulfonylfluoride (PMSF) (Sigma) and 1mg/ml of 
Pepstatin A. The resuspended pellet was stored in the -80oC freezer for overnight 
before downstream experiments.  
Protein expression of β2-microglobulin was also carried out using the same protocol.  
2.3.4 Inclusion bodies preparation 
The resuspended pellet was thawed at room temperature before addition of 12.5ml 
Lysis buffer per 5ml resuspended pellet. The buffer volumes can be scaled up by 
proportions. The Lysis buffer was supplemented with 0.5ml 1mg/ml DNase I, 10mM 
DTT and 5mM Magnesium chloride. The mixture was rocked vigorously on ice for 
20mins. After adding 10mM of NaEDTA (pH 8.0) to the mixture, the cell suspension 
was further lysed by sonication at 60% amplitude for a total of 10mins with cycles 
consisting of 5sec pulsing and 10sec break. The lysed cells were collected by 
centrifugation at 20,000rpm for 10mins, 4oC and the supernatant was discarded. The 
pellet was resuspended in 15ml of Wash Buffer I with 30µl 0.5M DTT, 30µl 0.1M 
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PMSF and 15µl 1mg/ml Pepstatin A before centrifugation at 20,000rpm for 10mins, 
4oC. This wash step was repeated 3 times and at the end of 3 wash steps, the 
supernatant was discarded. The pellet was further resuspended in 10ml of Wash 
Buffer II supplemented with 20µl 0.5M DTT, 20µl 0.1M PMSF and 10µl 1mg/ml 
Pepstatin A and centrifuged at 20,000rpm for 10mins, 4oC. After discarding the 
supernatant, 10ml of urea buffer supplemented with 20µl 0.5M DTT, 20µl 0.1M 
PMSF and 10µl 1mg/ml Pepstatin A was added to resuspend the pellet. The amount 
of urea buffer to add is dependent on the relative expression of each HLA-C protein. 
The cellular debris was pelleted by centrifugation at 20,000rpm for 20mins, 4oC and 
the supernatant containing the HLA proteins was collected in a clean tube. The 
supernatant was added with 20µl of 0.1M PMSF and 10µl 1mg/ml Pepstatin A per 
10ml of urea buffer. Finally, 20µl of protein sample was taken out for SDS-PAGE 
analysis protein quantitation while the remaining supernatant was stored in aliquots at 
-80oC. 
The inclusion bodies for β2-microglobulin was done separately and handled using the 
same protocol as for the HLA-C heavy chain.  
2.4 Quantitation using SDS-PAGE 
2.4.1 Buffers 
2x Laemmli Sample Buffer was prepared by adding 50µl of β-mercaptoethanol (Bio-
Rad) per 950µl of Laemmli sample buffer (Bio-Rad). The buffer was stored at room 
temperature after preparation.  
1x Tris-Glycine-SDS running buffer was made by diluting the 10x stock using milli-Q 
water to obtain a final concentration of 25mM Tris, 192mM Glycine, 0.1% SDS, pH 
8.3. The buffer was stored at room temperature.  
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The resolving gel buffer comprises of 1.5M Tris-HCl at pH 8.8 whereas the stacking 
gel buffer comprises of 0.5M Tris-HCl at pH 6.8.  
Coomassie blue staining solution was prepared by dissolving 0.6g of Coomassie Blue 
R250 powder (Bio-Rad) in a total volume of 500ml comprising of 250ml Methanol 
(Merck), 50ml Glacial Acetic Acid (Merck) and 200ml milli-Q water. The buffer was 
stored at room temperature.  
Destaining solution was prepared by mixing 250ml of Methanol (Merck), 50ml of 
Glacial acetic acid (Merck) and topping up with milli-Q water to a final concentration 
of 500ml. The buffer was stored at room temperature.  
2.4.2 Sample preparation 
The protein inclusion bodies concentrations for HLA-C heavy chain and β2-
microglobulin (β2m) light chain were quantitated using SDS-PAGE on a 12.5% 
resolving acrylamide gel and a 4% stacking acrylamide gel. Gels were cast using the 
Mini-Protean electrophoresis gel casting stand (Bio-Rad) and run on a Mini-Protean 
Tetra system at a constant voltage of 150V for 1h, in the presence of 1x Tris-Glycine-
SDS running buffer. After the proteins were subjected to SDS-PAGE, the 
concentrations were determined by comparing the intensities of the bands 
corresponding to the protein sample and standard bovine serum albumin (BSA) 
(Sigma). Samples were prepared by mixing 20µl of 2x Laemmli Sample Buffer to 
20µl of protein sample and boiled at 95oC for 10mins. 1µl, 2µl, 4µl and 8µl of protein 
samples were loaded into each well and compared with a range of 1µg, 2µg, 4µg and 
8µg of BSA standards. Gels were stained for 20mins using the Coomassie Blue 
staining solution with gentle shaking at room temperature before destaining several 




2.5 Peptide synthesis 
All the peptides used in this study were purchased from Mimotopes (Australia), and 
the peptide names are listed in Table 2 and Table 3. To test for the efficient refolding 
of HLA-C molecules under the established refolding conditions, a few peptides of 
various lengths which are known to elicit a T-cell response was selected (Bihl et al., 
2005; Breckpot et al., 2004; Honeyborne et al., 2010; Kondo et al., 2004; Larrieu et 
al., 2008; Wolfl et al., 2007). Some non-binding peptides were also included to serve 
as controls (Table 2). 
Upon successful confirmation of refolding conditions, another panel of peptides were 
chosen for the refolding assay. The majority of the peptides in the panel come from 
the Hepatitis B virus (HBV) and a small proportion of peptides are from other viruses 
which include Human Immunodeficiency Virus (HIV), Influenza A virus (Flu), 
Hepatitis C virus (HCV) and also melanoma-associated peptides. Majority of the 
peptides were nonamers, although peptides of other lengths were also included (Table 
3). 
All the lyophilised peptides were dissolved in dimethylsulfoxide (DMSO) (Sigma) to 














Table 2 Characterised HLA-C Cytotoxic T Lymphocyte (CTL) epitopes from various 
sources. From a literature search, several CTL epitopes were chosen and used for 
testing of our refolding assay. These peptides are known to bind to HLA-C and elicit a 
T-cell response (Bihl et al., 2005; Breckpot et al., 2004; Honeyborne et al., 2010; 
Kondo et al., 2004; Larrieu et al., 2008; Wolfl et al., 2007). Hence, the peptides 
should yield a positive signal in our refolding assay. Peptides were mainly 9 amino-














Table 3 Table of other peptides used for refolding assay. Majority of the peptides 
were derived from the Hepatitis B virus (HBV) while a small proportion of peptides 
are from other viruses which include Human Immunodeficiency Virus (HIV), 
Influenza A virus (Flu), Hepatitis C virus (HCV) and also melanoma-associated 
peptides (Bihl et al., 2005). Note that most peptides from the panel were nonamers but 




2.6 Refolding of HLA-C-peptide complexes 
2.6.1 Optimisation of refolding conditions 
The HLA-C-peptide complexes were refolded using a dilution method (Garboczi et al., 
1992). Refolding conditions such as the concentrations of Tris, NaEDTA and L-
Arginine monohydrochloride were optimised for maximum refolding efficiency. The 
molar ratios of the HLA heavy chain, light chain and peptide and also the redox 
potential were also taken into consideration. Varying the concentration of the single 
variable tested in each optimisation experiment, a series of refolding buffer was 
prepared with the rest of the components kept constant. All the optimisation 
experiments were performed under the same conditions of a 1ml total volume and 
refolded for 48h at 4oC. HLA-C-peptide complexes were then screened using the 
homogenous Western blot detection assay described later. 
2.6.2 Small-scale screening for complex formation 
After optimisation, small-scale refoldings of 1ml volume were set up to screen for 
HLA-C binding peptides. The refolding buffer containing 200ml of 100mM Tris (pH 
8.0), 400mM L-Arginine monohydrochloride, 2mM NaEDTA, 0.5mM oxidised L-
glutathione and 5mM reduced L-glutathione (Garboczi et al., 1992) with addition of 
200ul 0.1M PMSF and 100ul 1mg/ml Pepstatin A was aliquoted into 1.5ml tubes and 
pre-chilled before addition of heavy chain, light chain and peptide in a 1:5:8 molar 
ratio. The 1.5ml tubes were left to mix on a rotator in the cold room at 4ºC for 48 
hours.  
After 48 hours of refolding, each sample was loaded into a Spectra/Por Dialysis 
Tubing with 6000-8000 Daltons molecular weight cut-off and 10mm flat width 
(Spectrum Labs). One end of the tubing was tied with a knot whereas the other end 
was sealed off with the Snakeskin Dialysis Tubing Clips (Thermo-Scientific). The 
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dialysis tubing was cut and pre-washed with milli-Q water several times prior to 
sample loading. After which, the sample was dialysed in 10mM Tris (pH 8.0) at 4oC 
with stirring over a period of 16 hours.  
2.6.3 Large scale refolding for crystallisation 
 
Upon confirmation of complex formation by Western blot, production of refolded 
HLA-C-peptide complexes can be scaled up to obtain enough material for 
crystallisation purposes. Typically, about 1600-2000ml of initial sample will yield 
enough material for crystallisation screens and crystallisation optimisation 
experiments. A large starting volume is required to account for sample loss which 
may occur during sample concentration and purification.  
The peptide was added into the refolding buffer first, followed by slow addition of the 
heavy chain and light chain in their respective ratios. The refolding mixture was left 
to stir on a magnetic stirrer in the cold room at 4oC for 72 hours.  
After 72 hours of refolding, the sample was placed into a Snakeskin Dialysis Tubing 
with 10kDa molecular weight cut-off (Thermo-Scientific) and both ends of the tubing 
were sealed off with the Snakeskin Dialysis Tubing Clips (Thermo-Scientific). The 
dialysis tubing was pre-washed with milli-Q water several times prior to sample 
loading. Subsequently, the sample was dialysed against 10mM Tris (pH 8.0) at 4oC 
with stirring over a period of 16 hours before changing to fresh 10mM Tris (pH 8.0) 
buffer and dialysing again for 16 hours.  
2.7 Western blot detection of refolded complex 
2.7.1 Buffers 
The 2x Native loading buffer composed of 62.5mM Tris-HCl at pH 6.8, 0.1% 
bromophenol blue and 20% glycerol in milli-Q water. The buffer was stored at 4ºC. 
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1x Native running buffer was made by diluting the 10x Tris-Glycine buffer stock 
using milli-Q water to obtain a final concentration of 25mM Tris, 192mM Glycine, 
pH 8.3. The buffer was stored at room temperature.  
Transfer buffer was made by dissolving Tris powder and Glycine powder to a final 
concentration of 25mM and 192mM respectively. The solution was topped up with 
20% Methanol and milli-Q water before storage at room temperature.  
Tris-Buffered Saline-Tween 20 (TBST) buffer was made by diluting 20x TBS stock 
using milli-Q water to obtain a final concentration of 25mM Tris, 140mM sodium 
chloride, 3mM potassium chloride, pH 7.6 and finally adding 0.2% (v/v) of Tween-20 
(Sigma) into the buffer. The buffer was stored at room temperature. 
Blocking buffer was prepared by dissolving 15g of bovine serum albumin (BSA) 
(Sigma) in 500ml of TBST buffer. The buffer was stored at 4oC.  
Tris-Buffered Saline (TBS) buffer was made by diluting the 20x TBS stock using 
milli-Q water to obtain a final concentration of 25mM Tris, 140mM sodium chloride, 
3mM potassium chloride, pH 7.6. The buffer was stored at room temperature. 
2.7.2 Electrophoretic transfer 
The refolded HLA-C-peptide complexes were separated in a 10% native 
polyacrylamide gel. The samples were prepared by mixing 10µl of 2x Native loading 
buffer to 10µl of refolded sample and only 10µl was loaded into each well. 
Electrophoresis was carried out for 2h at 120V in the 4oC cold room in the presence of 
1x Native running buffer. Thereafter, the proteins on the gel were transferred to a 
polyvinylidene difluoride (PVDF) membrane (GE Healthcare) using a Mini Trans-
Blot Semi-Dry Transfer Cell (Bio-Rad). The gel was equilibrated with gentle shaking 
in 10ml of Transfer buffer for 5mins at room temperature before the transfer was done. 
In a separate container, the filter paper (Bio-Rad) was also soaked in Transfer buffer. 
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The PVDF membrane was activated with 100% Methanol for 1min by gentle agitation 
before soaking with Transfer buffer. 
The gel sandwich was assembled by putting one pre-wetted filter paper onto the 
Transfer Cell. This was followed by the activated PVDF membrane, the gel and a pre-
wetted filter paper. Air bubbles between the gel sandwich comprising of a filter paper, 
membrane, gel and filter paper were carefully rolled out using a roller before the 
cover of the Transfer Cell was secured. Electrophoretic transfer was performed by a 
constant voltage of 20V for 45mins at room temperature.  
The membrane was blocked in the Blocking buffer overnight at 4oC with gentle 
shaking after the proteins were transferred to the PVDF membrane. 
2.7.3 Antibody detection 
After overnight blocking, the sample membrane was first blotted with a mouse anti-
human HLA-ABC antigen monoclonal antibody W6/32 cell supernatant at a 1:10 
dilution in Blocking buffer for 30mins with shaking at room temperature. The 
membrane was then washed with TBST buffer 3 times, each time shaking at room 
temperature for 10mins. Incubation with secondary antibody, horse-radish peroxidise 
(HRP) conjugated goat anti-mouse polyclonal immunoglobulin (Dako) was done at a 
1:5,000 dilution in TBST for 30mins with shaking at room temperature. Similarly, the 
membrane was washed with TBST buffer 3 times, each time shaking at room 
temperature for 10mins and then a final wash with TBS buffer shaking at room 
temperature for 1min.  
The presence of refolded complex was visualised with the ECL Plus Western Blot 
Detection reagent (GE Healthcare) as per the kit’s procedure. After incubation at 
room temperature for 5mins, the membrane was exposed to an X-ray film (Fujifilm) 
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where the presence of a band indicates formation of a refolded HLA-C-peptide 
complex. 
2.8 Purification of HLA-C complexes 
2.8.1 Ion-exchange chromatography 
A positive band on Western confirms the formation of refolded HLA-C-peptide 
complexes and this drives the up-scale refolding and dialysis process for 
crystallisation. After dialysis, the refolded sample was filtered through a 0.22µM 
polyethersulfone (PES) membrane filter (Millipore) and purified by a two-step 
purification scheme. The refolded sample was first subjected to an ion-exchange 
column HiPrep DEAE FF 16/10 (GE Healthcare). To prevent overloading of the 
column, about 400ml of sample was loaded in each ion-exchange run. If the total 
sample volume exceeds 400ml, several runs have to be performed under the same 
conditions. Samples were eluted on a step-gradient of 10mM Tris/1M NaCl at a flow-
rate of 5ml/min whereby step increments were achieved within 0.5 column volume 
and the 15% and 30% steps were each maintained at 2 column volumes. Elution 
profiles of the proteins were monitored by UV-absorbance at 280nm. 1.5ml fractions 
were collected in a 2ml deep-well plate (Thermo-Scientific) and were analysed by 
SDS-PAGE under denaturing conditions. The fractions containing both heavy chain 
and light chains from the various runs were pooled and concentrated with a Vivaspin 
20 column (Sartorius Stedim). The Vivaspin 20 column was centrifuged at 3,000rpm, 
4°C until the final volume becomes 5ml.  
2.8.2 Gel-filtration chromatography 
The concentrated 5ml sample from the first purification step was injected into a gel-
filtration column HiLoad 16/600 Superdex 75 pg (GE Healthcare) equilibrated in 
20mM Tris (pH 8.0) at 4°C and eluted over 1.5 column volumes. Elution profiles 
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were monitored by UV-absorbance at 280nm and 0.5ml fractions were collected in 
1.5ml deep-well plate (Thermo-Scientific) at 1ml/min flow rate. Similarly, the eluted 
peaks were analysed by SDS-PAGE under denaturing conditions and the fractions 
containing both heavy chain and light chain were pooled together. The fractions were 
concentrated using a Vivaspin 6 column (Sartorius Stedim) to a concentration of 
about 8-10mg/ml. The final volume of the concentrated sample may vary according to 
refolding efficiency of each HLA-C-peptide complexes.  
2.9 Crystallisation of HLA-C complexes 
2.9.1 Crystallisation screen 
Crystallisation screens were manually set up using the hanging drop vapour diffusion 
method in a 48-well plate. In each well containing 250µl reservoir solution, 2µl of 
purified HLA-C-peptide complex was mixed slowly with 2µl of the reservoir solution 
to form a drop on a siliconised glass cover slide. Screens were set up with each of the 
96 conditions provided by the Crystal Screen kit and Index Screen kit (Hampton 
Research, CA). The Crystal Screen and Index Screen kits are based on a sparse matrix 
additive reagent system that screens for protein complexes. The crystallisation screen 
plates are placed carefully in an 18ºC incubator with minimal movement and vibration. 
Plates are viewed under the transmitted polarising binocular microscope (Olympus) 
first after 3 days and subsequently every single day.  
2.9.2 Crystallisation optimisation 
Upon observation of probable crystal formation in a particular crystallisation 
condition, crystallisation growth was optimised using the hanging drop vapour 
diffusion method. Similarly, 2µl of purified HLA-C-peptide complex was mixed 
slowly with 2µl of the reservoir solution to form a drop on the siliconised glass cover 
slide in each well containing 250µl of reservoir solution. Several wells were set up to 
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account for well-to-well variation and the plates were incubated in an 18ºC incubator 
and observed every day. The components of the reservoir solution may be altered or 
modified to achieve a single large crystal which is of diffraction quality.  
2.9.3 X-ray diffraction 
When the crystal is grown to a sufficient size for X-ray diffraction, single crystals 
were picked and subjected to X-ray analysis on the Bruker ccdProteum X-ray 
diffraction system (Institute of Molecular and Cell Biology (IMCB), A*Star). Data 
was collected using the Proteum2 suite for crystallography software and the HLA-C-
peptide structure was solved by the molecular replacement method.  
2.10 Circular dichroism thermal unfolding  
The thermal stability of HLA-C-peptide complexes was determined by circular 
dichroism (CD) using a Jasco J-810 spectropolarimeter equipped with a thermal 
controller (National University of Singapore (NUS), Faculty of Science, Department 
of Biological Sciences). The denaturation curves were obtained by monitoring the far-
UV CD spectra (200-260nm) using a protein concentration of 20µM in 20mM Tris 
(pH 8.0) buffer. The change in ellipticity at 218nm was continuously recorded in the 
temperature range 20-90ºC using a scan rate of 4ºC/min and a 1-mm pathlength 
cuvette. The thermal unfolding spectra was normalised to the basal line values 





CHAPTER 3 RESULTS 
3.1 HLA-C cloning  
A search in Allele Frequency Net Database yielded a list of 18 common HLA-C 
alleles in the global population. Allele-specific primers were designed to clone the 18 
HLA-C alleles from various cell lines and all alleles were cloned successfully into a 
bacterial expression vector. 
The first technical challenge would be to identify two restriction enzymes which do 
not recognise any of the 18 HLA-C cDNA sequences as internal cut-sites and cause 
random cuts along the sequence. Given that the HLA-C sequences are polymorphic in 
nature, it makes it challenging to choose a common pair of restriction enzymes that do 
not cut internally and yet allow cloning of the gene of interest into the multiple 
cloning sites of the pET-30a (+) bacterial expression vector.  
Another technical difficulty faced in HLA-C cloning is due to the low mRNA levels 
of HLA-C compared to its counterparts. This may result in a lower amount of HLA-C 
cDNA present in the cDNA library generated from the pool of extracted RNA. This 
will in turn greatly reduce the probability of isolating the desired HLA-C cDNA from 
a pool of other cDNAs that are present in much greater amounts. The way to 
circumvent this problem is by the use of locus and/or allele-specific primers 
specifically designed for each of the 18 HLA-C alleles (Davidson et al., 1985). 
Although the use of common sequences specific to each HLA locus is important for 
efficient cloning, the cloning process is further complicated by the high sequence 
homology that HLA-C shares with HLA-A and HLA-B. This makes it challenging to 
isolate the different HLA types based on the minor sequence differences that they 
share at the two ends of exons 2 to 4 and the designed primers may not be sufficiently 















Figure 4 PCR products from various cell lines. The band observed at 800-900 base 
pairs corresponds to the PCR product which may contain either HLA-A, HLA-B or 
HLA-C gene product. Identity of the PCR product requires confirmation by DNA 
sequencing. Note that the PCR condition is not optimised for the Cell line 3 which 
resulted in a faint band being observed. 
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Furthermore, the use of heterozygous cell lines significantly reduces the chances of 
obtaining the desired HLA-C clone. The use of homozygous cell lines or less stringent 
PCR conditions, such as a lowered annealing temperature, may serve as alternative 
approaches in the event of PCR amplification failure.   
In addition, working on the assumption that HLA-C transcripts are indeed present in 
much lesser amounts than HLA-A and HLA-B transcripts, there will also be less 
HLA-C cDNA present to serve as the DNA template during the PCR reaction. Thus, 
the probability of acquiring a successful clone will be reduced and more clones have 
to be screened before a correct clone is obtained. Thereafter, sequences have to be 
verified by first checking for the presence of the HLA-C insert (Figure 5) and then 





















Figure 5 Restriction enzyme analysis of pET-30a-HLA-C plasmids. After a 
enzymatic digestion reaction, the band observed at 800-1000 base pairs corresponds 
to the HLA insert that has been cloned into the multiple cloning sites while the band 
between 3000-5000bp corresponds to the pET-30a (+) plasmid backbone. Only the 
plasmids which were found to contain the insert were sent for sequence verification 
by DNA sequencing.  
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Using different combinations of the Forward and Reverse primers designed to isolate 
the HLA-C of interest, a panel of 18 HLA-C alleles that we had intended to isolate 
have been cloned into a bacterial expression vector. 
3.2 HLA-C expression levels in bacteria 
High-level expression of the HLA-A2 heavy chain protein in the form of inclusion 
bodies using E.coli strain BL21 (DE3) has been well-established (Garboczi et al., 
1992). Little is known or elucidated for HLA-C proteins. In bacterial protein 
expression, highly aggregated proteins known as inclusion bodies are normally found 
in the cytoplasm and inclusion bodies isolated from the cell lysates are usually 
contaminated with bacterial cell wall and membrane components. As such, there is a 
need to apply a series of selective extraction and wash steps with detergents and urea 
in order to obtain significant purification of the recombinant HLA-C protein. 
Subsequently, the inclusion bodies have to be solubilised using 8M urea before being 
used directly for refolding into a native and biologically active protein.  
As the recombinant protein is insoluble, complete cell lysis must be ensured to 
prevent leaching of contaminants when the pellets are washed with strong protein 
denaturants. Complete cell lysis is facilitated by a sonication step which breaks up the 
bacterial cells by means of ultrasound waves. At the same time, the sonication process 
may generate heat that will destroy or degrade the proteins. Hence, it is essential that 
sonication steps be performed on ice to achieve maximum protein recovery.  
The presence of bacterial contaminants may influence protein folding if the protein is 
going to be directly used for refolding purposes after solubilisation. However, the 
series of wash steps may cause minute amounts of samples to be lost during each step 
and the final yield of the purified recombinant protein may account for nearly 60% of 
the washed pellet protein.  
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Typically, about 5-25mg of HLA-C protein can be produced for every litre of 
bacterial culture. This is different in the case of HLA-A and HLA-B whereby about 
20-40mg of protein can be produced for every litre of culture. Furthermore, when the 
expression levels of 8 HLA-A alleles, 9 HLA-B alleles and 18 HLA-C alleles were 
compared, the HLA-C expression level in BL21 (DE3) was significantly lesser than 
its counterparts (Figure 6). 
Moreover, the levels of HLA-C expression also vary among various HLA-C alleles. 
As quantitated by SDS-PAGE gel electrophoresis, the amounts of HLA-C protein 
produced from the same starting volume of bacterial culture can be seen to be 
different across the 18 HLA-C alleles. For a fair comparison to be made, the protein 
expression conditions were kept constant with the same IPTG concentration and a 
constant 4h induction time. 
Of all the HLA-C alleles expressed, HLA-C*08:01 demonstrated the highest level of 
expression. Up to 25mg of HLA-C*08:01 protein can be obtained for every litre of 
bacterial culture and this eased the need to scale up the proportion excessively to 
obtain enough material for refolding. The concentration of HLA-C*08:01 inclusion 
bodies was determined by comparing the band intensity of various volumes of HLA-
C*08:01 with that of fixed amounts of Bovine Serum Albumin (BSA) protein 
standard (Figure 7). In addition, the different expression levels of all the 18 HLA-C 
alleles have allowed their classification into 2 categories: High expression and Low or 
no expression (Table 4). Only less than 5mg of protein can be obtained for every litre 







Figure 6 Protein expression levels of HLA-A, -B and –C alleles. The expression 
levels of 8 HLA-A alleles, 9 HLA-B alleles and 18 HLA-C alleles were compared. 
The total yield of protein obtained after protein expression in BL21 (DE3) bacteria (in 
mg) was normalised to the starting volume of bacterial culture (in litres). The level of 




















Figure 7 Quantitation of the expression of HLA-C*08:01 inclusion bodies using 
denaturing SDS-PAGE. As shown, the intensity of the band with 1µl of HLA-
C*08:01 was comparable to that of 4µg of BSA and hence this gave the HLA-
C*08:01 inclusion bodies a concentration of 4mg/ml. Up to 25mg of HLA-C*08:01 














Table 4 HLA-C expression levels. The expression levels of each HLA-C allele in 
E.coli bacterial strain BL21 (DE3) vary to a great extent even when the expression 
conditions are kept largely constant. There were problems in refolding of alleles with 
poor/no expression as large amounts of inclusion bodies have to be prepared. Only 
5mg of protein can be obtained for every 1 litre of bacterial culture for those alleles 
belonging to the Poor/No expression group.  
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The low refolding efficiency of HLA-C-peptide complexes compelled the production 
of large volumes of bacterial culture to account for loss during the wash steps in 
inclusion bodies preparation and also poor refolding yield. The loss of refolded HLA-
C-peptide complexes during column purification further necessitates the production of 
large amounts of starting material.  
However, production of the β2m light chain can be done at consistently high levels 
(30-60mg/L culture) that generated enough material for several refolding attempts. 
Similarly, the concentration of β2m inclusion bodies was determined by comparing 
the band intensity of various volumes of β2m with that of fixed amounts of BSA 
protein standard (Figure 8).  
The concentrations of inclusion bodies determined by denaturing SDS-PAGE can be 
used for calculating the amount of protein needed for refolding. The HLA-C and β2m 
light chain inclusion bodies are then refolded in the presence of a viral peptide using 


















Figure 8 Quantitation of the expression of β2-microglobulin (β2m) light chain using 
denaturing SDS-PAGE. As shown, the intensity of the band loaded with 1µl of β2m 
was comparable to that of 4µg of BSA and this gave the β2m inclusion bodies a 




3.3 HLA-C refolding assay 
The refolding course is often not a single-step reaction but a reaction with multiple 
folding intermediate conformations existing between unfolded and folded (native) 
state. Therefore, it is of importance to determine a set of optimal refolding conditions 
whereby different concentrations of external reagents or solvent additives can aid 
protein refolding directly from an unfolded to native state instead of misfolding or 
aggregating to form an intermediate structure.  
The refolding of HLA molecules has been studied extensively and it is widely 
accepted that HLA refolding assays are usually aided by the use of small molecule 
additives such as Tris and L-arginine monohydrochloride that can facilitate folding 
and protein stabilisation. This is often followed by the removal of denaturant (urea) 
that was used to solubilise the inclusion bodies.  
From the initial set of refolding conditions defined in the well-studied HLA-A*02 
molecules, different refolding parameters were taken into consideration and 
investigated for optimal refolding efficiency. Using HLA-A*02 as a model, it can 
allow the extension of refolding parameters to HLA-C molecules which share a high 
level of sequence similarity. Given that, there are several important parameters which 
are known to affect refolding of proteins from inclusion bodies (Tsumoto et al., 2003). 
For example, Tris plays an important role in the refolding process because it acts as a 
buffer to maintain conformational stability of the protein due to pH changes. The 
refolding efficiency appears to increase with increasing Tris concentration as Tris also 
seems to reduce protein aggregation. In addition, L-arginine monohydrochloride is a 
solubilising agent known to aid solubilisation of unfolded protein species and may act 
as a suppressor for protein aggregation (Reddy et al., 2005; Tischer et al., 2010). 
Therefore, Tris and/or L-arginine monohydrochloride, if present at the right 
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concentrations, will promote the formation of the refolded HLA-peptide complexes. 
Furthermore, as the HLA molecule is stabilised by the formation of several disulphide 
bonds (Dangoria et al., 2002), the refolding buffer has to be supplemented by a redox 
system, usually provided by glutathione and its oxidised form, to maintain unfolded 
proteins in the form of inclusion bodies in their reduced state.  
The stoichiometry of HLA refolding has also been investigated by structural studies. 
Crystal structures of HLA-A*02 molecules revealed that β2m binds to HLA-A*02 
heavy chain in a 1:1 molar ratio (Saper et al., 1991). At the same time, the antigen 
binding groove of HLA molecules is only able to accommodate one peptide at a time. 
However, under in vitro conditions, the proteins and peptide associate freely in 
solution and hence increasing the concentration of β2m will increase the probability 
of a HLA heavy chain associating with β2m to form a refolded complex in the 
presence of a binding peptide. Nonetheless, when β2m is present in much excess, it 
can likely interfere with the refolding process and decrease refolding efficiency.  
Subsequently, traces of denaturant still present in the refolding buffer may be 
removed by a dialysis step. Dialysis is a process to remove denaturant by gradual 
buffer exchange through a dialysis membrane. However, step-wise dialysis involving 
regular change of dialysis buffer, each time incrementally decreasing the 
concentration of denaturant present, may allow for better refolding efficiency. This 
will also prevent protein aggregation from partially folded species that may be present 
at intermediate denaturant concentrations. At the same time, refolded HLA-peptide 
complexes may degrade or dissociate over time. This calls for an optimal dialysis time 
that balances out between having the maximum number of refolded HLA-peptide 
complexes and the loss of complexes by protein degradation.  
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In this thesis, a refined refolding assay, which uses a set of conditions specific for 
refolding of HLA-C molecules and a homogenous read-out system based on a 
conformational-dependent antibody (W6/32), was described. The presence of refolded 
HLA-peptide complexes was detected by Western blot with the efficiency of 
refolding assessed by the corresponding band intensities. The band intensities were 
quantitated using the ImageJ software.  
3.3.1 Refolding of known HLA-C-peptide complexes  
 
To investigate if HLA-C molecules refold as well as HLA-A*02 molecules under the 
same set of conditions, the established conditions were extended to known HLA-C-
peptide complexes and observed for complex formation using Western blot. In the 
HLA-A*02 experiments, refolded HLA-peptide complexes can be detected even in a 
refolding volume as small as 1ml. Therefore, a small-scale refolding assay was set up 
for screening of potential HLA-peptide complexes that can form under in vitro 
conditions.  
In brief, the HLA-C heavy chain, β2m and peptide were mixed slowly into the 
refolding buffer at 4ºC and incubated for 48-72h before dialysing against 10mM Tris 
(pH 8.0). Thereafter, the solution was concentrated and used for Western blot to 
screen for complex formation. As shown in Figure 9, bands of varying intensities 
were observed in Western blot. This confirms that HLA-C-peptide complexes of 
different binding affinities can be refolded using the established refolding buffer. 
Moreover, HLA-C-peptide complexes migrated in the native gel at different mobility, 
with the high binding affinity complexes migrating at a faster rate than others.  
Antibody specificity was confirmed by the absence of a band in the control lanes 
which contained samples refolded without a peptide.  
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The Western blot results coincide with previous ELISPOT data that measured the 
effect of the various peptide mutations on viral recognition by cytotoxic T cells and 
on virus replicative capacity (Honeyborne et al., 2010). The studies revealed that the 
recognition of the T303A and T303I mutant peptide epitopes was reduced as 
compared to the wild-type YL9 epitope. This is consistent with the lower band 
intensities observed when HLA-C*03:04 is refolded with the T303A and T303I 
mutant peptide epitopes, as compared to HLA-C*03:04 refolded with the wild-type 
YL9 peptide epitope.  
On the other hand, refolding HLA-C*03:04 with a self-peptide (GAVDPLLAL) 
resulted in a complex which migrated at a much faster rate on the native gel compared 
to the others and this is suggestive of stable and high-affinity binding. The stability of 
this HLA-C*03:04-GAVDPLLAL complex was further confirmed by cell surface 
assays and crystallisation studies (Boyington et al., 2000; Zappacosta et al., 1997).  
Taken together, the refolding conditions established in this section can be applied for 
specific refolding of HLA-C-peptide complexes and sensitive detection of stable 
complexes. Hence, potential HLA-C-peptide complexes identified by the small-scale 
refolding assay may then be targets for crystallisation purposes by proportionally 
increasing the refolding volume.  
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Figure 9 Refolding of known HLA-C-peptide complexes. The presence of HLA-
C-peptide complexes was confirmed by Western blot, with the formation of 
bands of varying intensities. Band intensities, as quantitated using the ImageJ 
software, indicated presence of refolded complexes and their relative binding 
affinities. Band mobility also provided an indication to the peptide binding 
affinity. Results confirmed that the refolding buffer can be extended to refolding 






3.3.2 HLA-C refolding with HBV peptides and other viral peptides 
 
To explore if the different HLA-C alleles are able to bind to other peptides, a panel of 
48 Hepatitis B Virus (HBV) peptides was selected for the small-scale refolding assays. 
The peptides are representative of the intracellular pool of peptides which the 
proteasome can process and many of them are well-known to bind to HLA molecules 
and are presented on the cell surface to elicit a T-cell response. Hence the use of these 
peptides in our refolding screen will increase the likelihood of obtaining a refolded 
HLA-peptide complex.  
Western blot detection using W6/32 monoclonal antibody revealed that HLA-
C*08:01 binds to 3 peptides, namely HBV Core 18-27 (Gen B/C) FLPSDFFPSI, 
HBV Core 18-27 (Gen A/D) FLPSDFFPSV and the HBV Core 18-27 variant 
FLPSDYFPSV (Figure 10). The band intensity reflects how well the peptide bound to 
the HLA-C molecule. In addition, from the denaturing SDS-PAGE gel, there are 
equal amounts of heavy chain and light chain present in the samples suggesting that 
complex formation was not due to unequal loading amounts. The peptide size is too 
small to be detectable under denaturing SDS-PAGE conditions.  
Coincidentally, the 3 peptides which bound to HLA-C*08:01 are variants of the 
peptide sequence corresponding to positions 18-27 of the HBV Core protein. Of 
which, 2 peptides belong to different viral genotypes whereas the third peptide is a 
variant at the P6 residue of the same HBV (Gen A/D) peptide. The HBV Core 18-27 
peptide is well-studied to be HLA-A*02-restricted (Bertoletti et al., 1994). This 
implies that HLA-C*0801 may share the same peptide binding specificity as the 
HLA-A*02 molecules and may also be important for immune response against HBV.   
Moreover, HLA-C*08:01 is able to bind to other peptides tested that are not of HBV 
origin (Figure 11). Namely, HLA-C*08:01 can also bind to peptides such as the 
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Influenza matrix peptide (GILGFVFTL), HIV Gag peptide (SLFNTVATL) and 
Melanoma-associated peptide (AAGIGILTV). All of these peptides have a Thr at P8 
position and this points out to HLA-C molecules having a P8 preference. There was 
no binding to any of the HCV peptides included in the study, possibly because of a 
lack of binding anchors and/or strict requirements on peptide length.  
Likewise, other HLA-C alleles besides HLA-C*08:01 also demonstrated binding to 
HBV peptides and other peptides but with different refolding efficiencies (Figure 12). 
This suggests that the efficiency of the refolding buffer can be extended to different 
HLA-C alleles and HLA-C proteins are able to refold as well as HLA-A*02 
molecules under the same refolding conditions. An interesting point to note is that all 
the alleles tested which bound to the Influenza matrix peptide (GILGFVFTL) belongs 
to the HLA-C1 subgroup. 
Taken together, the results of the small-scale refolding assay suggest that the 
refolding buffer was not only optimal for the refolding HLA-A*02 molecules but also 
the HLA-C molecules chosen for our study. The small-scale refolding assay 
established also allowed the comparison of refolding efficiency of different HLA-C-














Figure 10 Refolding assay of HLA-C*08:01 with HBV peptides. As shown by 
Western blot,  HLA-C*08:01 demonstrated binding with 3 peptides, namely HBV 
Core 18-27 (Gen B/C) FLPSDFFPSI, HBV Core 18-27 (Gen A/D) FLPSDFFPSV 
and the HBV Core 18-27 variant FLPSDYFPSV (positions of refolded complexes are 
indicated by black arrows). Reducing SDS-PAGE gels stained with Coomassie 
Brilliant Blue are also shown to demonstrate equal loading and presence of heavy 












Figure 11 Refolding assay of HLA-C*08:01 with other peptides. HLA-C*08:01 was 
not only able to bind to HBV peptides but also peptides such as the Influenza matrix 
peptide (GILGFVFTL), HIV Gag peptide (SLFNTVATL) and the Melanoma-
associated peptide (AAGIGILTV). Note that these 3 peptides have a Thr at P8 

















Figure 12 Refolding assay of HLA-C alleles with other peptides. Among the alleles 
tested, HLA-C*01:02, HLA-C*07:01 and HLA-C*12:02 also bind to the Influenza 
matrix peptide (GILGFVFTL) and all alleles tested did not bind to any of the 3 HCV 
peptides chosen. Note that HLA-C*01:02, HLA-C*07:01 and HLA-C*12:02 all 




A detailed amino acid sequence analysis of all the 18 HLA-C alleles showed a high 
degree of sequence homology. Only the amino acid sequences of exons 2 and 3 are 
included because these 2 exons encode for the α1 and α2 domains of antigen binding 
groove that bind the peptide. From the phylogenetic analysis done with the Clustal W 
method, HLA-C*08:02 displayed the highest degree of sequence similarity with 
HLA-C*08:01 (Figure 13).  
However, when the same refolding assay was repeated for HLA-C*08:02 using the 
panel of HBV peptides, no binding was observed even for the 3 HBV peptides that 
bound to HLA-C*08:01 (Figure 14). The assay was performed under identical 
conditions with addition of equal amounts of HLA-C heavy chain and β2m light chain 
and also equal loading of sample in each of the wells. The W6/32 monoclonal 
antibody was also functional as it was able to detect the HLA-A*02:01-HBV Core 18-
27 (Gen A/D) complex as a positive control in Western blot. Although the W6/32 
antibody recognises a conformational epitope on the refolded HLA-peptide complex, 
the inclusion of a known HLA-C*08:02-peptide complex will serve as a better 
positive control to assess the ability of W6/32 to recognise HLA-C*08:02-peptide 
complexes. Despite this, only the HLA-A*02:01-HBV Core 18-27 (Gen A/D) 
complex was included for the experiments to provide consistency across all screening 
experiments. Nonetheless, the experiment was repeated at least 3 times to check and 
confirm the absence of complex formation. Even so, no observable band was detected 
even after a long film exposure time of 3mins. Hence, there was indeed no binding of 
any peptides to HLA-C*08:02 and that the difference in peptide binding specificity 















Figure 13 Phylogenetic analysis of the amino acid sequences of all 18 HLA-C alleles 
using the Clustal W method. The phylogenetic tree pointed out HLA-C*08:02 as the 
closest sequence neighbour of HLA-C*08:01 (indicated by the red arrow). Only the 
sequences for exons 2 and 3 are included as these 2 exons encode for the α1 and α2 














Figure 14 Refolding assay of HLA-C*08:02. Unlike HLA-C*08:01, HLA-C*08:02 
did not show binding to any of the HBV peptides, including the 3 peptides which 
bound to HLA-C*08:01. There was also equal sample loading and presence of the 
HLA-C heavy chain and β2m light chain (not shown). Note that the band 
corresponding to HLA-A*02:01 complexed with the HBV Core 18-27 (Gen A/D) 
serves as a positive control to show that the W6/32 antibody is functional. The wells 
with HLA-C*08:02 heavy chain alone as well as HLA-C*08:02 with β2m in the 
absence of peptide, serve as negative controls to show that the W6/32 antibody is only 
specific for refolded HLA-peptide complexes.  
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Further sequence analysis of amino acid sequences corresponding to exons 2 and 3 of 
HLA-C*08:01 and HLA-C*08:02 revealed 3 amino acid changes that are of different 
biochemical properties (Figure 15). Specifically, the 3 changes at position 138 (from 
Thr to Lys), position 152 (from Thr to Glu) and position 156 (from Leu to Arg) 
resulted in a change from uncharged to charged amino acid side-chains and these 
changes in amino acid property possibly displaced the binding peptide from the 
antigen binding groove.  
At the same time, based on the known HLA-C*04:01-QYDDAVYKL structure 
(1QQD), position 152 and position 156 have their side-chains pointing towards the 
bound peptide in the antigen binding groove (Figure 16). Hence, these residues can be 
speculated to have a role in peptide binding and determining peptide binding 
specificity.  
Moreover, the importance of amino acid residues at positions 152 and 156 in pocket E 
of the HLA-A*02:01 molecule have also been demonstrated to be critical for the 
formation of peptide-specific, HLA-A*02-restricted T-cell responses by mutational 
studies (Teng and Hogan, 1994). Therefore, peptide binding to HLA-C molecules 







Figure 15 Sequence alignment for HLA-C*08:01 and HLA-C*08:02. Alignment of the HLA-C*08:01 and HLA-C*08:02 amino acid sequences 
for exons 2 and 3 revealed 3 amino acid differences at positions 138, 152 and 156 (shaded in pink). Note that there is a change in amino acid 










Figure 16 HLA-C*08:02 amino acid differences. Mapping out the 3 amino acid 
differences at positions 138, 152 and 156 (pink) onto the available structure of HLA-
C*04:01-QYDDAVYKL showed that position 152 and position 156 have their side-
chains pointing towards the bound peptide (yellow) in the antigen binding groove, 
proposing a role in peptide binding and determining peptide binding specificity for 





3.4 HLA-C purification  
Upon successful detection of refolded HLA-C-peptide complexes by the W6/32 
antibody in Western blot, a list of complexes was short-listed for large-scale protein 
production, refolding and purification for crystallisation purposes. Of which, the 
refolding efficiency and yield of two complexes allowed for efficient screening of 
crystallisation conditions. In general, about 8-10mg/ml of sample is needed for 
screening using a single crystallisation condition. Existing crystallisation conditions 
established for HLA-C-peptide complexes have been quite diverse and distinct. Thus, 
there is a requirement for screening of more possible crystallisation conditions in 
order to identify the right condition. However, the desire to screen as many 
crystallisation conditions for a positive crystal hit drove the need to isolate complexes 
which the peptide bound to the HLA-C heavy chain with specificity and affinity.  
3.4.1 Purification of HLA-C*08:01 complexed with Cytomegalovirus (CMV) 
pp65 peptide VVCAHELVC 
 
The first HLA-C-peptide complex identified to have strong peptide binding affinity 
was that of HLA-C*08:01 complexed with the Cytomegalovirus (CMV) pp65 peptide 
VVCAHELVC. This peptide corresponds to position 198-206 of the CMV 
phosphoprotein 65 (pp65) protein which is a structural protein that is abundant 
throughout CMV infection (Stinski, 1978). It is also widely accepted that the CMV 
pp65 protein is the major immunodominant target of CD8+ T-cell response against 
CMV (McLaughlin-Taylor et al., 1994; Wills et al., 1996) and may be an appropriate 
antigen to target in efforts to provide immunity to CMV in an immunocompromised 
host.   
The purification profile using ion-exchange chromatography and gel-filtration 
chromatography in series was consistent with that of the band intensity observed on 
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the Western blot assay (Figure 17). The strong band intensity correlated with the 
collection of a large peak corresponding to the refolded HLA-C-peptide complex after 
passing through the gel-filtration column. Consequently when the peak fractions were 
pooled and concentrated, the yield and concentration of the refolded HLA-C*08:01-
VVCAHELVC complex were sufficient for screening of many crystallisation 
conditions.  
The first peak from the ion-exchange column containing both the refolded HLA-C-
peptide complex and free β2m is then injected into the next gel-filtration column 
which separates by size. The HLA-C-peptide complex is larger as compared to free 
β2m light chain and hence does not pass through the beads in the gel-filtration column 
and will be eluted earlier. The peak corresponding to the HLA-C-peptide complex 
was then collected and concentrated to a concentration of about 8-10mg/ml for 
crystallisation screens. The identity and composition of the peaks for both purification 
steps were confirmed by Western blot using the conformational-dependent antibody 
W6/32 and SDS-PAGE. Although the use of a few different types of column in 
succession will result in significant sample loss, the two-step purification process is 
necessary to obtain a sample of sufficient purity for crystallisation purposes. 
The HLA-C*08:01-VVCAHELVC complex was first identified to elicit a cytolytic 
activity of CTL cell lines (Kondo et al., 2004). Given that peptides which bind to the 
HLA molecule with higher stability and affinity are usually more immunogenic (Sette 
et al., 1994b; van der Burg et al., 1996), this reflects the sensitivity of the refolding 
assay to select for high-affinity HLA-C-peptide complexes which can eventually be 




Figure 17 Two-step purification scheme for HLA-C*08:01-CMV pp65 peptide VVCAHELVC. There was no peak corresponding to free HLA-
C heavy chain in the first ion-exchange step suggesting high refolding efficiency as all heavy chains participated in complex formation. 
Fractions corresponding to the first peak from the gel-filtration column, containing refolded HLA-C-peptide complex (detected by Western blot), 
were pooled and concentrated for crystallisation. SDS-PAGE showed the presence of both heavy chain and β2m and also the purity of the final 
concentrated sample.  
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3.4.2 Purification of HLA-C*08:01 complexed with Influenza matrix peptide 
GILGFVFTL 
 
The second HLA-C-peptide complex identified to have strong peptide binding affinity 
was that of HLA-C*08:01 coupled with the Influenza matrix peptide GILGFVFTL. 
This peptide corresponds to position 58-66 of the Influenza A virus matrix protein 
which is important for virus budding (Gomez-Puertas et al., 2000). In addition, the 
peptide was originally identified to be the minimal peptide epitope from the Influenza 
virus matrix protein that is highly effective in sensitising HLA-A*02 target cells to 
lysis and is an important target in peptide epitope studies of HLA-A*02 individuals 
(Bednarek et al., 1991). Nonetheless, all peptide binding studies and CTL assays were 
focused on HLA-A*02 and there is no evidence of this HLA-A*02-restricted peptide 
being able to bind to other MHC Class I molecules.   
In the first ion-exchange chromatography step, both the refolded complex and free 
β2m light chain are separated from free heavy chain using a step-gradient (Figure 18). 
The purification profile was also consistent with that of the band intensity observed 
on Western blot. In the ion-exchange chromatograph, the peak corresponding to free 
heavy chain is insignificant in size and this could mean that the refolding efficiency is 
very high such that all heavy chains participate in complex formation. In addition, this 
observation was supported by the large peak corresponding to refolded HLA-C-
peptide complex even when free β2m are still present in large amounts after gel-
filtration. Subsequently, when the fractions corresponding to the first large peak 
collected after gel-filtration were pooled and concentrated, a final sample of about 8-
10mg/ml was obtained. This enabled the screening of many possible crystallisation 
conditions that may give rise to crystal formation.  
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In this case, purification of the HLA-C*08:01-VVCAHELVC complex resulted in a 
bigger peak at the end of two purification steps relative to HLA-C*08:01-
GILGFVFTL. This may account for any difference in peptide binding affinity or 
stability of the 2 peptides to HLA-C*08:01. The identity and composition of each 
peak were confirmed by SDS-PAGE which showed the presence of both heavy chain 
and β2m. Running a SDS-PAGE gel can also help to give an indication of the purity 
of refolded HLA-C-peptide complexes as the crystallisation process is highly 
dependent on the availability of a pure and homogenous sample. The peptide is too 
small to be detected by SDS-PAGE but the Western blot assay is sensitive and 
specific enough to differentiate and exclude refolded complexes which do not contain 
a peptide.  
The ability to obtain a well-resolved peak with an optimal yield of protein sample will 
enhance the chances of getting a crystal as many crystallisation conditions can be 







Figure 18 Two-step purification scheme for HLA-C*08:01-Influenza matrix peptide GILGFVFTL. In the first ion-exchange step, the peak for 
free heavy chain was not observed suggesting that all of the heavy chain participated in complex formation. Subsequently, when the single peak 
was concentrated and injected into the second gel-filtration column, the peak corresponding to free β2m was very much larger than the peak for 
refolded HLA-C-peptide complex. This is expected as β2m was added in excess. Note that the peak for refolded HLA-C*08:01-VVCAHELVC 
is very much larger as compared to the peak for HLA-C*08:01-GILGFVFTL. 
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3.5 HLA-C crystallisation 
 
In theory, it is extremely difficult to predict the best condition in which nucleation 
and/or growth of well-ordered crystals can occur. This is also because the 
crystallisation conditions for existing HLA-C-peptide crystals are quite distinct from 
one another and the same conditions might not be applicable for our newly identified 
complexes. Therefore, in practice, it is more feasible to identify favourable conditions 
by screening a wide variety of crystallisation solutions using a very large batch of 
purified sample. From the initial conditions whereby signs of crystal growth are 
observable, optimisation can then take place to derive a best set of conditions for the 
growth of a pure crystal with high regularity and mosaicity.  
3.5.1 HLA-C crystallisation screening 
 
In our crystallisation set-up, as many as 192 conditions from the Crystal Screen Kit 
and Index Screen kit (Hampton Research) were screened at 18ºC using the hanging 
drop vapour diffusion method. The high refolding efficiency of both HLA-C*08:01-
CMV pp65 peptide (VVCAHELVC) and HLA-C*08:01-Influenza matrix peptide 
(GILGFVFTL) enabled the screening of many conditions and this increased the 
chance of getting a successful crystal. The sparse matrix design of these commercial 
kits also provided an easy, direct and systematic search strategy for initial screening 
of crystallisation conditions. Moreover, the advantages of the hanging drop vapour 
diffusion method are that it provides for greater flexibility during screening and 
optimisation. There is also ease of access and visualisation of the crystallisation drop.  
After the initial screening process, the Index Screen 54 (Hampton Research) reagent 
gave hints to the first signs of crystallisation. This condition is vastly different to that 
of other known conditions of HLA-C crystallisation. This condition is based on 
0.05M calcium chloride dehydrate, 0.1M Bis-Tris pH 6.5 and 30% v/v polyethylene 
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glycol monomethyl ether 550. Thereafter, optimisation experiments were set up to 
refine the conditions for large, single crystals that are of diffraction quality.  
With the available refolded HLA-C-peptide complexes, nucleation can be observed in 
the hanging drop from as early as 1 day after crystallisation set-up and diffraction-
quality crystals can be seen from 2 weeks after optimisation. As crystal formation of 
these HLA-C-peptide complexes occurred in large numbers (Figure 19 and Figure 20), 
there was a need to reduce the number of nucleation sites in the hope of getting 
homogenous, large and pure single crystals. Optimisation of the protein concentration 
was required because at a very low protein concentration, the concentration will be 
too low for nucleation leading to undersaturation and crystallisation failure; on the 
other hand, at extremely high protein concentrations, irreversible protein precipitation 
will occur. Thus, the right protein concentration has to be applied for supersaturation 
which will drive nucleation and optimal crystal formation.  
3.5.2 HLA-C crystallisation optimisation 
 
Optimisation conditions include altering the ratio of purified protein sample to 
reservoir solution in the crystallisation drop and also streak seeding. Reducing the 
volume and/or concentration of purified protein sample in the crystallisation drop will 
essentially decrease the number of spontaneous nucleation sites that might complicate 
single crystal isolation. On the other hand, streak seeding involves the transfer of 
small crystal (seeds) through a gentle dislodging action to another fresh drop that 
might potentially support the growth of bigger crystals. This technique basically 
provides a template on which additional molecules can assemble and eventually form 
into a large crystal of diffraction quality under proper conditions. This method is also 
particularly effectively in getting large, isolated crystals that are capable of giving a 
















Figure 19 Crystal growth formation of HLA-C*08:01-CMV pp65 peptide 
VVCAHELVC observed under the transmitted polarising binocular microscope after 
14 days. Hanging drop was set up under the following conditions: 0.05M calcium 
chloride dehydrate, 0.1M Bis-Tris pH 6.5 and 30% v/v polyethylene glycol 
monomethyl ether 550 at 18ºC. An isolated single crystal was picked for X-ray 













Figure 20 Crystal growth formation of HLA-C*08:01-Influenza matrix peptide 
GILGFVFTL observed under the transmitted polarising binocular microscope after 7 
days. Hanging drop was set up under the following conditions: 0.05M calcium 
chloride dehydrate, 0.1M Bis-Tris pH 6.5 and 30% v/v polyethylene glycol 
monomethyl ether 550 at 18ºC. The crystals appear to have an irregular shape and are 
clustered together. There was a need to break up the clusters using a fine needle to 
obtain an isolated single crystal for X-ray diffraction. 
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From the optimised crystallisation drop, an isolated single crystal was picked out 
using a cryo-loop and soaked in cryoprotectant before mounting onto the detector of 
the Bruker ccdProteum X-ray diffraction system. Correct alignment of the crystal will 
allow for improvement of completeness of the data set and the intensities and 
positions of the diffraction spots form the basis for structural analysis.  
As shown in Figure 21, the X-ray diffraction pattern resembles that of a protein 
crystal. The spots are sharp and well-defined and the symmetry of the diffraction 
pattern reflects the symmetry of the crystal. This is unlike the X-ray diffraction of a 
salt crystal which gives an ordered diffraction pattern with very strong spots or rings. 
The extracted spot intensities are then used for construction of a three-dimensional 
map showing the distribution of electrons in the structure after ascertaining the crystal 
symmetry, unit cell parameters, crystal orientation and resolution limit.   
Using a combination of streak seeding and protein concentration optimisation 
methods, the crystal structures of 2 novel HLA-C-peptide complexes were solved to a 
















Figure 21 X-ray diffraction pattern of the HLA-C*08:01-Influenza matrix peptide 
GILGFVFTL. A single large crystal was mounted onto the Bruker ccdProteum X-ray 
diffraction system after soaking in cryoprotectant. The diffraction pattern and spot 
intensities were used to determine the structure of the HLA-C-peptide complex using 





3.5.3 HLA-C crystallisation statistics 
X-ray diffraction analysis showed that the HLA-C crystals grow in a monoclinic form 
and contain both chains of HLA-C: the 3 domains of heavy chain defined by exons α1, 
α2 and α3 (the first 276 amino acid residues) and β2-microglobulin (β2m). Thereafter, 
the crystal structures of HLA-C*08:01-CMV pp65 peptide (VVCAHELVC) and 
HLA-C*08:01-Influenza matrix peptide (GILGFVFTL) were determined to a 
relatively high resolution of 2.18Å and 1.84Å respectively. Completeness of data 
collection was more than 95% for both structures and hence allowed for detailed 
analysis of the diffraction pattern. Using molecular replacement methods, the HLA-C-
peptide structures were refined to a reasonable agreement between the observed and 
calculated structure factors shown in Table 5. There was also good stereochemistry 
and geometry. Specifically, the crystals belong to space group C2 with unit cell 
dimensions a=94Å, b=76Å and c=62Å. The unit cell volume is consistent with one 
complex in the asymmetric unit. Furthermore, analysis of the Ramachandran Plot 
revealed that about 97% of the residues were within the most favoured region. In 
addition, about 3% of the residues lie in the allowed region and no residues were 





a) Values in parentheses refer to highest resolution shell. 
b) Rcryst=Σ||Fo|–|Fc||/ Σ Fo. 
c) Rfree is the same as Rcryst but calculated on 5% of the data excluded from refinement. 
 
Table 5 Data collection and refinement statistics for novel HLA-C crystal structures. 
The crystal structures of HLA-C*08:01-CMV pp65 peptide (VVCAHELVC) and 
HLA-C*08:01-Influenza matrix peptide (GILGFVFTL) were solved to a resolution of 
2.18Å and 1.84Å respectively with completeness of data collection reaching to more 
than 95%.  There was also good stereochemistry and geometry 
 




Space group C2 C2 
Molecules in AU 1 1 


















Completeness (%)a 99.9(99.9) 97.5(89.90) 
   
Rmergea 0.114(0.415) 0.041(0.302) 
I/σ(I)a 4.47 (2.10) 12.11(3.30) 
Multiplicity 5.19(3.31) 12.65(2.64) 
 
Refinement 
Rcrysta b 0.217(0.27) 0.180(0.23) 
Rfreea c 0.272(0.29) 0.229(0.26) 
Number of reflections 18250 32697 
Number of atoms 3363 3559 




Bond length (Å) 0.006 0.012 
Bond angles (°) 1.0 1.5 
 
Ramachandran Plot 
Most favoured region 97.6 97.07 
Allowed region 2.4 2.93 
Disallowed region 0 0 
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3.5.4 Crystal structure of HLA-C*08:01 complexed with Cytomegalovirus 
(CMV) pp65 peptide VVCAHELVC 
 
In this thesis, we present 2 novel HLA-C-peptide crystal structures. The first of which 
is the HLA-C*08:01 allele complexed with Cytomegalovirus (CMV) pp65 peptide 
VVCAHELVC. This structure was solved to 2.18Å using molecular replacement 
methods with HLA-C*04:01 as a search model (Fan and Wiley, 1999). The CMV-
pp65 peptide has been established to be the minimal epitope presented by HLA-
C*08:01 and this HLA-C-peptide combination elicited cytolytic activity of the CTL 
cell lines generated by pulsing the cells with the peptide (Kondo et al., 2004). Our 
crystal structure hence provided the structural basis to this functional interaction 
between HLA-C*08:01 and the CMV pp65 peptide.  
Exons 2 to 4 encoding for the antigen-presenting α1 and α2 domains and α3 domains 
of HLA-C*08:01 were first overexpressed as inclusion bodies in E.coli and refolded 
with β2m and the nonameric CMV-pp65 peptide (VVCAHELVC) using the dilution 
method established in the earlier part of this project. The presence of refolded HLA-
C-peptide complexes was verified by a Western blot assay which utilises a 
conformational-dependent antibody W6/32 that recognises an antigenic determinant 
common to HLA-A, -B and -C molecules. The high refolding efficiency and high 
yield obtained from the two-step purification process then drove crystallisation 
screening of many conditions for a crystal of diffraction quality.  
The overall structure of the HLA-C*08:01-VVCAHELVC is similar to that of HLA-
A and HLA-B molecules coupled with various peptides. The resolved structure is a 
heterodimer comprising of two polypeptides, the HLA-C*08:01 heavy chain with 3 α 
domains (residues 1 to 276) and a non-covalently linked β2m light chain. The top 
structural domain in HLA-C*08:01 is made up of α1 and α2 domains and contains the 
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antigen binding groove. The α3 domain is positioned under the lower left corner of α1 
and α2 whereas β2m is situated directly under the center of the top domain. The α1 
and α2 domains fold nearly identically to form a deep antigen binding groove or cleft 
in which antigenic peptides can bind. When viewed from the top, the sides of the 
antigen binding groove are made of 2 adjacent α-helices on top of an 8-stranded β-
sheet (Figure 22). The antigen binding groove typically binds a single peptide and has 
a shape and size depending on the properties of the residues lining it. The residues 
lining the antigen binding groove with their side-chains pointing towards the peptide 
will determine the nature and properties of the peptide that will bind.  
Furthermore, the width (spacing between the α1 and α2 helix surfaces) and depth of 
the antigen binding groove vary throughout the site. Specifically, the ends of the 
antigen binding groove are narrower as compared to the central region. In the 
structure of HLA-A*02, the C-terminal end of the groove narrows to about 6Å. 
However, in the structure of HLA-C*08:01, there is a slight kink on the α2-helix 
which allowed its orientation towards the α1-helix. The kink or hinge region on the 
α2-helix is particularly evident when the peptide is viewed from the ends of the 
antigen binding groove (Figure 23). In addition, the depth of the antigen binding 
groove is governed by the depth of each of the 6 binding pockets or depressions 
within it. The peptide bound in the antigen binding groove adopts an extended 
conformation as the narrow ends of the antigen binding groove did not allow the 
formation of a helical peptide conformation. The extended peptide form can not only 
fit into the ends of the antigen binding groove but at the same time exposes the 
peptide backbone amide side-chain residues along the groove. The hydrogen bond 
networks are important for high-affinity peptide binding and for maintenance of a 












Figure 22 Schematic top view of the α1 and α2 domains of HLA-C*08:01 heavy 
chain (in blue) and the VVCAHELVC peptide (in yellow). The antigen binding 
groove is made up of 2 adjacent helical regions on top of an 8-stranded β-sheet and 
this forms a cleft in which a single peptide can bind. The peptide binds in an extended 
conformation in the antigen binding groove. As illustrated by the arrow (↑), there is a 
slight kink on the α2 helix that orientates it towards the α1-helix. Figure was 









Figure 23 Schematic overview of the structure of HLA-C*08:01 in complex with the 
CMV-pp65 peptide VVCAHELVC. The VVCAHELVC peptide (in yellow) is viewed 
from the (A) N-terminal and (B) C-terminal end. The α chain of HLA-C*08:01 is 
shown in blue with the individual subdomains indicated. The β2-microglobulin light 
chain is shown in red. The kink or hinge region in the α2-helix is particularly evident 





The peptide makes important contacts with the residues lining the antigen binding 
groove and this determines the specificity of the peptide which can bind with high 
affinity. In the structure of HLA-C*08:01-VVCAHELVC, P1-P3 and P8-P9 side-
chains of the peptide are responsible in making 14 polar contacts with the HLA-
C*08:01 heavy chain (Table 6). It is hence likely that the peptide is anchored into 
antigen binding groove by both its N- and C-terminal ends and structural variations 
may occur in the central portion of the peptide.  
As in the structure of HLA-C*04:01 complexed with a nonameric consensus peptide 
QYDDAVYKL (Fan and Wiley, 1999), most of the contacts found between the 
peptide main-chain atoms and HLA-C side-chains in HLA-C*08:01-VVCAHELVC 
are conserved among HLA molecules (Figure 24). At the N-terminal, the P1Val main-
chain atoms form 3 hydrogen bond contacts with 3 tyrosine residues from HLA-
C*08:01 (Tyr 7, 159 and 171). This is similar to the structure of HLA-C*04:01 
whereby P1Gln of the peptide also forms hydrogen bonds with the same 3 tyrosine 
residues.  
The main-chain NH2 group of P2Val also makes a conserved hydrogen bond 
interaction with the side-chain carboxylate of Glu 63 in the P2 pocket. This 
interaction can also be observed in HLA-A*02, HLA-B*27 and HLA-C*04 structures. 
Glu has a negatively charged side-chain and the protonation state of this side-chain 
may determine the peptide binding strength in a peptide-dependent manner and 
modulate stability of the HLA-C-peptide complex.  
Furthermore, mutational studies of the TCR have identified Lys 66 in having a dual 
role in T-cell recognition and peptide recognition by most peptide-specific HLA-
A*02-restricted T-cells (Baxter et al., 2004). This is consistent with our HLA-
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C*08:01-VVCAHELVC structure whereby Lys 66 interacts with P2Val to form a 
hydrogen bond, supporting the hypothesised role of Lys 66 in peptide recognition.  
In the structures of HLA-A*02:01, HLA-A*68:01, HLA-B*2705 and HLA-C*04:01, 
residue Tyr 99 functions as an important contact residue in the P2 pocket (Fan and 
Wiley, 1999; Guo et al., 1993). Similarly, in the structure of HLA-C*08:01, the role 
of this residue is reiterated with the formation of a hydrogen bond between the main-
chain NH2 group of P3Cys with the side-chain hydroxyl group of Tyr 99.   
Other conserved hydrogen bonds are found at the C-terminal where the terminal 
carboxylate oxygen of P9Cys interacts with the side-chains of Thr 143 and Lys 146. 
Additionally, among the conserved hydrogen bond interactions, dimorphic residues 
77 and 80 of HLA-C alleles are also involved in peptide interaction. Together with 
Tyr 84 and Thr 143, they form a polar pocket surface which may make hydrogen 
bonds with the main-chain polar atoms of a peptide residue whose side-chains fit into 
the pocket and this may contribute to a strong anchoring effect of the P9 pocket.  
The peptide conformation is however not a result of internal hydrogen bonds found 
within the peptide but rather, due to the nature of the specificity pockets of HLA-
C*08:01.  
Taken together, hydrogen bond networks that exist at the peptide’s N-terminal end 
(P1 and P2) formed by Tyr 7 of the β-sheet as well as Tyr 159 and Tyr 171 in the α2 
domain and the peptide’s C-terminal end (P8 and P9) formed by Tyr 84 in the α1 
domain as well as Thr 143, Lys 146 and Trp 147 of the α2 domains, serve not only to 
hold the peptide in the antigen binding groove at its ends but also to stabilise the 










Table 6 Hydrogen bonds from CMV pp65 peptide VVCAHELVC to HLA-C*08:01 
heavy chain. A total of 14 hydrogen bonds were identified and many of which were 
conserved among the HLA-A and –B molecules. Bond interactions are mainly 














Figure 24 Hydrogen bonds interactions (red dashes) between the peptide residues of 
CMV pp65 VVCAHELVC peptide (yellow) and HLA-C*08:01 heavy chain (blue). 
The side-chains involved in hydrogen bonding interaction with the peptide are shown 
in cyan. Most of the contacts found were conserved in HLA structures. Note that there 






When the peptide is viewed from the side (Figure 25), the peptide is slightly 
protruded at the middle with both its end anchored into the antigen binding groove. 
Specifically, P4-P6 positions of the peptide are slightly bulging whereas positions P7 
and P8 are buried within the antigen binding groove. This could mean that the P4-P6 
positions are more exposed for receptor interaction. It is hence in line with the view 
that these exposed residues serve as sites for TCR recognition and confer cytolytic 
properties to the CMV pp65 peptide. At the same time, surface plasmon resonance 
(SPR) experiments have demonstrated a dependence of KIR binding on the size of the 
P8 residue (Boyington et al., 2000). These studies showed that although Leu at P7 
was slightly favoured for KIR2DL2 binding to HLA-C*03, P8 residues larger than 
Val essentially abrogated KIR2DL2 binding. The CMV pp65 peptide coincidentally 
has P7Leu and P8Val which are favourable for KIR binding but surface accessibility 
due to the hydrogen bond interactions discouraged KIR interaction for this particular 
HLA-C-peptide combination.  
Furthermore, most HLA proteins have strict requirements on peptide length. 
Variations in peptide length may have impact on the binding and function of an 
antigenic peptide. The importance of length was supported by information provided in 
the Immune Epitope Database (IEDB) where T-cell epitope searches revealed that 
HLA-C molecules preferentially bind to nonameric peptides, although binding of 
peptides of other length is also possible (Bell et al., 2009). Indeed, peptides shorter 
than the minimal epitope VVCAHELVC failed to exhibit any cytolytic activity 
whereas longer peptides elicited a sub-optimal response in ELISPOT assay (Kondo et 
al., 2004). In this particular structure, having a longer peptide may cause a larger 
bulge that may potentially disrupt receptor interaction and influence functional 














Figure 25 The CMV pp65 VVCAHELVC peptide viewed from the side. The peptide 
is anchored at its N-terminal and C-terminal onto the antigen binding groove. 
However, the peptide is positioned rather high in the antigen binding groove, possibly 
because of the polar contacts that P1-P3 and P8-P9 side-chains of the peptide make 
with the HLA-C*08:01 heavy chain. Positions P4-P6 are exposed to the surface and 







3.5.5 Crystal structure of HLA-C*08:01 complexed with Influenza matrix 
peptide GILGFVFTL 
 
A second novel HLA-C-peptide crystal structure of the HLA-C*08:01 allele 
complexed with the Influenza matrix peptide GILGFVFTL was solved to 1.84Å using 
molecular replacement methods with HLA-C*04:01 as a search model (Fan and 
Wiley, 1999). This is the first instance that this HLA-A*02:01-restricted peptide is 
demonstrated to bind to a HLA-C allele from a structural point of view. This 
Influenza matrix peptide (GILGFVFTL) is derived from the Influenza A virus matrix 
protein from positions 58-66 where anti-influenza CD8+ T-cell response in HLA-
A*02 positive individuals are exclusively found (Bednarek et al., 1991).  
The antigen-presenting α1 and α2 domains and the α3 domain of HLA-C*08:01 were 
similarly refolded with β2m and the nonameric Influenza matrix peptide 
GILGFVFTL and subsequently verified by W6/32 antibody in Western blot assay. 
Large-scale refolding and purification were performed to obtain a high purity protein 
sample for crystallisation screens and finally a crystal of diffraction quality.  
The resolved structure of the HLA-C*08:01-GILGFVFTL complex can be seen to be 
similar to that of the HLA-C*08:01-VVCAHELVC complex. Likewise, the structure 
is a heterodimer comprising of two polypeptides, the HLA-C*08:01 heavy chain with 
three α domains (residues 1 to 276) and a non-covalently linked β2m light chain. The 
antigen binding groove is similarly made up of 2 adjacent α1 and α2 helices on top of 
an 8-stranded β-sheet with a prominent hinge region on the α2-helix (Figure 26). 
Similar to the CMV pp65 peptide, the Influenza matrix peptide also binds in the 
antigen binding groove with an extended conformation. Peptide anchoring is achieved 




In this case, the side-chains of the Influenza matrix peptide GILGFVFTL make 13 
contacts with the HLA-C*08:01 heavy chain and most are concentrated on the ends of 
the peptide (Table 7). It is thus likely that the contacts at both the N- and C-terminal 
ends hold the peptide into the antigen binding groove.  
Most of the contacts found between the peptide main-chain atoms and HLA-C side-
chains were conserved in the structure of HLA-C*08:01-GILGFVFTL (Figure 27). 
This is similar to the structures of HLA-C*04:01-QYDDAVYKL (Fan and Wiley, 
1999) and HLA-C*08:01-VVCAHELVC which was presented earlier.  
At the N-terminal end, P1Gly main-chain atoms form 3 hydrogen bond contacts with 
3 tyrosine residues from HLA-C*08:01 (Tyr 7, 159 and 171). The same 3 tyrosine 
residues were employed in the structures of HLA-A*02 (Saper et al., 1991), HLA-
C*04:01-QYDDAVYKL (Fan and Wiley, 1999) and HLA-C*08:01-VVCAHELVC, 
suggesting the significance of these 3 residues in coordinating the N-terminal peptide 
conformation to form the P1 specificity pocket in the antigen binding groove. These 3 
tyrosine residues, together with Tyr 59 and Tyr 99, form a polar pocket surface to 
facilitate the formation of hydrogen bond networks to anchor the peptide into the 
groove.  
In addition, the P2Ile side-chain is firmly positioned by two hydrogen bonds from its 
amide group to the side-chains of Glu 63 and Lys 66. Lys 66 forms a salt bridge with 
Glu 63 on top of pocket B and this may result in a stable local conformation that 
significantly enhances peptide binding. In the structure of HLA-C*04:01, Glu 63 and 
Lys 66 also make hydrogen bonds with the peptide but bondings were made with the 
P1Gln residue. This may be because the side-chain of the P1 residue points upwards 
and thus did not fit into any of the specificity pocket, giving rise to flexibility in 
peptide binding. Indeed, structural comparison of 5 structures of HLA-A*02 
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molecules bound with different viral peptides revealed that P1 side-chains can occupy 
overlapping volumes of space in all 5 peptides (Madden et al., 1993).  
In addition, residues such as Tyr 99 and Phe 99 line the P2 pocket of HLA-C*03 and 
HLA-C*04 respectively; but in the case of HLA-C*08:01, Tyr 99 interacts with the 
P3 residue. This suggests that Tyr 99 can be shared by multiple pockets and may 
interact extensively with the peptide backbone to exert an impact on T-cell 
recognition and/or NK cell recognition.   
In HLA-C molecules, there is selective binding of peptides with acidic side-chains at 
the P4 position. This is contributed by a KYRV motif of residues 66, 67, 69 and 76 on 
the α1-helix (Zemmour and Parham, 1992). However, in HLA-C*08:01-GILGFVFTL, 
the Influenza matrix peptide with P4Gly was still able to bind possibly because of its 
small side-chain and the hydrogen bond that Arg 69 forms with the carbonyl oxygen 
backbone of P4Gly.  
Other conserved hydrogen bonds are found at the C-terminal where the terminal 
carboxylate oxygen of P9Leu interacts with the side-chains of Lys 146 and Trp 147. 
Lys 146 of the HLA-C*08:01 heavy chain is of particular mention as it makes 3 
hydrogen bonds with P8 and P9 positions of the GILGFVFTL peptide. These 
interactions, together with Trp 147, provide a strong anchor to hold the peptide in the 
antigen binding groove at the C-terminal and also to stabilise the overall three-
dimensional conformation of the HLA molecule. The Lys 146 residue has also 
occasionally been implicated in TCR binding-induced conformation changes due to 
its conservation in HLA-A, -B and –C molecules (Reche and Reinherz, 2003). This 
observation further highlights the role of Lys 146 in execution of HLA functions.  
Furthermore, peptide conformation is also not a result of internal hydrogen bonds 












Figure 26 Schematic top view of the α1 and α2 domains of HLA-C*08:01 heavy 
chain (in green) and the GILGFVFTL peptide (in magenta). The antigen binding 
groove is made up of 2 adjacent helical regions on top of an 8-stranded β-sheet. As 
illustrated by the arrow (↑), a structural kink exists on the α2-helix where the adjacent 
loop region protrudes up and toward the α1-helix. This is similar to the antigen 
binding groove of the HLA-C*08:01-VVCAHELVC complex. Figure was generated 











Table 7 Hydrogen bonds from Influenza matrix peptide GILGFVFTL to HLA-
C*08:01 heavy chain. A total of 13 hydrogen bonds were identified and many of 
which were conserved among HLA-A and –B molecules. Bond interactions are 
mainly concentrated at the peptide ends and are generated using PyMOL. Note that 
Lys 146 is the hydrogen bond partner for 3 residues on the peptide and these 




















Figure 27 Hydrogen bonds interactions (red dashes) between the peptide residues of 
Influenza matrix GILGFVFTL peptide (magenta) and HLA-C*08:01 heavy chain 
(green). Side-chains involved in hydrogen bonding interaction with the peptide are 
shown in cyan. Most of the contacts found are conserved in HLA structures. Lys 146 
forms 3 hydrogen bonds with P8 and P9 positions of the peptide and serves to 
stabilise the three-dimensional structure. Note that there was no internal hydrogen 




In Figure 28, the N-terminal and C-terminal end of the peptide is viewed from both 
ends of the antigen binding groove. The bulge region at the top of the antigen binding 
groove is contributed by an adjacent loop region in the α2-helix that protrudes up and 
towards the α1-helix. The GILGFVFTL peptide has its main-chain deep in the antigen 
binding groove at the N-terminal and is slightly protruded from the surface of the 
complex as a result of a kink at P3 and P4 of the peptide. P5Phe shows the highest 
surface accessibility by pointing upwards from the antigen binding groove. Thereafter, 
the peptide main-chain gradually returns towards the floor of the antigen binding 
groove at the C-terminal. Moreover, when the peptide was viewed from the side 
(Figure 29), it can be observed that the peptide is indeed positioned rather high in the 
antigen binding groove. The peptide is anchored at its ends but the bulky nature of the 
peptide side-chains, in particular P7Phe, makes it difficult to fit into the E pocket. 
This exposes peptide residues P4 to P6 that have their roles in TCR interaction and 
supports the findings that this peptide is mainly associated with CTL response 
(Bednarek et al., 1991; Morrison et al., 1992).  
Peptide residues P7 and P8 have been observed to play a key role in affecting the 
binding of KIR to HLA-C molecules (Malnati et al., 1995; Rajagopalan and Long, 
1997). In the structure of HLA-C*08:01-GILGFVFTL, P7Phe is buried deep towards 
the β-sheet while P8Thr points towards the α1 helix. Therefore, the effect of KIR 
binding to HLA-C*08:01 is likely to be mediated by the conformation changes 
associated with peptide binding to accommodate the bulky P7Phe side-chains. On the 
other hand, the highly exposed P8Thr, with its side-chains forming a slight protrusion 
on the HLA-C*08:01 surface, will possibly form a contact point for KIR interaction. 
All these highlight the possibility of the GILGFVFTL peptide having a dual role in 








Figure 28 Schematic overview of the structure of HLA-C*08:01 in complex with the 
Influenza matrix peptide GILGFVFTL. The GILGFVFTL peptide (in magenta) is 
viewed from the (A) N-terminal and (B) C-terminal end. The α chain of HLA-
C*08:01 is shown in green with individual subdomains indicated. The β2-
microglobulin light chain is shown in red. The GILGFVFTL peptide has its main-
chain deep in the antigen binding groove at the N-terminal and is slightly protruded 
from the surface of the complex with P5Phe showing the highest surface accessibility. 

















Figure 29 The Influenza matrix GILGFVFTL peptide viewed from the side. The 
peptide is anchored at the N-terminal and C-terminal onto the antigen binding groove. 
However, the peptide is positioned rather high in the antigen binding groove, possibly 
because of the bulky nature of the peptide side-chains, especially P7Phe. Figure was 




3.5.6 Comparison of the crystal structures of HLA-C*08:01-VVCAHELVC 
and HLA-C*08:01-GILGFVFTL  
 
To further investigate HLA-C peptide binding specificity, we generated a structural 
alignment of the 2 novel HLA-C crystal structures (Figure 30). For clarity of 
presentation, only 1 HLA-C heavy chain and 1 β2m were shown in the figures. Since 
the heavy chain used for both structures were the same, overlapping the 2 novel HLA-
C-peptide structures presented will allow comparison of the 2 different peptide 
conformations. Using PyMOL, the 2 structures superimposed with a root mean square 
deviation (RMSD) value of 0.604797Å, suggesting that there were minimal structural 
variation between the 2 novel HLA-C-peptide structures.  
This observation also indicates that there is limited conformational variation of the 
HLA-C heavy chain in response to binding of different peptides. Although it has been 
proposed that peptide binding could induce a conformational change in the HLA 
heavy chain (Bluestone et al., 1992), it was difficult to make a comparison due to the 
absence of a structure for a peptide-free HLA-C complex. Nonetheless, a peptide-free 
HLA-C complex may not be stable under in vitro conditions for crystallisation 
purposes. Therefore, it is likely that the immunogenicity of these peptide epitopes is 
not caused by a conformational change in the MHC Class I molecule but rather 
dominated by its MHC-bound conformation (Tynan et al., 2005b).  
The most striking difference between the 2 novel HLA-C-peptide structures is 
contributed by their different peptide conformations. The two peptides adopted a 
slightly different conformation from one another when viewed from the top or from 
the side (Figure 31). The terminal ends of the peptide bound similarly in both 
structures but the peptide backbone made slight conformation adjustments in the 
center of the antigen binding groove in response to changes in peptide sequence. This 
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may be due to the nature and properties of the peptide side-chains that caused the 
peptide to be positioned differently into the antigen binding groove. The center parts 
of the antigen binding groove are most exposed for receptor recognition (P4-P6 for 
TCR recognition or P7-P8 for KIR recognition) and are hence important determinants 
of the antigenic identity of the HLA-C-peptide complex.  
Among the exposed residues which are implicated in receptor binding, residues 77 
and 80 on HLA-C molecules contribute to the specificity of HLA/KIR interactions. 
The novel crystal structures of HLA-C*08:01 reiterate the importance of residue 77 
and 80 (Figure 32). Mapping the position of Ser 77 in HLA-C*08:01 showed that it is 
buried within the antigen binding groove and makes contacts with the P9 positions of 
both peptides (Figure 32A). Moreover, mutational studies have shown that the 
presence of a Ser 77 residue is crucial for protection from lysis by group 2 NK cell 
clones (Biassoni et al., 1995). Therefore, it can be hypothesised that a bound peptide 
confers protective effects against NK cell lysis through direct NK cell contacts or 
conformation changes induced by peptide binding. On the other hand, Asn 80 is 
exposed and protrudes out from the antigen binding groove (Figure 32B). This makes 
Asn 80 a potential contact point for interaction with KIR. At the same time, the P8 
side-chains of both peptides are positioned upwards from the antigen binding groove, 
allowing for KIR contact.  
In spite of a surface accessible Asn 80 residue that allows for interaction with residue 
44 of KIR and an exposed P8 side-chain, a direct association between NK cell 
recognition and these novel HLA-C-peptide complexes cannot be established until 







Figure 30 Structural alignment of HLA-C*08:01-VVCAHELVC and HLA-C*08:01-
GILGFVFTL. (A) Top view of the antigen binding groove with both peptides 
superimposed. (B) The antigen binding groove as viewed from the N- and C-terminal 
of the peptide. Overlapping of the 2 structures (RMSD 0.604797Å) revealed that 
binding of the 2 peptides did not cause a significant conformation difference in the 
HLA-C*08:01 heavy chain. The Influenza matrix peptide GILGFVFTL is shown in 
magenta while the CMV pp65 peptide VVCAHELVC is shown in yellow with the 
HLA-C*08:01 heavy chain in green. For clarity, only one HLA heavy chain and one 









Figure 31 Top and side views of the CMV pp65 peptide VVCAHELVC (yellow) and 
Influenza matrix peptide GILGFVFTL (magenta). The peptides are superimposed 
using PyMOL and the peptide conformations are visualised from the top and side of 
the antigen binding groove. In the top panel, the peptides are depicted in the stick 
format whereas the bottom panel shows the peptide in ribbon format. The peptide 
ends are structurally conserved and structural variation mainly occurs at the center 











Figure 32 Positioning of Ser 77 and Asn 80 on HLA-C heavy chain. (A) Ser 77 (red) of HLA-C*08:01 (blue and green) is buried deep into the 
antigen binding groove and makes contacts with the CMV pp65 VVCAHELVC (yellow) or Influenza matrix GILGFVFTL peptide (magenta). 
(B) On the other hand, Asn 80 (red) of HLA-C*08:01 points upwards from the α1 helix in both complexes. Thus, Asn 80 is likely to serve as a 
potential KIR binding site. Note that Ser 77 and Asn 80 mainly contact the peptide at P9. Figures were generated using PyMOL.  
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Furthermore, the HLA-C side-chains that are involved in making contacts with the 
bound peptide are mostly conserved in both complexes as well as other MHC Class I 
complexes. This aspect allowed the tight anchoring of peptide in the antigen binding 
groove, independent of MHC subtype or peptide sequence. These specific interactions 
between the anchor residue and the corresponding allele-specific pocket provide 
binding affinity and specificity to endure peptide presentation on the cell surface for 
recognition by T-cells or NK cells.  
Several common residues are involved in making contacts with the peptide P1 to P3 
positions. In both structures, the conserved Tyr 7, Tyr 159 and Tyr 171 are 
responsible for the hydrogen bond network at P1 position. The salt-bridge formed by 
Glu 63 and Lys 66 as well as Tyr 99, also plays a part in anchoring P2 and P3 
positions respectively. On the peptide’s C-terminal end, Trp 147 is the major amino 
acid involved in interaction with the peptide P8 position while Lys 146 is responsible 
for making multiple hydrogen bonds to anchor the peptide at the P9 position. All 
these helped to identify P1 as another anchor position for HLA-C molecules apart 
from P2 and P9 positions. With the similarities imposed by these common residues, 
more insights to the peptide-binding motifs of HLA-C*08:01 can be elucidated.   
Nonetheless, even when the peptide contacts are conserved in both structures, the 
orientations of each of the individual side-chains may vary according to its location 
along the antigen binding groove. This is in part determined by the biochemical 
properties and depth of each of the binding pockets and these features may differ from 
allele to allele. Typically, deep pockets such as pockets A, B and F serve as major 
pockets to bind residues with large side-chains whereas a shallow pocket such as 
pocket C does not tolerate peptides with large side-chains as a consequence of bulky 
residues lining it (Saper et al., 1991). In addition, the electrostatic environment 
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provided by charged amino acid residues in the pocket can also impact peptide 
presentation. The effect of electrostatic repulsion, as influenced by the protonation 
states of key residues in pocket B, is well-characterised in HLA-B*27 molecules 
(Narzi et al., 2008). However, in the HLA-C*08:01 structures, electrostatic 
interactions in the antigen binding groove do not appear to have as great an effect as 
in HLA-B*27 where Glu 45 and Glu 63 are considered to be the key residues 
involved in binding of the main anchor P2Arg within pocket B. Glu 45 and Glu 63 
appear to adopt different protonation states depending on the peptide and in turn, alter 
the peptide binding affinity. In HLA-C*08:01, the electrostatic interactions are 
hampered by the conserved Gly 45 such that only Glu 63 is implicated in formation of 
a hydrogen bond network. Therefore, peptide stabilisation at the P2 position is not 
only peptide-dependent but also HLA subtype-dependent.  
Additionally, pocket F residues Asp 74 and Asp 77, as well as the salt bridge formed 
by Asp 116 in HLA-B*2705, and the P9 position of the bound peptide also contribute 
to stability in peptide binding. In contrast, pocket F of HLA-C*08:01 is lined by Asp 
74, Ser 77 and Phe 116. With these differences in amino acid residues, there is a 
disruption to the salt-bridge interaction and creation of an uncharged and small pocket 
for binding of a P9 residue with a small aliphatic side-chain. This is primarily because 
of the bulky nature of Phe 116 and the presence of only 1 Asp residue in the interface 
of pocket F. The large side-chain of Phe 116 prevented the insertion of a large 
incoming P9 residue due to space constraints (Figure 33A). Furthermore, Asp 74 is 
located at the far end of pocket F and hence unable to contact any region of a basic P9 
side-chain (Figure 33B). Taken together, these properties clearly allowed for binding 
of both peptides which have a small and aliphatic side-chain such as P9Leu or P9Cys 




Figure 33 Pocket F residues that are important in determining the nature of the P9 residue. (A) Phe 116 (red) points upwards from the bottom of 
the antigen binding groove and thus limits the size of the P9 residue that can insert into pocket F. (B) Asp 74 (red) alone cannot create a 
negatively charged environment deep in the pocket and cannot attract a basic P9 side-chain due to its location on the HLA-C*08:01 heavy chain 
(green). Overall, pocket F residues created an uncharged and small pocket that can only bind to a P9 residue with a small aliphatic side-chain. 
This is consistent with the novel structures of HLA-C*08:01 where the peptides with P9Leu (magenta) and P9Cys (yellow) can bind.  
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The effect of steric hindrance is also observed in the peptide conformation of the both 
peptides. This is in part dependent on the peptide sequence and also the local 
environment of the antigen binding groove.  
Due to the presence of 2 bulky Phe residues at P5 and P7 positions of the 
GILGFVFTL peptide, the effect of steric hindrance can be thought to be more 
pronounced than VVCAHELVC where His is the only bulky residue found in the 
peptide sequence. The close proximity between P5Phe and P7Phe in GILGFVFTL 
may enhance steric interaction such that there is a conformational change in peptide 
side-chain orientation. This may provide an explanation why P5Phe and P7Phe point 
in opposite directions. On the other hand, the cyclic ring of P5His in VVCAHELVC 
may also impose steric constrains such that there is twisting of the peptide main-chain 
that might lead to alterations in side-chain orientations. For reasons as such, there is 
evident structural variation from P5 through P8 of the peptide suggesting 
conformational flexibility in the peptide to adapt to changes in peptide sequence 
and/or local environment.   
The 2 novel HLA-C structures pose interesting insights into the peptide binding 
specificity of HLA-C molecules as they add on to knowledge about the important 
points of contacts between a HLA-C molecule and its binding peptide.  The important 
points of contacts are achieved by the peptide conformation as well as conserved 
hydrogen bond networks present in the antigen binding groove. The interplay between 
peptide sequence and physical and biochemical constrains imposed by the important 
residues present in the antigen binding groove will give rise to a unique peptide-
binding motif that confers functional properties to each HLA-C-peptide complex.  
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3.5.7 Comparison of the crystal structures of HLA-C*08:01-VVCAHELVC and 
HLA-C*08:01-GILGFVFTL with HLA-C*04:01-QYDDAVYKL (1QQD) 
 
Structures of HLA-C*08:01 bound to both peptides have demonstrated that the bound 
peptide conformation is largely dependent on the structural constraints imposed by the 
biochemical properties of the residues lining the antigen binding groove and/or 
peptide sequence. It is hence of interest to investigate the peptide binding specificities 
to different HLA-C alleles as a result of variations in biochemical environments.  
For comparison, the crystal structures of available HLA-C structures are taken into 
consideration. A structural alignment of HLA-C*04:01-QYDDAVYKL (1QQD) with 
HLA-C*08:01-VVCAHELVC and HLA-C*08:01-GILGFVFTL was generated using 
PyMOL (Figure 34). For clarity of presentation, only one heavy chain of HLA-
C*08:01 was illustrated in the figures. The HLA-C heavy chain of all the structures 
superimposed with minimal conformation variation (Figure 34A) while the bound 
peptides adopted different main-chain conformations at positions P4 through P8 
(Figure 34B). This confirms that the HLA-C heavy chain does not undergo any major 
conformational change induced by binding of different peptides. The peptide is also 
observed to be strongly anchored into the antigen binding groove through its ends. 
Interestingly, the peptide conformation of the nonameric peptide QYDDAVYKL 
showed a higher degree of similarity with the CMV pp65 VVCAHELVC peptide than 
the Influenza matrix GILGFVFTL peptide. This is interesting because the nonameric 
peptide QYDDAVYKL and CMV pp65 VVCAHELVC peptide are implicated with 
different functional roles. The QYDDAVYKL peptide is associated with KIR binding 
when in complex with HLA-C*04:01 but the VVCAHELVC peptide is linked with 
the activation of CTL responses when bound to HLA-C*08:01, demonstrating a 
dynamic role of the peptide in receptor binding (Fan et al., 2001; Kondo et al., 2004). 
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Apart from main-chain conformation variations, variations in positions of the peptide 
side-chains were also apparent. This could be due to the different binding pocket 
environment in the antigen binding groove. P7 and P8 peptide side-chains displayed 
the greatest degree of conformational variation. While P7Leu and P7Phe of the CMV 
pp65 VVCAHELVC peptide and Influenza matrix GILGFVFTL peptide respectively, 
have their side-chains pointing towards the α2 helix, P7Tyr of the nonameric peptide 
QYDDAVYKL is projected deep into the antigen binding groove and points towards 
the α1 helix (Figure 35A). Furthermore, although the P8 side-chains of all 3 peptides 
point upwards from the antigen binding groove, the P8Lys side-chain of 
QYDDAVYKL is tilted more towards the P7 residue as compared to the other 2 
peptides (Figure 35B). Taken together, the orientations of the peptide side-chains and 
the overall bound peptide conformation may be integral to each specific 
HLA/receptor pair involved in immune cell recognition and this may in turn influence 
the effector functions of each HLA subtype. 
Pocket analyses of the residues lining the antigen binding grooves of HLA-C*04:01 
and HLA-C*08:01 show that the similarity in peptide binding specificity may be 
attributed by the similar biochemical properties in the binding pocket environment 
(Table 8). Conserved residues are observed in pocket A of both HLA-C*04:01 and 
HLA-C*08:01. In pocket B, most of the residues are conserved between the 2 HLA-C 
heavy chains with the exception of residue 9. A Tyr 9 residue in HLA-C*08:01 is in 
place of Ser 9 in HLA-C*04:01 and the bulky nature of Tyr may limit the size of 
pocket B in HLA-C*08:01. Consequently, this could explain why the two peptides 
with P2Val and P2Ile can bind to HLA-C*08:01. On the other hand, Ser 9 in HLA-




When pocket D residues of the 2 HLA-C heavy chains were compared, it was found 
that 2 of the pocket residues at positions 152 and 156 differ between the 2 alleles. 
HLA-C*04:01 has a Glu and Arg at positions 152 and 156 respectively and the close 
proximity of Glu 152 and Arg 156 can allow for formation of a salt-bridge since they 
are of opposite charge. Alternatively, Arg 156 can orient towards P3 to interact with a 
negatively charged P3 side-chain and this provides an explanation for the binding of 
HLA-C*04:01 to QYDDAVYKL with a negatively charged P3Asp. On the other 
hand, HLA-C*08:01 has a Thr and Leu at positions 152 and 156 respectively. Both 
residues are of neutral charge and do not have any potential to form any salt-bridges 
and hence this supports the observation of HLA-C*08:01 binding to peptides with 
P3Leu and P3Cys which are uncharged.   
Analysis of pocket F residues also pointed out amino acid differences at residue 77. 
However, this change from an Asn in HLA-C*04:01 to a Ser in HLA-C*08:01 did not 
significantly affect peptide binding specificity in binding a P9Leu. Coincidentally, the 
HLA-C heavy chain residue 77 makes hydrogen bonds with the peptide and is also an 
important residue involved in the specificity of NK cell recognition. It is thus likely 
that the peptide conformation, partly controlled by residue 77, can impose limited 
peptide binding specificity for receptor binding which is in turn dependent on the 







Figure 34 Structural alignment of HLA-C*04:01-QYDDAVYKL (1QQD) with 
HLA-C*08:01-VVCAHELVC and HLA-C*08:01-GILGFVFTL. (A) The antigen 
binding grooves are viewed from the top. HLA-C*04:01 is shown in purple. Only 1 
HLA-C*08:01 heavy chain (green) is shown for clarity of presentation. Minimal 
conformation variation of the HLA-C heavy chains was observed. (B) The peptides 
are viewed from the side as they lie in the antigen binding groove. Superimposition of 
bound peptides revealed significant structural main-chain differences 
(QYDDAVYKL-blue, VVCAHELVC-yellow and GILGFVFTL-magenta). Different 









Figure 35 Relative orientations of P7 and P8 positions of the peptides in HLA-
C*04:01-QYDDAVYKL (1QQD), HLA-C*08:01-VVCAHELVC and HLA-
C*08:01-GILGFVFTL. Only 1 HLA-C*08:01 heavy chain (green) and the P6 through 
P8 positions of each peptide (QYDDAVYKL-blue, VVCAHELVC-yellow and 
GILGFVFTL-magenta) were shown for clarity of presentation. (A) The antigen 
binding groove is viewed from the peptide’s C-terminal end. P7Leu and P7Phe of 
VVCAHELVC and GILGFVFTL respectively, have their side-chains pointing 
towards the α2 helix whereas P7Tyr of QYDDAVYKL is projected deep into the 
antigen binding groove and points towards the α1 helix. (B) Superimposition of bound 
peptides from P6 to P8 revealed significant differences in side-chain orientations. The 
P8 side-chains of all 3 peptides point upwards from the antigen binding groove but the 
P8Lys side-chain of QYDDAVYKL is tilted more towards P7 as compared to the 







Table 8 Pocket analysis of HLA-C*04:01-QYDDAVYKL (1QQD), HLA-C*08:01-
VVCAHELVC and HLA-C*08:01-GILGFVFTL. Pocket A is generally conserved 
among the two HLA-C alleles. With the exception of residue 9, most of the residues 
were conserved between HLA-C*04:01 and HLA-C*08:01. The bulky nature of Tyr 9 
in HLA-C*08:01 may limit the size of pocket B, allowing only peptides with side-
chains such as P2Val and P2Ile to bind. The presence of charged residues in pocket D 
of HLA-C*04:01 may enforce the requirement of a charged P3 residue but not for 
HLA-C*08:01. In addition, analysis of pocket F residues also pointed out amino acid 
differences at residue 77. However, this change from an Asn in HLA-C*04:01 to a 
Ser in HLA-C*08:01 did not affect peptide binding specificity in binding a P9Leu. 
Residues that differ between the 2 molecules are highlighted in cyan. P2 and P9 




3.5.8 Comparison of the crystal structures of HLA-C*08:01-VVCAHELVC and 
HLA-C*08:01-GILGFVFTL with HLA-C*03:04-GAVDPLLAL in complex 
with KIR2DL2 (1EFX) 
 
HLA-C molecules play a key role in mediating NK cell responses and target cell lysis 
is mainly regulated by HLA-C/KIR interactions. Although other residues have been 
implicated, KIR recognition has been found to be mostly dependent on residues 77 
and 80 of the HLA-C heavy chain as well as peptide residues 7 and 8 (Winter et al., 
1998). Moreover, the allotypic specificity of HLA-C/KIR interactions is mainly 
facilitated by the interface formed between key residues of the 2 HLA-C subgroups 
and their respective KIR subtype. For instance, the KIR2DL1 and KIR2DS1 receptors 
can only interact with HLA-C*02, C*04, C*05 and C*06 allotypes, whereas 
KIR2DL2 and KIR2DL3 can only recognise the HLA-C*01, C*03, C*07 and C*08 
allotypes.  
To date, the crystal structures of 2 HLA-C-peptide complexes coupled with their 
respective KIR have been determined and the molecular mechanism of KIR 
recognition has been elucidated through this structural information. The first 
KIR/HLA-C-peptide complex resolved is that of HLA-C*03:04-GAVDPLLAL in 
complex with KIR2DL2 (1EFX), and this is followed by HLA-C*04:01-
QYDDAVYKL in complex with KIR2DL1 (1IM9). Similar to HLA-C*03:04, HLA-
C*08:01 belongs to the HLA-C1 subgroup which potentially interacts with the 
KIR2DL2 or KIR2DL3 receptors through Ser 77 and Asn 80.  
Hence, to compare the conformation difference upon KIR binding, a structural 
alignment was generated in PyMOL using HLA-C*03:04-GAVDPLLAL in complex 
with KIR2DL2 (1EFX) together with the 2 novel HLA-C*08:01-peptide complexes 
presented earlier (Figure 36). Only 1 heavy chain of HLA-C*08:01 was depicted for 
clarity of presentation in the figures. The 2 structures superimposed with a root mean 
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square deviation (RMSD) value of more than 3Å, suggesting that there is a great 
degree of structural variation between the 2 molecules. When viewed from the top of 
the antigen binding groove, the overall topology between the 2 molecules is 
conserved except for variations that occur near the C-terminal end of the groove 
(Figure 36A). It can be seen that the antigen binding groove of HLA-C*08:01 is 
widened at the C-terminal end of the peptide when compared with HLA-C*03:04-
GAVDPLLAL bound with KIR2DL2. This is because of the structural kink or hinge 
region in α2 helix that offers flexibility to the structure and it could also imply that 
there is a conformational change in the HLA-C heavy chain upon KIR binding. 
Among other charged residues which contributed to charge complementarity in KIR 
recognition, the KIR2DL1/HLA-C*03:04 interface also comprises of 4 salt-bridges 
formed between KIR2DL2 and HLA-C*03:04 (Glu 21-Arg 69, Glu 106-Arg 151, Asp 
135-Arg 145 and Asp 183-Lys 146) (Boyington et al., 2000). In particular, Arg 145, 
Lys 146 and Arg 151 are located at the hinge region and it is likely that formation of 
the salt-bridges shifted the α2 helix closer to the α1 helix causing the antigen binding 
groove of HLA-C*03:04 to narrow at the peptide’s C-terminal. Apart from variability 
in the α1α2 domain, the loop regions in α3 domain also adopt a different position 
relative to α1α2 in each structure (Figure 36B). 
Moreover, the peptide binding mode to HLA-C did not differ much for the 3 
complexes (Figure 37). Each of the peptide has their ends anchored into the groove 
via a number of conserved hydrogen bonds. Main-chain conformations of positions 
P4 to P8 demonstrated the greatest degree of variation with the peptide side-chains 
adopting different orientations from one another. Analysis of the side-chain 
orientations revealed that P5Pro of GAVDPLLAL bound with HLA-C*03:04 is 
buried deep into the antigen binding groove whereas P5Phe and P5His of 
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VVCAHELVC and GILGFVFTL respectively are slightly projected from the surface 
of the groove. Pro has a distinctive cyclic structure which locks its backbone dihedral 
angle at -75º and hence confers Pro an exceptional conformational rigidity compared 
to the other amino acids. This potentially caused twisting of the main-chain 
conformation from P5 of peptide GAVDPLLAL. As a result of the structural 
constrains imposed by P5Pro, the P6 and P7 side-chain orientations of GAVDPLLAL 
also differ from VVCAHELVC and GILGFVFTL. The most evident difference is that 
of P7 whereby P7Leu of GAVDPLLAL projects upwards and out of the antigen 
binding groove but P7Leu and P7Val of the two other peptides point towards the α2 
helix and into the groove. This sequence-dependent peptide conformation may 
influence functional specificity and may offer insights to peptide conformational 
changes induced by receptor recognition. 
As such, it is likely that KIR interaction induces minor HLA-C heavy chain 
conformational changes as a form of functional adaptation and at the same time, KIR 
recognition also induces peptide conformational changes such that the peptide P7 






Figure 36 Structural alignment of KIR2DL2-HLA-C*03:04-GAVDPLLAL (1EFX) 
with HLA-C*08:01-VVCAHELVC and HLA-C*08:01-GILGFVFTL. (A) The 
antigen binding grooves are viewed from the top. The HLA-C*03:04 heavy chain is 
shown in purple. Only 1 HLA-C*08:01 heavy chain (green) is shown for clarity of 
presentation. Minimal conformation variation of the HLA-C heavy chains was 
observed except widening of the antigen binding groove at the C-terminal end in 
HLA-C*08:01. (B) Regions of high variability in the α2 domain as well as α3 domain 















Figure 37 Superimposition of the peptides bound to HLA-C*03:04 (GAVDPLLAL-
cyan) and HLA-C*08:01 (VVCAHELVC-yellow and GILGFVFTL-magenta). The 
peptides are viewed from the side as they lie in the antigen binding groove. 
Significant structural main-chain differences are observed at positions P4 through P8. 
Side-chain orientations also differ among the peptides where the P6 and P7 side-chain 
orientations of GAVDPLLAL differ from VVCAHELVC and GILGFVFTL. These 
differences possibly occur as a result of the structural constrains imposed by P5Pro in 
GAVDPLLAL. Figures were generated using PyMOL.  
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3.5.9 Comparison of the crystal structure of HLA-C*08:01-GILGFVFTL with 
HLA-A*02:01-Influenza matrix GILGFVFTL (2VLL) 
 
The HLA-A, -B and –C heavy chains share high sequence homology (Davidson et al., 
1985). Nonetheless, unique polymorphisms in amino acid residues or locations, 
possibly generated through selective pressure, can be found in HLA-C molecules. The 
majority of polymorphisms in the antigen binding groove resulted in new HLA-C 
alleles being discovered whereas some polymorphic variations are unique to only 
HLA-C. This suggests that the functional significance of HLA-C may be different 
from HLA-A and HLA-B molecules.  
Therefore, to investigate the peptide binding specificities in different HLA types, the 
structures of HLA-A*02:01-Influenza matrix GILGFVFTL peptide (2VLL) and 
HLA-C*08:01-Influenza matrix GILGFVFTL peptide were superimposed using 
PyMOL. Consistent with the high sequence homology, there exist minor structural 
differences between the 2 complexes coupled with the same peptide. HLA-A*02:01 
and HLA-C*08:01 bound to the Influenza matrix peptide with a similar overall 
topology with minor structural variations occurring at the loop regions of the HLA 
heavy chain (Figure 38A). The relative orientations of each individual α domains of 
the heavy chain and β2m in HLA-A*02 and HLA-C*08 did not differ much upon 
binding of the same peptide. It can hence be deduced that peptide binding did not 
induce significant conformational adjustments in the HLA heavy chain and it is the 
structure of the bound peptide that confers antigenic uniqueness to determine the 
antigenic identity of the complex (Tynan et al., 2005b). This observation is consistent 
with the comparisons done in the previous sections. When both structures were 
viewed from the top and/or from both ends of the peptide, the characteristic hinge 
region on the α2-helix is also particularly evident (Figure 38B).  
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Furthermore, in line with the structures of other HLA molecules, the peptide is 
anchored into the antigen binding groove by its ends, indicating that conserved and/or 
polymorphic residues may be responsible for stable peptide binding and at the same 
time, impose a restriction on the length of the bound peptide. 
Careful analysis of the peptide conformations also revealed that although the peptide 
adopted a different conformation in both structures, the most striking difference 
occurs in the center part of the peptide at P4 and P5 where the peptide is most 
exposed to receptor contact (Figure 39). The main-chain conformations of both 
peptides share a common backbone twisting but the peptide side-chains point in 
various orientations. When bound with HLA-A*02:01, P5Phe of the GILGFVFTL 
peptide points sideways towards the α2 helix and down into the groove whereas 
P5Phe of the GILGFVFTL peptide bound to HLA-C*08:01 points upwards and out of 
the groove (Figure 40). In this case, steric hindrance imposed by P7Phe cannot be 
taken into consideration because both peptides under comparison were the same. Thus, 
the biochemical properties of the local environment in which the peptide is located in 
may influence the ability of the P5 side-chain to adopt different orientations via its 
interaction with binding pocket residues.  
Indeed, detailed analysis of pocket residues associated with peptide binding 
confirmed the presence of many conserved and polymorphic interactions within the 
antigen binding groove that act as determinants to influence bound peptide 
conformation (Table 9). Nevertheless, some contacts are MHC subtype-specific but 
general for all peptides satisfying the appropriate binding motif. 
Pocket A residues responsible for binding of the peptide P1 position are conserved 
between the 2 HLA molecules whereas other pocket residues vary. The conserved 
pocket A residues are important for making hydrogen bonds with the peptide to 
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ensure the precise positioning of the peptide’s N-terminal in the antigen binding 
groove. This is mainly achieved by 4 highly conserved tyrosine residues Tyr 7, Tyr 59, 
Tyr 159 and Tyr 171. In addition, strong anchoring at the P2 and P9 primary anchors 
is also achieved by conserved hydrogen bonding interactions. The peptide P2 position 
is stabilised by Glu 63 and Lys 66 whereas C-terminal anchoring at the P9 position is 
dependent on peptide interactions with Tyr 84, Thr 143 and Lys 146. Apart from these 
conserved interactions, the polymorphic residue 77 is also involved in the hydrogen 
bond network. Even though residue 77 is different in HLA-A*02:01 and HLA-
C*08:01, hydrogen bonding can still occur between the peptide backbone and the 
HLA side-chain.  
Polymorphism in the residues of other binding pockets may alter the physical and 
biochemical properties of the binding pocket for peptide interaction and hence result 
in a different bound peptide conformation. For instance, in HLA-A*02:01, there are 
no deep pockets in the center of the antigen binding groove but the hydrophobic 
residues lining the inner wall of the α2 helix may be responsible for the projection of 
P5Phe towards the α2 helix. On the other hand, polar and hydrophilic residues such as 
Thr 152 and Gln 155 that line the inner wall of the α2 helix of HLA-C*08:01 may 
hinder the projection of the hydrophobic P5Phe deep into the groove. This 
demonstrates the ability of P5Phe side-chain to exploit different hydrophobic packing 
interactions and adopt various conformations to adapt to each HLA type even though 




Figure 38 Structural alignment of HLA-A*02:01-GILGFVFTL (2VLL) with HLA-
C*08:01-GILGFVFTL. (A) The antigen binding grooves are viewed from the top. 
The HLA-A*02:01 heavy chain is shown in orange. Only 1 HLA-C*08:01 heavy 
chain (green) is shown for clarity of presentation. Consistent with high sequence 
homology, HLA-A*02:01 and HLA-C*08:01 showed minimal conformation variation 
at the α1α2 domains of the HLA heavy chains upon binding of the same peptide. (B) 
The α3 domain and β2m also did not differ much in their conformations. The 

















Figure 39 Superimposition of the GILGFVFTL peptide bound to HLA-A*02:01 
(purple) and HLA-C*08:01 (magenta). The peptides are viewed from top of the 
antigen binding groove and from the side as they lie in the antigen binding groove. 
Peptides are similarly anchored in the antigen binding groove via its terminal ends. 
Significant structural main-chain differences are observed at positions P4 and P5 but 
the main-chain conformations are generally conserved with differing side-chain 





Figure 40 Orientation of P5Phe in Influenza matrix GILGFVFTL peptide when bound to HLA-A*02:01 and HLA-C*08:01. (A) The antigen 
binding groove is viewed from the side. Only 1 heavy chain (green) and the P4 through P6 positions of each peptide (GILGFVFTL binding to 
HLA-A*02:01-purple and GILGFVFTL binding to HLA-C*08:01-magenta) were shown for clarity of presentation. When bound with HLA-
A*02:01, P5Phe of the GILGFVFTL peptide points towards the α2 helix whereas P5Phe of the Influenza peptide bound to HLA-C*08:01 
projects upwards and out of the groove. (B) When the antigen binding groove is viewed from the peptide’s N-terminal, P5Phe of the 





Table 9 Pocket analysis of HLA-A*02:01-GILGFVFTL (2VLL) and HLA-C*08:01-
GILGFVFTL. Pocket A is conserved among the two alleles while polymorphic 
residues in other binding pockets likely altered the physical and biochemical 
properties of each pocket to give rise to a different peptide conformation. Residues 
that differ between the 2 molecules are highlighted in cyan. P2 and P9 residues 
participating in hydrogen bond network with the peptide are highlighted in pink.  
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3.6 Thermal stability of HLA-C molecules 
Circular dichroism (CD) spectrometry has been well-established to be useful in the 
determination of thermal stability of HLA-A and HLA-B molecules (Liu et al., 2011; 
Reinelt et al., 2001). Hence the thermal stability of the HLA-C-peptide complexes 
defined in the study can be studied the same way and used for comparison with HLA-
A*02. 
To compare the thermal stability of different HLA-peptide complexes, the samples 
were prepared under the same refolding conditions and subjected to CD spectroscopy. 
The thermal denaturation experiment for each HLA-peptide complex were followed 
over a fixed temperature range of 20-90ºC and fixed time period at a protein 
concentration of 20µM in 20mM Tris (pH 8.0) buffer. The change in ellipticity at 
218nm at various temperatures is representative of thermal unfolding and will give an 
indication of how the secondary structures changes over time. In general, a less stable 
HLA-peptide complex will require a lower temperature to induce thermal unfolding 
as indicated by a change in ellipticity at 218nm. The secondary structures are held 
together by disulphide bridges present within the antigen binding groove of HLA-C 
and hence should be reversible. 
As observed on the thermal unfolding spectra (Figure 41), HLA-C*08:01-HBV Core 
18-27 variant FLPSDYFPSV peptide complex demonstrated the lowest thermal 
stability where an increase in ellipticity was observed at around 40ºC. On the other 
hand, the increase in ellipticity for HLA-A*02:01-Influenza matrix GILGFVFTL 
peptide complex only occurred at around 60ºC, indicating that the complex has the 
greatest thermal stability as compared to the rest of the HLA-peptide complexes. The 
HLA-A*02:01-Influenza matrix GILGFVFTL peptide complex and HLA-C*08:01-
CMV pp65 VVCAHELVC peptide complex, both known to elicit a CTL response 
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(Kondo et al., 2004; Morrison et al., 1992), exhibited a similar thermal unfolding 
profile with an increase in ellipticity occurring at around 60ºC. This highlights the 
requirement of a relatively stable HLA-peptide complex to await recognition by the 
TCR and subsequently elicit a CTL response.  
In addition, the HLA-C*08:01-GILGFVFTL peptide complex unfolded at a lower 
temperature relative to the HLA-C*08:01-VVCAHELVC peptide complex. This 
implies that HLA-C*08:01-VVCAHELVC is more stable than HLA-C*08:01-
GILGFVFTL. These findings fit the purification profile observed in our study where 
the peak corresponding to the purified HLA-C*08:01-VVCAHELVC complex is 
much larger than the peak for HLA-C*08:01-GILGFVFTL.  
The HLA-C*08:01-GILGFVFTL complex was also less stable relative to HLA-
A*02:01-GILGFVFTL. The relative stability of these complexes may reflect that 
even though HLA-A*02:01 with HLA-C*08:01 share a similar peptide binding 
specificity, the peptide binding stability and/or affinity differ between the 2 HLA 
types. Therefore, even though both HLA-A*02:01 with HLA-C*08:01 can present the 
same peptide, there may be functional differences displayed by each HLA subtype. 
However, functional analysis of HLA-C*08:01-GILGFVFTL is still lacking and 
requires further investigation.  
The thermal unfolding study can also be supplemented with a full-wavelength CD 
spectrum acquired at a 5 or 10 degree-interval to assess the contribution of different 
secondary structure types present in the HLA-C-peptide complex. Even though CD 
cannot provide structural information at high resolutions like X-ray crystallography, 
this technique can be applied to explore the HLA-C-peptide interactions and 











Figure 41 Circular dichroism thermal unfolding. (A) The HLA-C*08:01-Influenza 
matrix GILGFVFTL peptide, HLA-A*02:01-Influenza matrix GILGFVFTL peptide, 
HLA-C*08:01-CMV pp65 VVCAHELVC peptide and HLA-C*08:01-HBV Core 18-
27 variant FLPSDYFPSV peptide are shown using black, red, green and blue lines 
respectively. Each thermal unfolding experiment was carried out using 200µl sample 
at 20µM protein concentration. The HLA-A*02:01-Influenza matrix GILGFVFTL 
peptide complex has the greatest thermal stability as compared to the rest of the HLA-
peptide complexes. (B) Normalising the data to the maximum ellipticity observed at 
90°C whereby protein dissociation is maximum, the order of stability of the refolded 
HLA-peptide complexes remain the same as in Figure 41A. Results are expressed as 




CHAPTER 4 DISCUSSION 
4.1 HLA-C cloning and expression  
The regulation of HLA-C surface expression occurs at several levels: transcription, 
translation and post-translation. At the transcriptional level, HLA-C heavy chain 
mRNA is thought to have a high-turnover rate (McCutcheon et al., 1995). 
Furthermore, a single base pair insertion or deletion at position 263 of the 3’-
untranslated region in HLA-C mRNA results in the formation of a target site for 
microRNA binding causing post-transcriptional cleavage and destabilisation 
(Kulkarni et al., 2011). After protein translation, the HLA-C heavy chain does not 
associate efficiently with β2-microglobulin and further accumulates in the ER while 
waiting for the restricted peptide repertoire to bind (Neisig et al., 1998). This 
ultimately leads to ER retention and degradation of the immature HLA-C molecules 
while waiting for peptide loading. Even when the HLA-C heavy chain eventually gets 
associated with a binding peptide, a di-hydrophobic signal present in the HLA-C 
cytoplasmic tail promotes rapid internalisation and degradation of HLA-C which 
further limits HLA-C surface expression levels (Schaefer et al., 2008). All these 
factors confound existing experimental set-ups that impede efficient HLA-C cloning 
and expression.  
In this thesis, the use of locus and/or allele-specific primers and optimised PCR 
conditions specific to each of the 18 HLA-C alleles was used to overcome problems 
in cloning associated with high mRNA turnover rates. Although attempts to express 
HLA-C proteins using a bacterial expression system also revealed a lower expression 
level as compared to HLA-A and HLA-B proteins, this short-coming can be 
overcome by optimising downstream experiments.  
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A possible explanation for the low levels of HLA-C expression in E.coli is the codon 
usage of E.coli bacteria. This is because there is generally a codon usage bias whereby 
high bias is usually seen in highly expressed genes. On the other hand, unfavourable 
codon usage is usually seen for moderately or lowly expressed genes and this can 
significantly reduce the maximum translation rate of a protein. Codon optimisation of 
the lowly expressed HLA-C gene will potentially minimise the problem of bias codon 
usage and increase the protein expression of HLA-C alleles. Nonetheless, the 
experimental procedures described in this thesis generated sufficient HLA-C proteins 
for further downstream experiments.  
The library of HLA-C alleles was chosen on the basis of high global distribution and 
hence the study serves to be an extensive coverage of the peptide-binding motif of 
most HLA-C alleles.  
4.2 HLA-C refolding 
Even though the expression level of HLA-C molecules was still lesser than that of 
HLA-A and HLA-B molecules in the E.coli strain BL21 (DE3), enough protein can 
be obtained for refolding. This is because a homogenous and sensitive refolding assay 
optimised for refolding of HLA-C-peptide complexes was developed using HLA-
A*02 as a model.  
Current HLA-peptide binding assays utilise either cell-bound or solubilised HLA 
molecules (Sette et al., 1994a; van der Burg et al., 1995). However, the cell-bound 
peptide binding assays may be limited by the low surface expression of the HLA type 
as well as rely on the displacement of peptide from preformed complexes. In addition, 
the peptides that these HLA molecules can present may also be limited to those which 
the cells can process intra-cellularly and eventually present on the cell surface. Thus, 
refolding of HLA molecules is known to occur at low efficiency in vivo. Other 
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strategies of cell-free HLA-peptide binding assay made use of HLA molecules 
isolated from cell lysates or produced by recombinant DNA technology which may 
represent an improvement to existing assays. An important feature for the use of 
recombinant HLA molecules in peptide binding assays is its high reproducibility. This 
is because the assay system resembles the way HLA-peptide complexes can form in 
vivo with the intra-cellular assembly process depending on the number of empty 
heavy chains available for peptide loading in the ER. In some cases, the efficiency of 
assembly was further enhanced by the incorporation of preformed disulphide bonds 
within the HLA heavy chain (Ostergaard Pedersen et al., 2001). Furthermore, in vitro 
HLA-peptide binding assays using recombinant molecules need only very small 
amounts of protein and peptide. Hence, the assays can be performed in a cost-
effective, rapid and reproducible manner.  
Existing analyses of allele-specific peptide-binding motifs are largely focused on 
HLA-A*02 molecules and vast information can be obtained about refolding of HLA-
A*02 molecules using recombinant methods. A refolding approach involving dilution 
and dialysis was chosen as our framework for investigation and feasibility of the 
refolding assay was tested against known HLA-A*02-peptide complexes (Garboczi et 
al., 1992). Thereafter, a series of optimisation experiments, involving alterations of 
refolding buffer components concentrations and the ratios of heavy chain, β2m and 
peptide, were designed to achieve high refolding efficiency. Finally, a set of refolding 
conditions specific for efficient refolding of HLA-C with a binding peptide was 
derived. The efficiency of the refolding assay was also validated by several known 
HLA-C-peptide complexes published to have roles in T-cell or NK cell function 
before testing on all 18 alleles.  
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Additionally, the sensitivity and specificity of the refolding assay were assured and 
achieved by a conformation-dependent monoclonal antibody (W6/32) in Western blot. 
Western blot serves as a read-out system to detect the presence of a HLA-C-peptide 
complex and to provide an indication of the refolding efficiency by band intensity. 
Information derived from the refolding experiments can be used for generation of a 
peptide-binding motif specific for each allele through a well-designed peptide panel 
which may include a set of polyalanine analog peptides. For instance, polyalanine 
analog peptides have been widely used to determine the role of secondary anchors in 
peptide binding to HLA-A molecules (Collins et al., 1999; Ruppert et al., 1993). 
Using polyalanine analogs of a parental peptide ALAKAAAAV containing the 
reported HLA-A*02 peptide-binding motif in an in vitro peptide binding assay, the 
role of secondary anchors in determining the HLA-A*02 binding capacity of a peptide 
ligand can be studied (Ruppert et al., 1993). Similarly, by the use of polyalanine 
analog peptides, the effect of peptide length and composition on binding to HLA-
Aw*68 can be investigated using an in vitro refolding assay and CD spectrometry 
thermal stability experiments (Collins et al., 1999). In this manner, these alanine 
scanning experiments may be applied to further explore the peptide-binding motif of 
HLA-C molecules.  
As a proof of principle, peptides which are known to bind to HLA-C in functional 
experiments were tested using the established and optimised refolding assay. 
Thereafter, the small-scale refolding assay was applied to screen for potential HLA-C-
peptide complex formation that may offer insights in the peptide binding specificities 
of the 18 highly-occurring HLA-C alleles.  
The established refolding assay provided another option to identify peptides which 
can bind to recombinant HLA-C molecules, regardless of whether the peptides can be 
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generated, processed or transported in the cell. Selective binding of peptides from a 
large random pool of synthetic nonamers allowed the analysis of allele-specific 
peptide-binding motifs. Furthermore, refolded HLA-C-peptide complexes can be 
selected solely based on binding affinities and the peptide-binding motifs for any 
HLA allele can be screened even though it has a low level of cell surface expression. 
Information obtained through assessment of binding requirements offered an 
expanded motif which may be applicable for prediction and design of peptides that 
bind to the HLA protein with enhanced affinity.  
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4.2.1 HLA-C1 subgroup alleles bind to Influenza A virus (GILGFVFTL) peptide 
 
The small-scale refolding assay identified many potential complexes formed by the 
different combinations of HLA-C alleles with peptides from HIV, HCV, Influenza 
virus and even melanoma-associated peptides. Of all the alleles tested, it is interesting 
to note that HLA-C*01:02, HLA-C*07:01 and HLA-C*12:02, all belonging to the 
HLA-C1 subgroup, bound to the Influenza virus (GILGFVFTL) peptide which 
corresponds to positions 58-66 of the Influenza A virus matrix protein. This may 
imply that HLA-C1 subgroup alleles share a common peptide binding specificity to be 
able to bind to the same peptide or probably execute a similar functional role in 
Influenza A virus infection.  
Indeed, the involvement of HLA-C1 alleles together with the corresponding KIR 
genotype, in influencing the differential innate immune responsiveness to Influenza A 
virus infection have been elucidated (Ahlenstiel et al., 2008). With the use of multi-
color flow cytometry techniques to analyse for CD107a expression and degranulation, 
NK cells inhibited by HLA-C1 homozygous subjects showed a stronger increase in 
CD107a expression after Influenza A virus infection as compared to the NK cells 
inhibited by HLA-C2 homozygous individuals. In addition, a relatively higher level of 
IFN-γ was secreted at earlier time points after virus infection in HLA-C1 homozygous 
individuals. However, it is unlikely that the stronger NK cell response is due to the 
KIR2DL3/HLA-C1 compound genotype compared with KIR2DL1/HLA-C2 
compound genotype as the HLA-C1 subgroup is composed of multiple HLA-C alleles, 
each of a different peptide-binding motif. As such, the HLA-C alleles may each 
present a different peptide but activate the same KIR. In our study, we identified that 
HLA-C*01:02, HLA-C*07:01 and HLA-C*12:02 may share a common peptide-
binding motif and perhaps have a role in presenting the GILGFVFTL peptide to 
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KIR2DL3 to result in differential NK cell functional responsiveness to Influenza A 
virus infection.  
4.2.2 HLA-C alleles exhibit peptide length specificity 
The small-scale refolding assay also revealed that none of the alleles tested was able 
to bind to the 3 selected peptides of HCV origin. This may be due to the restricted 
peptide repertoire that did not fit into the peptide-binding motif of any of the alleles 
tested. Moreover, 2 out of the 3 HCV peptides are 10 amino acids in length which 
may be energetically unfavourable for structural binding to HLA-C.  
It is well-established that HLA-A molecules generally bind peptides of 8-10 amino 
acids in length but binding of longer peptides can still occur and exert an impact on T-
cell recognition (Burrows et al., 2008; Rammensee et al., 1993). For example, in 
HLA-A*02, naturally processed peptides longer than 9 amino acid residues in length 
was found to bind with high affinity when a Leu residue was present at P2 (Chen et al., 
1994). Longer peptides can also adopt different conformations to accommodate to 
binding in the antigen binding groove of HLA-A*02. The importance of the P2 
anchor was reiterated by another study where HLA-A*02:01 refolding assays 
involving denatured recombinant molecules. In this study, the authors used a series of 
wild-type and analog peptides to demonstrate that as long as the peptide had the 
correct primary anchor residues, binding of an analog peptide of up to 13 amino acids 
can occur (Robbins et al., 1995). Therefore, the HCV peptides included in our study 
may not have the right P2 anchor residue for peptide binding into the antigen binding 
groove of any of the 18 HLA-C alleles.  
Peptide length specificity was further confirmed by structural characterisation of 
MHC Class I molecules which have always focused on HLA molecules binding to 
nonameric peptides. To date, 7 MHC Class I complexes with bound peptides of 
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longer than 10 amino acids have been solved (Guo et al., 1992; Miles et al., 2006; 
Miles et al., 2005; Probst-Kepper et al., 2004; Speir et al., 2001; Stewart-Jones et al., 
2005; Tynan et al., 2005a). Crystallographic analyses showed that the longer peptides 
bound to the HLA molecule with a bulging conformation and are accommodated by 
additional kinking of the peptide backbone near the center of the antigen binding 
groove (Guo et al., 1992). Peptide kinking is necessary to maintain the conserved 
hydrogen bond interactions between HLA heavy chain and the peptide’s terminal 
ends. However, by adopting a kinked and extended conformation that will result in 
the loss of more central HLA-peptide interactions, the binding energy contributed by 
the hydrogen bonding network may be significantly affected. Thus, anchoring of a 
longer peptide into the antigen binding groove must be facilitated by conserved 
hydrogen bonds located at the peptide ends, giving rise to length specificity.  
4.2.3 HLA-C association with HCV  
Even though there was no observable binding to any of the HCV peptides, 
epidemiological observations have linked HLA-C with HCV. At least 2 independent 
studies have shown that individuals who spontaneously resolve HCV infection were 
more likely to express the KIR2DL3 gene in combination with its cognate HLA-C1 
subgroup ligands. This HLA-C/KIR combination is suggested to have a weaker 
inhibitory interaction that can be easily overcome to activate NK cells to elicit an 
antiviral response against HCV (Khakoo et al., 2004; Romero et al., 2008). In a more 
recent study, it was further confirmed that KIR2DL3 and HLA-C1 are associated with 
positive outcomes across a spectrum of clinical profiles after HCV infection (Knapp 
et al., 2010). The study also pointed out the possibility that HCV-derived peptides 
may affect NK cell reactivity through its interaction with KIR2DL3. However, these 
data only highlight the relevance of HLA-C/KIR genotypes in the immune response 
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of HCV. Genetic association studies involving patients who were well-documented 
with HCV clearance or persistence have also identified the HLA-C genes that affected 
the outcome of an HCV infection through molecular typing (Thio et al., 2002). It was 
found that HLA-C*01:02 was associated with viral clearance whereas HLA-C*04 was 
associated with viral persistence even though it is in strong linkage disequilibrium 
with HLA-B*35 and HLA-B*53. 
Nevertheless, functional work is still lacking to unravel the precise mechanisms of 
disease protection. For this reason, our refolding assay may prove useful in the bid to 
obtain a positive HLA-C-HCV peptide complex that may interact with KIR2DL3 if 
we extend our peptide panel to cover more peptides derived from HCV. Subsequently, 
identification of potential HLA-C-peptide complexes will allow for exploration of the 
functional interaction between the HLA-C-peptide complex and its corresponding 
KIR by NK cell activation assays.  
4.2.4 Association of HLA-C*08:01 with HBV 
Regardless of the peptide length specificity, peptides of 10 amino acids in length were 
shown to be able to bind to HLA-C*08:01. The HLA-C*08:01 molecule is 
particularly interesting because the allele also demonstrated binding to the other viral 
peptides included in our study.  
HLA-C*08 was first discovered in the Caucasian population and found to be in strong 
linkage disequilibrium with HLA-B*14 and HLA-B*15:02 in the Chinese population 
(Middleton et al., 2003). The HLA-C*08 allele group has also been primarily 
associated with hypersensitivity to a drug called nevirapine which is primarily a non-
nucleoside reverse-transcriptase inhibitor used to treat HIV-1 infection (Littera et al., 
2006). A genetic association study was performed on HIV-1 infected individuals and 
it was found that there was a statistically significant association between a nevirapine-
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hypersensitivity reaction and HLA-C*08. The authors also hypothesised that the 
nevirapine drug or its metabolite, when coupled with the HLA-C*08 antigen, may 
cause some severe hypersensitive reactions and HLA typing before drug treatment 
will allow for a more careful choice of drugs that will reduce fatality.  
In our refolding study, HLA-C*08:01 formed complexes with 3 decameric peptides, 
FLPSDFFPSI, FLPSDFFPSV and FLPSDYFPSV, which are variants of the HBV 
Core 18-27 peptide. The HBV Core 18-27 peptide is frequently associated with the 
generation of HBV-specific CTL responses in HLA-A*02 individuals and contains a 
HLA-A*02 peptide-binding motif (Bertoletti et al., 1994). Hence, there is a likelihood 
that HLA-C*0801 share the same peptide binding specificity as the HLA-A*02 
molecules such that they are able to bind the same set of peptides. However, detailed 
binding pocket comparisons between HLA-A*02 and HLA-C*08 bound to the same 
peptide, done using structural studies, are necessary to support this hypothesis.  
Apart from HCV, previous studies have also associated HLA-C with HBV. Similar to 
HCV infections, it was noted that different HLA-C/KIR combinations can confer 
susceptibility to or protection from chronic Hepatitis B (Gao et al., 2010). Specifically, 
the KIR2DL3 homozygotes in the presence of HLA-C1C1 genotype confer protection 
against chronic Hepatitis B. This is consistent with the case of HCV infections when 
KIR2DL3 in combination with HLA-C1 are positive determinants in disease outcome. 
More recently, a case-control study involving HBV-associated Hepatocellular 
carcinoma (HCC) patients further established a close correlation between HLA-C, 
KIR and HBV (Pan et al., 2011). All of the studies reported the association of these 
genetic factors in disease development but failed to address the role of the peptide in 
HLA-C/KIR interactions. Identification of a peptide which is able to bind to HLA-C 
and in turn recognise KIR will enhance personalised Hepatitis B treatment aiming at 
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HCC prevention. Furthermore, functional studies relating to HLA-C*08:01 (which 
belongs to the HLA-C1 subgroup) and the HBV Core 18-27 peptide may provide 
insights into the association between HLA-C and HBV from a different viewpoint.  
In addition, other than FLPSDFFPSI and FLPSDFFPSV, the decameric 
FLPSDYFPSV variant was also able to bind to HLA-C*08:01 even though it has a 
bulky P6Tyr residue in the center part of the peptide. This observation supports 
crystallographic analyses which revealed the lack of hydrogen bonds at the center 
region of the peptide when longer peptides bind to HLA molecules (Guo et al., 1992). 
The loose hydrogen bond interactions found in the center of the antigen binding 
groove possibly account for conformational flexibility that allowed binding of a 
P6Tyr as long as the peptide ends are anchored by conserved hydrogen bonds. Under 
conditions as such, the thermal stability of this HLA-C*08:01-FLPSDYFPSV 
complex is expected to be affected. Indeed, CD spectroscopy data presented in our 
study suggest that refolded HLA-C*08:01-FLPSDYFPSV complexes begin to unfold 
at around 40-50ºC which is relatively lower than HLA-A*02-peptide complexes and 
other known HLA-C-peptide complexes included in the study. Nonetheless, the exact 
hydrogen bond interactions between HLA-C and the peptide will require verification 
by structural analysis.   
4.2.5 HLA-C*08:01 demonstrates P8 preference  
Apart from binding HBV peptides, HLA-C*08:01 can also form complexes with 
peptides such as the Influenza matrix peptide (GILGFVFTL), HIV Gag peptide 
(SLFNTVATL) and Melanoma-associated peptide (EAAGIGILTV). An interesting 
point to note is that all 3 peptides have a Thr at P8 position, highlighting that HLA-
C*08:01 also exhibits P8 peptide preference and that heavy chain residues 
coordinating with the peptide P8 or P9 position may be essential for peptide 
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anchorage. This P8 peptide preference was first described in the crystal structure of 
HLA-C*03:04 (Boyington et al., 2000) and proposed to play a role in KIR interaction. 
Surface Plasmon Resonance (SPR) binding measurements done using several 
variations of the GAVDPLLAL peptide at P8 position revealed that the affinity of 
KIR2DL2 for HLA-C*03:04 is dependent on the size of the P8 side-chain. Binding 
affinity generally decreases when the P8 side-chain increases in size but residues 
larger than Val abrogated KIR2DL2 binding. Consequently, the P8 residue of the 
bound peptide imposes structural constrains to provide another level of specificity for 
the interaction between HLA-C and KIR. Limited peptide specificity for receptor 
binding may also depend on the different peptide conformations observed in each 
HLA-C-peptide complexes as the nature of the peptide side-chains will in turn 
influence side-chain orientations. Detailed analysis into the role of P8 in coordinating 
KIR binding will enhance understanding of HLA-C/KIR interaction.  
The size of the Thr side-chain is similar to that of Val except for the difference 
observed in their side-chains - a hydroxyl-group is found in Thr in place of a methyl-
group for Val. The hydroxyl-group can be proposed to take part in the hydrogen bond 
networks present within the antigen binding groove and influence the bound peptide 
conformation. Indeed, in the 2 novel HLA-C*08:01 structures, the peptide P8 position 
plays an integral part in forming hydrogen bonds with heavy chain residues. 
Particularly in HLA-C*08:01-GILGFVFTL, the hydroxyl-group of P8Thr makes 
several hydrogen bonding contacts with Lys 146 and Thr 147 which may contribute to 
stabilisation of the HLA-C-peptide complex as well as peptide anchorage. It is 
however uncertain whether conserved hydrogen bonds can be made when the HIV 
Gag (SLFNTVATL) peptide and Melanoma-associated peptide (EAAGIGILTV) bind 
to HLA-C*08:01 or other alleles until further structural analyses are carried out.  
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Nonetheless, despite the fact that there is no functional evidence being uncovered 
between HLA-C with the Influenza matrix peptide (GILGFVFTL), HIV Gag peptide 
(SLFNTVATL) and Melanoma-associated peptide (EAAGIGILTV), the HLA-C 
allele group is often associated with these disease outcomes.  
For example, HLA-C molecules have been identified to have an emerging role in 
HIV-1 infection due to its surface expression. The level of HLA-C expression has 
been implicated to be a key element in control of HIV viral load where slower disease 
progression correlates with higher HLA-C surface expression (Corrah et al., 2011). 
Previously, genome-wide studies have identified a single nucleotide polymorphism 
(SNP), located 35kb upstream of the HLA-C transcription initiation site (-35C/T), to 
be a major determinant in controlling viral load (Fellay et al., 2007). Analysis of 
multiple -35 SNP genotypes and HLA-C alleles revealed a correlation between the 
SNP genotypes and distribution of HLA-C surface expression which in turn affected 
disease progression. In particular, HLA-C*07, which is in strong linkage 
disequilibrium with the -35T SNP genotype (Pereyra et al., 2010) and has a low 
surface expression, is thought to be associated with HIV-1 disease progression. 
However, further characterisation of the various SNP genotypes in conferring 
susceptibility to or protection against disease progression ought to be carried out. At 
the same time, HLA-C may present antigens more efficiently to the CTLs such that 
there is better recognition and lysis of HIV-1 infected cells by HLA-C-restricted 
CTLs. In fact, in a HIV-1 infected cohort, characterised HLA-C-restricted CTL was 
found to be up to 54% of the total CTL response (Makadzange et al., 2010). These 
HLA-C-restricted CTLs expressed surface markers and activities that are 
phenotypically identical to that of HLA-A and HLA-B-derived CTLs. Taken together, 
the HIV Gag peptide identified through the refolding assay may represent another 
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CTL epitope presented by HLA-C. Though high HLA-C expression is beneficial for 
disease clearance, it may be limited by the inhibitory effect of HLA-C on the NK cell 
response. This is because elevated HLA-C expression may increase susceptibility to 
various infections or malignancies that require an effective NK cell response for 
disease control.  
Besides HIV-1 infection, the HLA-C allele group is also increasingly being associated 
with melanoma. For instance, T-cell epitopes derived from MAGE genes or 
differentiated melanoma antigen have been discovered for HLA-C*07 and HLA-C*08 
(Breckpot et al., 2004; Castelli et al., 1999; Larrieu et al., 2008; Wolfl et al., 2007). 
These antigens can serve as targets for cancer immunotherapy if used in combination 
with other peptides or proteins. Such vaccines may overcome the heterogeneous 
expression of tumor-associated antigens and partially counteract tumor escape. 
Therefore, the melanoma-associated peptide identified in our homogenous refolding 
assay may be functionally tested to be a HLA-C-restricted epitope before being 
incorporated into immunologically-based therapies.  
The P8 preference may also be attributed by heavy chain residues which are 
responsible for making hydrogen bonding and electrostatic interactions with the 
peptide P8 or P9 position and in turn anchoring it into the antigen binding groove. In 
fact, electrostatic interactions are reported to have significant roles in peptide binding 
to HLA molecules. For example, the antigenic features of HLA-B*27 are shaped 
through short and long range electrostatic interactions formed by residues lining the 
antigen binding groove with the bound peptide (Narzi et al., 2008). In a similar 
manner, peptide stabilisation at the peptide P8 position may be dominated by 
electrostatic interactions that tolerate selective binding of a P8Thr.   
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The effect of electrostatic interactions can also be applied to explain why HLA-
C*08:01 bound to several HBV peptides whereas HLA-C*08:02 did not. A probable 
explanation would be that the 3 amino acid differences between HLA-C*08:01 and 
HLA-C*08:02 generated a different electrostatic environment that hindered peptide 
binding. Mapping out the 3 residues onto the solved structure of HLA-C*08:01 
(Figure 42), it can be observed that residue 138 points outward of the antigen binding 
groove and hence unlikely to contribute to any effect in peptide binding specificity. 
However, residues 152 and 156 are strategically located with their side-chains 
pointing into the antigen binding groove. In HLA-C*08:01, the carbonyl backbone of 
Thr 152 may potentially form a hydrogen bond with the amide backbone of Leu 156 
to create a spacious pocket with both hydrophobic and hydrophilic patches that can 
accommodate a heterogenous range of amino acid side-chains. This may provide the 
basis of peptide binding specificity of HLA-C*08:01 to be able to bind to different 
arrays of peptides with different P3 residues in the study. This is also consistent with 
the observation that HLA-C*08:01 can bind to the 3 HBV Core 18-27 peptide 
variants with a P3Pro, highlighting the sensitivity of the established refolding assay.  
HLA-C*08:02, on the other hand, belongs to a different group of MHC Class I 
molecules which shares a negatively charged Glu at position 152 and a positively 
charged Arg at position 156. Consequently, it can be deduced that the formation of a 
salt-link between Glu 152 and Arg 156 will orient Arg 156 away from the peptide P3 
side-chain. As a result of a different electrostatic environment, the requirement for a 
negatively charged P3 residue becomes less stringent and pocket D may become non-
specific. Furthermore, it is tempting to speculate that Arg 97 and Asn 114 may almost 
completely fill pocket D such that the pocket can no longer tolerate the binding of a 
P3Pro. For reasons as such, the HBV Core 18-27 peptide may not be able to bind as 
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well to the antigen binding groove of HLA-C*08:02 to form a stable complex that is 
detectable by the Western blot assay. Nonetheless, when structural information for 














Figure 42 Schematic top view of the antigen binding groove of HLA-C*08:01 in 
green, CMV pp65 peptide (VVCAHELVC) in yellow and the Influenza matrix 
peptide (GILGFVFTL) in magenta. Amino acid differences (in red) between HLA-
C*08:01 and HLA-C*08:02 was mapped out onto the crystal structure of HLA-
C*08:01. Residue 138 points outward of the antigen binding groove and is thus 
unlikely to have any interaction with the bound peptide. On the other hand, residues 
152 and 156 are strategically located with their side-chains pointing into the antigen 
binding groove and may affect peptide binding specificity of HLA-C*08:02. Note that 
all 3 amino acid differences resulted in a change in amino acid property from being 
uncharged to charged. Figure was generated using PyMOL.  
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4.3 HLA-C purification and crystallisation 
HLA-C-peptide complexes with a positive band in Western blot are short-listed for 
crystallisation. The crystallisation process requires large-scale refolding of HLA-C-
peptide complexes to cater for sample loss during purification. A two-step purification 
scheme involving a first-step ion-exchange chromatography in series with a second-
step gel-filtration chromatography was designed for high-throughput and high-yield 
purification of refolded HLA-C-peptide complexes. The use of several purification 
steps in succession was essential to remove any trace of contaminants during sample 
preparation as contaminants or micro-heterogeneity may affect crystal growth and 
nucleation rate (Thomas et al., 1998).  
Additionally, as the sample loss during purification and concentration of sample in 
between steps can be quite substantial, it necessitates a large starting volume of 
refolding sample to eventually obtain a protein sample which is of high purity and 
concentration. To achieve crystal growth, the concentration of purified sample also 
has to be adjusted to the right supersaturation level. Having a high supersaturation 
level will result in the formation of numerous nuclei that will grow into many small 
crystals. Therefore, there is a need to reduce the supersaturation levels to maintain a 
balance between spontaneous formation of nuclei and energetic requirements of the 
crystallisation process. Typically, a protein concentration of around 8-10mg/ml is 
required for crystallisation set-up as it is at this concentration range that optimal 
nucleation takes place and single, large crystals can be obtained. 
Moreover, the established crystallisation conditions for existing HLA-C-peptide 
complexes are quite diverse and distinct from one another (Table 10). For instance, 
the HLA-C*04:01-QYDDAVYKL (1QQD) complex was crystallised using 12% 
polyethylene glycol (PEG) 8000, 0.2M calcium acetate and 0.1M sodium cacodylate, 
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pH 6.5 as the reservoir solution at 18ºC. However, when HLA-C*04:01-
QYDDAVYKL is coupled with a KIR2DL1 receptor (1IM9), the crystallisation 
conditions became 5% polyethylene glycol (PEG) 6000, 80mM magnesium chloride, 
6% glycerol and 50mM [N-(2-acetamindo)iminodiacetic acid] (ADA) at pH 6.5. 
Crystallisation of the HLA-C*03:04-GAVDPLLAL coupled with KIR2DL2 (1EFX) 
was done with the conditions set at 6% polyethylene glycol (PEG) 20,000, 50mM 
calcium chloride and 50mM sodium cacodylate at pH 6.5, 25ºC. Evidently, the 
conditions for these existing crystals vary considerably and thus, this drove the desire 
to screen as many conditions as possible for a potential lead. Subsequently, initial 
screening conditions may be further refined to alter the number of nucleation sites that 
may be vital in getting a single, large crystal of diffraction quality.  
After a series of screening and optimisation experiments, the condition established for 
both the HLA-C*08:01-peptide complexes presented in this thesis comprises of 
0.05M calcium chloride dehydrate, 0.1M Bis-Tris pH 6.5 and 30% v/v polyethylene 
glycol monomethyl ether (PEG MME) 550 at 18ºC. This condition is vastly different 
from the already established and published conditions, possibly due to a difference in 
nature of the HLA-C heavy chain sequence.  
Nonetheless, all of the HLA-C crystals, including those already deposited in the PDB 
and of the 2 novel crystals presented, required a crystallisation buffer with a pH of 6.5. 
This is true even for the HLA-A*02:01-GILGFVFTL crystal structure. This suggests 
the importance of pH in maintaining a folded structure as protein solubility will 
change dramatically as pH variation occurs in the range of ~0.5 pH units. Since pH 
affects the crystallisation process, a buffer (Tris or Bis-Tris) must be present to 
maintain the pH range. Finally, a precipitant is also required for protein precipitation 
out of the solution. PEG remains a popular water-soluble polymer of choice as a 
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precipitant as it can hydrate as well as alter the dielectric constant of the solvent to 
maintain protein solubility. In general, the higher the molecular weight of PEG, the 
more effective it is at reducing protein solubility. In our crystallisation set-up, 
polyethylene glycol monomethyl ether (PEG MME) serves as a precipitant when in 
combination with a salt. Often, a salt is also included in the crystallisation solution 
where it was considered that low salt concentrations screened the macromolecular 
charges and decreased electrostatic repulsion forces present between the molecules 
during crystal packing. Furthermore, under conditions of controlled temperature and 
evaporation rate, the protein solution will become supersaturated at a critical point 
and crystallises. The temperature conditions required for HLA-C-peptide 
crystallisation did not vary significantly among the crystals present but temperature 
has a similar effect on protein solubility and may be optimised to reduce the number 
of nucleation sites for crystal formation.  
The next crystallisation challenge lies in transportation of the crystal from the growth 
solution to a cryoprotectant solution using a suitable mounting loop before X-ray 
diffraction. The molecular contacts within the crystal consist of hydrogen bonds and 
weak ionic interactions, making the crystal a very fragile object. Therefore, extreme 
care has to be taken to prevent fracturing of crystal while maintaining hydration. 
Given the advantages associated with single data-set collection using only 1 crystal, it 
is important that the protein crystal can withstand long-term exposure to high-
intensity X-rays. X-rays will cause the crystal to deteriorate over time owing to the 
generation of free radicals by an intense X-ray source and heating by the beam. 
Therefore it is advisable to employ the use of a cryoprotectant and a liquid nitrogen 
source to cool the crystal and minimise radiation damage during data collection. A 
cryoprotectant mainly stabilises the crystal and prevents evaporation of solvent. 
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Taken together, the choice of a right cryoprotectant coupled with good crystal quality 
and appropriate data collection strategy ultimately determines the success of X-ray 




Table 10 Overview of crystallisation conditions. The crystallisation conditions for previous HLA-C-peptide complexes as well as those coupled 
with their respective KIR receptors and HLA-A*02:01-GILGFVFTL are summarised in this table. Crystallisation conditions are distinct and 
diverse between different complexes and appear to be heavy chain-dependent and pH-dependent.   
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4.4 Overall comparison with existing HLA-C crystals 
The crystal structures of 2 novel HLA-C-peptide complexes, namely HLA-C*08:01-
CMV pp65 peptide (VVCAHELVC) and HLA-C*08:01-Influenza matrix peptide 
(GILGFVFTL), are presented in this thesis. For the past 10 years, there was no new 
structural information about HLA-C-peptide complexes being made available in the 
PDB. With the additional structures being solved, they contribute structural insights to 
the limited knowledge of HLA-C in immunology. At the same time, it signifies the 
technological advancements made over the past decade to enable crystallisation of 
these novel complexes at a high resolution.  
The HLA-C*08:01-CMV-pp65 peptide (VVCAHELVC) complex has been 
functionally characterised to elicit cytolytic activity of the CTL cell lines generated by 
pulsing the cells with the nonameric peptide (Kondo et al., 2004). The peptide is a 
fragment of the CMV pp65 protein from positions 198-206 and is a novel CTL 
epitope presented by HLA-C*08:01. This has important implications for immunologic 
monitoring of individuals expressing each specific HLA allele. Moreover, the same 
study also identified other novel CTL epitopes derived from the CMV pp65 antigen 
that are restricted by HLA-A, -B and –C alleles. Hence, our crystal structure provided 
the structural basis to this functional interaction between HLA-C*08:01 and the CMV 
pp65 peptide and binding pocket information derived from structural studies can be 
applied as a useful tool to predict potential binding peptides.  
The Influenza matrix peptide (GILGFVFTL) is well-established to elicit anti-
influenza CD8+ T-cell response in HLA-A*02 positive individuals (Bednarek et al., 
1991). Apart from HLA-A*02, there is no evidence of the peptide being shown to 
bind to other alleles. On the other hand, refolding data from our study identified 
binding of the peptide with HLA-C alleles such as C*01:02, C*07:01 and C*12:02, 
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all of which belong to the HLA-C1 subgroup. HLA-C1 subgroup alleles may hence 
play an important role in presentation of the Influenza virus peptide and/or share a 
similar peptide-binding motif as HLA-A*02 molecules. The presence of 2 different 
alleles at each HLA locus can result in a more efficient CTL response to a virus and in 
turn, a lower risk of disease. This effect of HLA class I heterozygosity has been 
demonstrated in human T-cell lymphotropic virus type I (HTLV-I)-infected 
individuals (Jeffery et al., 2000). In the study, the authors presented evidence that the 
HLA-C*08 allele protected against HTLV-I infection and its association with reduced 
provirus load was independent of and additive to the protective effect exerted by 
HLA-A*02. In addition, the authors pointed out increasing evidence that certain 
apparently unrelated MHC proteins can have very similar specificities in binding a 
broadly similar range of epitopes depending on the main anchor residues of their 
peptide ligands. Thus, the ability of HLA-A*02 and HLA-C1 subgroup alleles to 
present the same peptide may represent the importance of a strong CTL response in 
susceptibility to and/or protection from Influenza A infection.    
Overall, the 2 structures of HLA-C*08:01 is generally similar to that of the 3 existing 
HLA-C crystals with the presence of many conserved interactions between the HLA-
C heavy chain and its bound peptide. Analysis of these conserved interactions was 
facilitated by high resolution of the crystals. In both structures, the peptides bound in 
an extended conformation with its terminal ends firmly anchored into the antigen 
binding groove through a hydrogen bond network. Even though the local environment 
in the antigen binding groove provided by the HLA-C*08:01 heavy chain was the 
same in both structures, the orientation of peptide side-chains differ based on peptide 
sequence variation. Greatest variation in positioning of peptide side-chains was 
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observed in the center part of the peptide where the peptide is most exposed to 
receptor recognition.  
The structures also revealed specificity pockets of different size, shape and 
biochemical properties along the antigen binding groove that act as primary and 
secondary anchors for peptide binding. Presence of salt-bridges and hydrogen bonds 
within the antigen binding groove can influence the peptide conformation and 
determine peptide affinity and HLA-peptide complex stability. Although high peptide 
affinity for HLA does not correlate with immunodominance all the time (Mullbacher 
et al., 1999), peptides binding with high affinity to HLA may form more stable HLA-
peptide complexes leading to increased immunogenicity (Sette et al., 1994b; van der 
Burg et al., 1996). In addition, the primary and secondary peptide anchors may bind 
the peptide strongly to confer a lower dissociation rate that will allow persistence of a 
stable HLA-peptide complex at the cell surface to allow for T-cell recognition and 
enhance immunogenicity.  
Taken together, the crystal structures of HLA-C*08:01 defined a novel peptide-
binding motif for HLA-C molecules. Previously, peptide-binding motifs which 
include a preference for Pro in position P2 and hydrophobic/aromatic residues at the 
peptide C-terminal for HLA-C molecules have been proposed for HLA-C*06:02 and 
HLA-C*07:01 (Dionne et al., 2004). These studies also reported a role for P1 as an 
anchor position apart from the canonical P2 and P9 primary anchors.  
However, a P2Pro is only tolerated in HLA-C*08:01 due to constrains imposed by the 
local environment of the antigen binding groove as well as the overall peptide 
conformation. Instead, non-polar residues such as Val, Ile or even Leu are preferred at 
P2. Position 45 of the HLA heavy chain have been reported to serve an important role 
in determining the peptide-binding motif where it exclusively contacts the P2 position 
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of a given peptide in more than 85% of HLA-peptide structures (Badrinath et al., 
2011). A polymorphic difference between HLA-B*44:08 which has a Met 45 and 
HLA-B*44:02 which has a Lys 45 resulted in an alteration in peptide-binding motif. 
Met 45 potentially created a more hydrophobic side of the binding pocket to 
accommodate binding of aliphatic residues such as Leu at P2. This phenomenon is 
also observed in HLA-A*02 structures which preferentially binds a Leu at P2. In 
contrast, Lys 45 can cause the loss of a hydrogen bond to the peptide and selects out 
incompatible peptides. For the case of HLA-C, a unique and conserved Gly is found 
at position 45 of the heavy chain. Glycine, being small and uncharged, does not 
impose any spatial or electrostatic constrains and hence can allow the binding of Val, 
Ile or Leu at the P2 position. On the other hand, position P9 of HLA-C*08:01 exhibits 
a higher level of flexibility in being able to bind to aliphatic residues such as Cys 
which is polar and Leu which is non-polar. This is consistent with the conserved 
interactions found in the deep pocket F of HLA-C*08:01.   
Furthermore, although X-ray crystallography allowed the high resolution visualisation 
of the HLA-C-peptide structures, this technique is still unable to completely 
rationalise the dynamics of HLA-C-peptide interactions. On the other hand, molecular 
dynamics (MD) simulations may offer a more powerful way to study the 
conformational dynamics of the HLA-C-peptide interactions at a high resolution in 
space and time. This approach has been used extensively to investigate the 
conformational changes upon peptide binding to give more insights into the affinity 
and specificity of the HLA-C-peptide interactions. For instance, MD simulations of 
HLA-A*02:01 complexed with a tumor-specific antigenic peptide revealed the 
flexibility and importance of the α3 and β2m domains in binding efficiencies of the 
peptide after taking into consideration the structural and energetic features of the 
172 
 
complex (Wan et al., 2004). Similarly, MD experiments have shown that the KYRV 
motif on HLA-C molecules impairs flexibility of the HLA-C heavy chain to result in 
poor assembly and selective in terms of peptide binding (Sibilio et al., 2008). 
Although there is currently no experimental three-dimensional structure available for 
an empty HLA-C molecule, comparative MD simulations using the crystal structure 
of HLA-C*08:01 in the absence and presence of a binding peptide will provide hints 
on the flexibility of the structure and conformational changes that may be 
accompanied by peptide binding. Nonetheless, until crystallographic data for an 
empty HLA-C molecule becomes available, MD simulations remain an important tool 
for the study of protein dynamics from which binding affinity and specificity of the 
HLA-C-peptide interactions can be inferred.  
Therefore, the use of X-ray crystallography can be enhanced when complemented 
with MD simulations.   
4.5 Thermal stability of HLA-C 
While peptide dissociation constants can be determined using the thermal 
denaturation profiles obtained from circular dichroism experiments, the stability of 
HLA-peptide complexes can also be monitored. In our experimental set-up, the 
thermal denaturation profiles correlated well with the band intensity patterns obtained 
by Western blot and peak intensity observed in the purification profile. It is expected 
that complexes such as HLA-A*02:01-Influenza matrix GILGFVFTL peptide 
complex and HLA-C*08:01 CMV pp65 VVCAHELVC peptide complex, which are 
known to elicit a CTL response, unfold at a higher temperature as compared to the 
rest of the complexes. This is because the HLA-peptide complex has to be relatively 
stable on the cell surface to be recognised by a TCR and subsequently mount an 
immune response.  
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Furthermore, the HLA-C*08:01-HBV Core 18-27 variant FLPSDYFPSV peptide 
complex is observed to be the least stable among all tested complexes. This is not 
surprising as there is a peptide length specificity exhibited by the HLA-C molecules 
which proposes that longer peptides bind less energetically favourably into the 
antigen binding groove. This view is supported by structural analyses which reported 
additional kinking of the peptide backbone near the center of the antigen binding 
groove with the loss of several conserved hydrogen bond interactions between the 
HLA heavy chain and the peptide (Guo et al., 1992). As a result, the HLA-C*08:01-
FLPSDYFPSV complex destabilises and unfolds at a relatively lower temperature.  
Taken together, the stability of HLA-C –peptide complexes, measured by circular 
dichroism, may aid in the selection of peptides in peptide-based vaccines.  
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4.6 Conclusions and perspectives 
In summary, an optimised refolding assay for HLA-C molecules involving the use of 
recombinant molecules expressed in bacteria and a library of viral peptides was 
developed to screen for potential HLA-C-peptide complexes. Detection of complexes 
was achieved through a sensitive Western blot assay that discriminates non-binding 
peptides and/or low-affinity complexes from stable HLA-C-peptide complexes 
through differences in band intensity. This method shows that HLA-C proteins were 
able to fold into a native ternary conformation in the presence of the β2m light chain 
and a peptide of virus origin and selects successfully refolded HLA-C-peptide 
complexes based on peptide binding to each HLA-C allele. Furthermore, thermal 
unfolding of HLA-C-peptide complexes was measured by circular dichroism and is 
coherent with the band intensity observed on Western blot as well as the peak 
intensity observed on the purification profile.   
Although some of the complexes identified through this refolding assay may not have 
a functional role, the refolding assay serves as a powerful tool to provide allele-
specific peptide-binding motifs. Extension of peptide binding studies to a wider panel 
of peptides will enhance understanding of the binding properties unique to HLA-C 
molecules.  
After screening with potential binding peptides, a few high-affinity HLA-C-peptide 
complexes were short-listed for purification and crystallisation. A two-step 
purification scheme was designed to yield HLA-C-peptide complexes in high purity 
and concentration. Thereafter, crystallisation screening and optimisation attempts 
gave rise to single, large crystals of X-ray diffraction quality that generated structural 
data at high resolution. The HLA-C*08:01 molecule crystallised with two peptides: 
the Cytomegalovirus pp65 protein peptide (VVCAHELVC) which in combination 
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with HLA-C*08:01 is known to elicit a cytotoxic T-cell response, and the Influenza 
matrix peptide (GILGFVFTL) which is HLA-A*02-restricted. The 2 novel crystal 
structures revealed the presence of numerous conserved hydrogen bond interactions 
and facilitated examination of HLA-C binding pockets in greater detail. Therefore, the 
crystallographic data highlight the possibility that HLA-C may share a common 
peptide-binding motif and have a similar role as HLA-A*02 in antigen presentation.  
Taken together, characterisation of MHC-peptide binding specificities by structural 
studies provide valuable information for understanding how peptides bind to HLA-C 
molecules and aid in development of more precise and comprehensive tools for 
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